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Abstract 
There are two main mechanisms of tolerance, one in the thymus and one in the 
periphery. Anergy, a peripheral mechanism, is a state of hypo-responsiveness 
where T-cells fail to respond to antigenic stimulus. A breakdown in 
immunological self-tolerance leads to autoimmunity and so provides an exciting 
research area for therapeutic intervention in autoimmune disease. 
Differential display studies comparing anergic and activated CD4+ T-cells 
identified claudin domain containing protein 1 (CLDND1) to be differentially 
expressed between these two states. In addition, preliminary experiments 
performed in our lab identified CLDND1 as a potential negative regulator of 
CD4+ T-cell activation. 
The aim of this study was to identify the role of CLDND1 in CD4+ T-cells. 
Antibodies against CLDND1 were raised and validated before use to determine 
CLDND1 expression in immune cell subsets and during T-cell activation. The 
function of CLDND1 in T-cells was investigated using gene silencing or over-
expression techniques. CLDND1 expression was also sought in the 
autoimmune disease, rheumatoid arthritis (RA), to identify whether CLDND1 
may be involved in disease pathogenesis. 
Antibodies were successfully raised against CLDND1 and CLDND1 was found 
to be transiently up-regulated during CD4+ T-cell activation. CLDND1 gene 
silencing attempts, while successful at the RNA level, did not translate to a 
reduction in CLDND1 protein, suggesting CLDND1 may be regulated 
independently of gene transcription. Over-expression studies were consistent 
with CLDND1 being a negative regulator of T-cell proliferation or an inducer of 
cell death, depending on the activating stimulus used. CLDND1 expression was 
found to correlate with rheumatoid factor (RF) status in early RA patients and 
may suggest a role for CLDND1 in the disease setting. Some findings identify 
similarities between CLDND1 and other proteins, providing links for functional 
pathways and a plethora of further avenues of research.
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Chapter 1. Introduction 
CD4+ T-cells are a population of mononuclear cells that underpin key elements 
of the adaptive immune response. Diverse responses can be induced, which 
depend on the context of T-cell activation. Full activation is a critical step in 
mounting an effective immune response. Given the pivotal role of T-cells, tight 
regulation of their activity is essential, starting in the thymus and continuing into 
the periphery, to control for aberrant T-cell activation. Failure in these regulatory 
mechanisms plays a major role in the pathogenesis of autoimmune diseases. 
1.1 T-cell Selection in the Thymus 
Following development from a common lymphoid progenitor in the bone 
marrow, T-cell precursors migrate to the thymus where a small proportion of 
these cells differentiate into mature CD3 α:β CD4+ T-cells. A small portion of 
precursor cells also develop into CD3 γ:δ T-cells, but these cells will not be 
covered here. Several steps are involved in the generation of mature CD4+ T-
cells; from double negative precursor cells, which express neither CD3 T-cell 
receptor (TCR) nor CD4/CD8 co-receptor upon entry into the thymus, through to 
double positive thymocytes, which express a pre-TCR, CD4 and CD8, to single 
positive CD4 thymocytes, which retain TCR expression and CD4 expression. 
Two selection processes occur during this transition to single positive CD4 
thymocytes to prevent the selection of non-responsive or highly self-reactive 
TCR, which are dependent on interactions between the TCR and the major 
histocompatibility complex (MHC) class II molecules present on a range of cell 
types. CD4/CD8 double positive thymocytes initially express low levels of a 
specific TCR, of which most do not recognize self-MHC class II molecules. 
These cells fail the positive selection process and die by neglect. CD4/CD8 
double positive cells that recognize self-MHC class II go on to mature into single 
positive thymocytes and express high levels of a specific TCR. CD4 single 
positive thymocytes then undergo negative selection, which eliminates those 
cells capable of strongly responding to self-antigens presented by medullary 
dendritic cells (mDC) and medullary thymic epithelial cells (mTECs), thus 
preventing the formation of self-reactive T-cells. The remaining single positive 
T-cells make up approximately 2 % of the starting population and are exported 
from the thymus to form the peripheral T-cell repertoire. The survival of newly 
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formed T-cells is determined by sustained and repeated contact with MHC: self-
peptide complexes, similar or identical to those that originally positively selected 
them, in combination with signals through the interleukin-7 (IL-7) cytokine 
receptor (Janeway et al., 2001). 
1.2 T-cell Activation 
Upon initiation of an immune response, antigen presenting cells (APC) process 
and present on MHC class II molecules peptides derived from antigenic 
proteins. These cells are then capable of activating CD4+ T-cells provided the 
three criteria for stimulation are provided. Recognition of the antigen presented 
on MHC class II molecules of professional APC is required by the TCR. This 
event is accompanied by co-stimulatory molecule interaction from APC, such as 
CD28 expressed on T-cells interacting with the B7 molecules, CD80 and CD86, 
on APC (Kalergis, 2003). The third signal required to elicit T-cell activation is an 
appropriate cytokine milieu (Curtsinger and Mescher, 2010). 
Recognition of antigen bound to MHC class II molecules by the TCR in the 
presence of a pro-inflammatory environment leads to the formation of the 
immunological synapse (IS) and initiates a complex signalling pathway in the T-
cell, mediated not only by the TCR, but also through co-stimulatory and 
adhesion molecules found within the synapse. The importance of the IS function 
has been the centre of much discussion (Dustin et al., 2010). One of the first 
steps in this signalling cascade involves phosphorylation of the immunoreceptor 
tyrosine-based activation motifs (ITAMs) of the TCR complex, mediated by the 
src family of tyrosine kinases (e.g. lymphocyte-specific protein tyrosine kinase 
(lck) and fyn) (Palacios and Weiss, 2004). The syk family kinase, zeta-chain-
associated protein kinase (zap)-70, is recruited to the phosphorylated ITAMs 
through src homology 2 (SH2) domains, where it is phosphorylated and 
activated (Visco et al., 2000). Ultimately, linker for activation of T-cell (LAT) 
molecules are activated which leads to the initiation of multiple pathways such 
as the ras/extracellular-signal-regulated kinases (ERK)/mitogen-activated 
protein kinase (MAPK), and the calcium/calcineurin and the phosphoinositide 3-
kinase (PI3K)/protein kinase C (PKC) pathway. These pathways up-regulate the 
transcription factors activator protein-1 (AP-1), nuclear factor of activated T-cells 
(NFAT) and nuclear factor kappa-light-chain-enhancer of activated B-cells 
(NFκB), which positively regulate the induction of T-cell proliferation genes 
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(Wonerow and Watson, 2001, Oh-hora and Rao, 2008) (Figure 1). Of these 
genes activated, IL-2 is considered to be an important factor for both auto- and 
paracrine activating signalling. 
 
 
Figure 1. T-cell signalling events during full T-cell activation 
Full triggering through the TCR and co-stimulatory molecules results in the 
activation of the three main pathways: PI3K/PKC, ERK/MAPK and the 
calcium/calcineurin pathway to activate the transcription factors NFkB, AP-1 
and NFATs. Co-operation between these transcription factors results in IL-2 
production, which through positive feedback mechanisms, activates mTOR and 
leads to the progression of the cell cycle. 
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1.2.1 Importance of IL-2 signalling 
IL-2 binds to a heterotrimeric IL-2 receptor comprised of non-covalently 
associated α (CD25), β (CD122) and γ (CD132) subunits. IL-2 binds to the α 
and β chains, while the γ-and β subunits initiate signal transduction. IL-2/IL-2 
receptor signalling initiates the janus kinase (JAK)/ signal transducer and 
activator of transcription (STAT) signalling pathway and induce a positive 
feedback loop through the activation of MAPK and PI3K pathways (Lan et al. 
2008). IL-2 signalling also leads to the activation of the serine/threonine protein 
kinase, mammalian target of rapamycin (mTOR); shown to be an important 
activator of cell cycle progression (Figure 1) (Morice et al., 1993, Nourse et al., 
1994). 
The expression of IL-2 is controlled at multiple levels. The IL-2 promoter 
sequence contains binding sites for the NFAT family of proteins, AP-1 and 
NFκB, all of which require occupation for the transcription of IL-2 (Rooney et al., 
1995, Choi et al., 2009, Shapiro et al., 1997). Co-stimulatory signalling via 
CD28 during T-cell activation is a major pathway to activate NFkB, and so this 
pathway is crucial for IL-2 transcription. CD28 activates PKCθ through PI3K or 
by growth factor receptor-bound protein (Grb)-2. These signalling pathways 
lead to the degradation of the inhibitory IκB kinase (IKK) subunit of the NFkB 
complex and lead to the activation of genes containing NFkB binding elements 
(Tuosto, 2011), such as IL-2.  
1.2.2 Calcium signalling 
TCR triggering activates phospholipase C (PLC)-γ, which cleaves 
phosphatidylinositol bisphosphate (PIP2) into inositol 1-4-5-trisphosphate (IP3) 
and diacylglycerol (DAG) and initiates intracellular Ca2+ ([Ca]i) signalling 
pathways  (Figure 1). The original paradigm involves IP3 binding to IP3 
receptors expressed on the membrane of the endoplasmic reticulum (ER). [Ca]i 
stores are released which induce a conformational change in stromal interaction 
molecule (STIM)-1, an ER Ca2+ sensor, which ultimately activates calcium 
release-activated calcium channel protein (Orai)-1 at the plasma membrane, 
resulting in [Ca]i influx. The increase in [Ca]i may activate the calcium-
calmodulin kinase pathways, and calcineurin, a Ca2+-dependent phosphatase, 
which dephosphorylates members of the NFAT family, allowing their nuclear 
localization and transcription of target genes (Robert et al., 2011). This 
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paradigm however, would not explain how differences in [Ca]i signal intensity 
can govern T-cell activation, tolerance or anergy (Qu et al., 2011), or 
differences in the [Ca]i regulation between T-cell subsets, where the rise of [Ca]i 
elicited by TCR engagement is lower in T-helper (Th)2 cells compared to Th1 or 
Th17 cells (Weber et al., 2008). More recently, additional types of calcium 
channels have been identified on T-cells, including adenosine-5'-triphosphate 
(ATP)-responsive purinergic P2 receptors (P2X), which are ATP-gated ion 
channels that permit the influx of extracellular cations; N-methyl-D-aspartate 
activated receptors (NMDA), a class of ligand-gated glutamate receptors 
originally found in the nervous system to play a crucial role in neuronal cell 
function; and the voltage-dependent Ca2+ channels, which are typically 
activated in excitable cells such as nerve or muscle cells in response to 
membrane polarisation. Emerging roles for these receptors in T-cells are 
becoming elucidated, yet specific mechanisms of how they fit with the current 
paradigm are still under investigation (Omilusik et al., 2013). 
1.3 Types of T-Effector Cells 
Differentiation of activated naïve CD4+ T-cells into functionally distinct helper T 
subsets is crucial for proper host defence and normal immunoregulation (Figure 
2). Originally, CD4+ T-cells were viewed as having two major fates: Th1 cells, 
which express T-bet, selectively produce interferon (IFN)-γ and target 
intracellular pathogens; and Th2 cells, which express GATA-binding factor 
(GATA)-3, produce IL-4 and IL-5, and target extracellular pathogens. More 
recently, newer lineages have been added. Regulatory T (Treg) cells express 
the transcription factor forkhead box P3 (Foxp3), a range of inhibitory receptors, 
secrete anti-inflammatory cytokines such as TGF-β and IL-10, and are 
important in the regulation of T-cell and APC immune responses. Th17 cells, 
distinguished by their expression of transcription factor RAR-related orphan 
receptor gamma (RORγ)-t and the secretion of IL-17, are important for 
protection from fungi and extracellular bacteria. Another two subsets of cells 
Th9 and Th22, named due to the secretion of IL-9 or IL-22, play similar roles to 
Th2 and Th17 cells, respectively. The newest lineage of cells, follicular helper T 
(Tfh) cells are crucial for providing B-cell help by promoting class switching of B-
cells and are defined by expression of B-cell lymphoma-6 protein (Bcl-6) and IL-
21, along with surface molecules programmed cell death protein (PD)-1, C-X-C 
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chemokine receptor type (CXCR)-5 and inducible T-cell co-stimulator (ICOS) 
(Hirahara et al., 2013, Nakayamada et al., 2012). 
 
 
 
 
Figure 2. CD4+ T-cell subsets 
Naïve CD4+ T-cells differentiate into functionally distinct helper T-cell subsets, 
defined by expression of particular transcription factors and cytokines, which 
are imperative for proper host defence and normal immunoregulation. 
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1.4 The Regulation of T-cell Activation 
There are two main types of mechanisms that regulate CD4+ T-cell activity, 
termed central and peripheral tolerance. Central tolerance mechanisms have, in 
part been discussed above. As this mechanism relies on avidity interactions 
between self-peptide MHC class II molecule complexes, low-avidity 
autoreactive T-cells that are not eliminated, or T-cells bearing reactivity to self-
peptide MHC class II not expressed at sufficient quantities on mTECs, escape 
to the periphery and rely on peripheral tolerance mechanisms to prevent 
aberrant activation of these cells. Peripheral tolerance mechanisms include: 
immune deviation, where particular T-cell responses are skewed to a different 
subset profile; T-cell suppression by Treg or tolerogenic APC; anergy, where T-
cells fail to respond to antigenic stimulus; and the existence of immune 
privileged areas, where antigens from these sites, such as the eye, induce 
tolerance in the T-cells rather than an inflammatory response. 
1.4.1 Control of APC activation 
APC require activation before they can assist in T-cell activation, and so serves 
as a T-cell regulatory mechanism. Prior to migration to a lymph node for antigen 
presentation, immature DC reside in parenchymal tissues, surveying for 
infection or injury through constant macropinocytosis of the local environment. 
DC constantly process available antigens through MHC class II-rich endosomal 
compartments and are poised to deliver a high density of peptide-MHC class II 
complexes to the surface should activation occur. The immature DC express a 
variety of pathogen recognition receptors (PRRs), such as toll-like receptors 
(TLR), which are activated in response to microbial products, necrosis, 
mechanical trauma and pro-inflammatory cytokines. As a result of DC 
activation, DC mature and undergo a dramatic change in their morphology and 
antigen processing. They up-regulate MHC class II expression and B7 co-
stimulatory molecules, CD80 and CD86, as well as C-C chemokine receptor 
(CCR)-7 and CD40. The DC migrates to T-cell–rich regions of the lymph node 
where it directs T-cell activation. Full DC maturation is associated with the 
synthesis of pro-inflammatory cytokines, which can regulate the differentiation 
of the responder T-cells (Mueller, 2010). Incomplete activation of DC generates 
tolerogenic DC (tolDC) which induce tolerance in naive T-cells. TolDC induce 
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tolerance through the presentation of antigen with inadequate co-stimulation 
and cytokine production for effector T-cell activation, resulting in T-cell anergy, 
deletion or induction of Treg (Thomson and Robbins, 2008, Jonuleit et al., 
2001). 
1.4.2 Treg 
Treg can arise as a consequence of self-antigen recognition during T-cell 
maturation in the thymus (nTreg), or following self-antigen recognition in the 
periphery (iTreg). Both subtypes expand on recognition of antigen and increase 
their suppressive activity. nTreg are characterised by the high expression of 
Foxp3, CD25, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell 
death protein-1 (PD-1), which are important for their suppressive function. 
These cells require TCR triggering and probably IL-2 to exert their suppressive 
effects on bystander cells (Maggi et al., 2005). iTreg are comprised of 
transforming growth factor (TGF)-β producing (Th3 cells) and IL-10 producing 
(Tr1) cells. In pathological conditions, iTreg can revert to effector forms, e.g. 
Th17, that contribute to immunopathology (Heiber and Geiger, 2012). 
1.4.3 Anergy 
In T-cells, the term anergy refers to a state of hypo-responsiveness upon 
antigen encounter. This state requires the cell to remain viable in excess of 24 
hours: the time required to initiate an apoptotic death process (Schwartz, 1990). 
There is no consensus in the literature regarding phenotypic changes and 
signalling events that occur during the induction of anergy, due to variations in 
experimental procedure. The type of stimulus seems to be a major variable: for 
example, T-cells can be stimulated with antigen in the absence of co-stimulation 
or stimulated persistently to induce anergy. There are also major deviations, 
explained below, in findings between anergic T-cells studied in vitro or in vivo 
(Schwartz, 2003).  
Due to this complexity, Schwartz, (2003) has subcategorised anergic 
phenotypes based on T-cell characteristic traits and proposes a two model 
anergy system: clonal anergy and adaptive tolerance, although it is stated that 
there are exceptions which do not fall into either category. Clonal anergy is a 
growth arrest state occurring when a TCR is stimulated in the absence of co-
stimulation or when co-stimulation is present but TCR stimulation is weak. 
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Adaptive tolerance describes cells which display a state of generalised inhibition 
of proliferation and effector function, occurring when a T-cell is exposed to a 
superantigen or repeated exposure to an antigen (Schwartz, 2003). This model 
of anergy differs from clonal anergy in several ways (Table 1 and Figure 3).  
 
Characteristic traits Clonal anergy Adaptive tolerance 
T-cell subset Pre-activated Naïve 
Antigen persistence required No Yes 
Proliferation upon induction No Yes 
Inhibition of proliferation Yes Yes 
Inhibition of IL-2 Yes Yes 
Inhibition of IFN-γ No Yes 
Inhibition of IL-4 No Yes 
Production of IL-10 No Some 
Major defect in signalling pathway Ras/MAP kinase Tyr kinase 
Block in IL-2R signalling No Yes 
Reversible by IL-2 Yes No 
 
Table 1. Characteristics of the anergy phenotypes 
Main characteristic traits of clonal anergy and adaptive tolerance. Table was 
adapted from Schwartz, (2003). 
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Figure 3. T-cell signalling events during anergic stimulation 
Clonal anergy and adaptive tolerance are two distinct anergic states, but both 
result in abrogated IL-2 transcription. In clonal anergy, sub-optimal TCR 
triggering through lack of co-stimulation, low antigenic peptide or through CD3 
antibody results in defects in the ras/MAPK pathway, preventing the activation 
of AP-1. In adaptive tolerance, sustained TCR signalling results in proximal 
TCR signalling defects which affect [Ca]i signalling and subsequent NFAT 
activation. 
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Clonal anergy has primarily been regarded to occur in previously activated T-
cells and can be reversed by IL-2 (Schwartz, 2003). These cells contain defects 
in the activation of the MAPK family (Fields et al., 1996, DeSilva et al., 1996), 
which was localised to ineffective guanosine triphosphate (GTP) loading of ras 
(Smida et al., 2007, Olenchock et al., 2006) primarily through DAG kinase 
(DGK)α inhibition (Ebinu et al., 1998, Zhong et al., 2008, Zha et al., 2006). 
DGKα selectively inhibits AP-1 activation (Olenchock et al., 2006), which is 
critical for the induction of clonal anergy (Kang et al., 1992). mTOR deficiency 
under a normally activating stimulus also results in anergy, which has also been 
linked to the regulation of DGKα (Gorentla et al., 2011, Zheng et al., 2007).  
Adaptive tolerance models have proposed defects in the proximal TCR/CD3 
signalling pathway. The levels of the src family tyrosine kinase, fyn, are 
disproportionally increased in adaptive tolerance, compared to lck, yet the 
importance of this is still to be resolved due to conflicting data from fyn -/- mice 
(Stein et al., 1992, Choi and Schwartz, 2007). Zap-70 levels are elevated and 
so tolerant TCR bind more zap-70 than activated TCR; but its function is 
impaired due to insufficient stabilising phosphorylation events. LAT 
phosphorylation is also significantly reduced (Choi and Schwartz, 2007). [Ca]i 
signalling is also impaired, which prevents the activation of NFAT (Chiodetti et 
al., 2006).  
1.4.4 Negative regulators of the immune response 
T-cell activation can be controlled by both internal and cell surface proteins, 
which compete with activating signals. An array of inhibitory molecules have 
been identified on T-cells, which counteract the induction of the immune 
response, such as T-cell immunoglobulin-3 (TIM-3) interaction with galectin-9 
(gal-9) on APC to induce T-cell death, and lymphocyte activation gene-3 (lag-3), 
a ligand for MHC class II on DC, which plays an inhibitory role in T-cell 
activation (Li X et al 2012, Triebel F 2003). Two well established examples of 
cell surface proteins which control T-cell activation are CTLA-4 and PD-1. 
CTLA-4 is a structural homologue of CD28 and competes with CD28 signalling 
in T-cells by binding to the B7 co-stimulatory molecules, CD80 and CD86, on 
APC. Experiments from CTLA-4-/- mice and the use of CTLA-4-specific 
monoclonal antibody (mAb) have indicated a role for CTLA-4 in the counter-
regulation T-cell activation, as these cells resist anergy induction in response to 
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antigen administration in the absence of infection or adjuvant (Kearney et al., 
1995, Perez et al., 1997, Greenwald et al., 2001). PD-1 is a member of the 
CD28 and CTLA-4 immunoglobulin superfamily and interacts with PD-L1 and 
PD-L2 on APC. Evidence from blocking PD-1/PD-L1 interactions with anti-PD-
L1 antibody, and from PD-1-/- mice studies, indicate a role for PD-1 in the 
inhibition of TCR mediated T-cell proliferation and cytokine secretion, through 
inhibition of proximal TCR phosphorylation events, an independent mechanism 
to CTLA-4. PD-1 signalling is thought to prevent a decrease in T-cell motility 
and thus preventing stable T-cell-DC conjugate formation and development of 
the IS (Freeman et al., 2000, Fife et al., 2009, Gianchecchi et al., 2013). 
1.5 Immune Cells in Disease 
Circulating autoreactive T-cells are present in all individuals yet as the 
prevalence of autoimmune disorders affects only a proportion of the population, 
this suggests that a breakdown in regulation of these autoreactive T-cells is an 
important mechanism in autoimmune disease initiation. A breakdown in 
peripheral tolerance mechanisms is thought to play a key role in the 
pathogenesis of the autoimmune disease, RA. 
1.6 RA 
RA is a complex, heterogeneous, inflammatory autoimmune disease which has 
an estimated prevalence of 0.5-1 % in developed regions (Choy, 2012). The 
disease is systemic, and extra-articular features may be present, but the 
synovial joints are the primary site of pathology. Although the aetiology of RA is 
unknown, the susceptibility and severity of RA are likely to encompass both 
genetic and environmental factors, many of which are still to be elucidated. As 
characterisation of the disease develops, it is clear that RA can be further 
subdivided into different disease entities depending on α-citrillunated antibody 
(CCP) status (Trouw et al., 2013). Within the CCP positive disease setting, the 
prevalence of shared epitopes found in the human leukocyte antigen (HLA)-
DRB1 gene, autoantibodies, the infiltration of immune cells in the joint and the 
successful application of T- and B-cell ablation strategies all implicate a role for 
the immune system in the disease (Pratt et al., 2009). 
Originally, RA was treated as a disease where joint damage and disability 
occurred slowly. However, studies have shown that in 90 % of cases, damage 
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occurs within two years of the disease onset and in some instances is already 
present at symptom onset (Emery, 1994, McGonagle et al., 1999). The extent of 
the damage at these time-points reliably correlates with severity of lesions in 
later stage disease (McQueen et al., 2001). These findings led to the “window of 
opportunity” hypothesis which is based on the existence of a time frame, of 
roughly 12 weeks, in which the response to therapy results in long-term 
sustained benefits of treatment (Quinn and Emery, 2003).  
1.7 Synovial Joints 
Synovial joints are comprised of several tissues: synovial membrane, articular 
cartilage and subchondral bone, which are surrounded by the joint capsule 
(Figure 4). The synovial membrane is comprised of two types of synoviocytes; 
macrophage- and fibroblast-like. The fibroblast-like cells secrete viscous 
synovial fluid which both lubricates the joint and allows for the diffusion of 
nutrients. The articular cartilage is formed by one cell type only, the 
chondrocyte, which through the secretion of proteins, collagen and 
proteoglycans, plays a central role in the formation and maintenance of the 
cartilage. The subchondral bone lies underneath the cartilage and is comprised 
of collagen, proteoglycans, glycoproteins, glycosaminoglycans and growth 
factors, calcified in hydroxyapatite. The two primary cell types of the 
subchondral bone, osteoclasts and osteoblasts, are responsible for the re-
modelling of the bone in response to load-bearing requirements and calcium 
and magnesium homeostasis. In RA, the primary disease target is the synovial 
membrane (Hui et al., 2012, Datta et al., 2008, Goldring and Marcu, 2009). 
 
 
 
 
 
Katherine L. Crossland                                                        Chapter 1. Introduction 
14 
 
Figure 4. Normal and RA disease joint physiology 
In the healthy joint the synoviocytes of the synovial membrane line the joint and secrete synovial fluid to maintain joint homeostasis. In 
RA, the synovial membrane becomes hyperplastic and infiltrated by chronic inflammatory cells. Expansion of the synovial membrane 
leads to the degradation of the cartilage and subchondral bone. 
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1.8 Proposed Models of RA Pathogenesis 
The major pathology occurring in RA is destruction of articular cartilage and 
subchondral bone by the infiltrating synovium, where the disease process 
begins (Figure 4). Synovitis is initiated by the influx or local activation of 
mononuclear cells which leads to a hyperplastic synovial lining which expands 
and forms villi. In late state disease, the dysregulation and expansion of the 
synovium leads to the degradation of cartilage due to the release of proteolytic 
enzymes and activation of osteoclasts which destroys the bone (Choy, 2012). 
There are a number of proposed key players for the pathogenesis of RA, such 
as B- and T-cells, but disease progression is likely to encompass a complex 
signalling network between all these factors, described below. 
1.8.1 B-cells 
The success of rituximab, a B-cell depleting therapy, in the treatment of RA has 
confirmed the importance of B-cells in disease pathogenesis (Edwards and 
Cambridge, 2006). As well as their role in the secretion of autoantibodies, B-
cells can process and present antigenic peptides to pre-primed CD4+ T-cells, 
culminating in a classical adaptive immune response (Edwards and Cambridge, 
2006). Of the autoantibodies detected in RA, RF and CCP have been identified 
as markers of disease classification, given their presence before clinical onset 
of disease (Rantapaa-Dahlqvist, 2009). Deposition of RF immune complexes 
occurs in the rheumatoid synovium, where these complexes fix complement, 
leading to a positive-feedback loop whereby B-cell activation is re-enforced and 
this process can also perpetuate the inflammatory immune response through 
recognition of antibody constant regions by FCγ-receptors present on a variety 
of immune cell subsets, such as macrophages and lymphocytes (Edwards and 
Cambridge, 2006). 
1.8.2 T-cells  
Both CD4+ and CD8+ T-cells are present in the synovium of RA patients 
(Matthews et al., 1993, Fox, 1997, Breedveld and Verweij, 1997), with the CD4+ 
T-cell subset comprising 30-50 % of synovial tissue cells (Zvaifler et al., 1994). 
In the blood and synovium of RA patients, these cells have an activated 
phenotype, characterised by the up-regulated expression of HLA-DR, CD69 and 
CD27 (Cush and Lipsky, 1988, Breedveld and Verweij, 1997, Iannone et al., 
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1994). However, in vitro, these cells have been shown to proliferate poorly in 
response to mitogenic stimuli, to have defects in [Ca]i signalling and a similar 
phenotypic characteristic to anergic T-cells (Carruthers et al., 1996, Ali et al., 
2001, Hatachi et al., 2003). Numerous mouse models of RA indicate defects in 
CD4+ T-cell signalling, with a post-activated memory phenotype and low 
proliferative capacity (Thomas et al., 2008). These findings along with the 
therapeutic effects of tolerance inducing mechanisms, such as CLTA-4-Ig, a 
molecule that mimics the action of CTLA-4 by binding to the B7 molecules 
CD80 and CD86 on APC (von Kempis et al., 2012), would suggest defects in 
peripheral tolerance mechanisms in RA, leading to the recognition of 
autoantigens in the joint and initiation of an autoimmune response. 
More recently, a role for Th17 cells has been implicated in not only RA 
pathogenesis, but in many other autoimmune diseases (Kirkham et al., 2013). 
Studies have demonstrated elevated levels of IL-17 in the blood and synovium 
of RA patients, which positively correlate with joint damage (Kirkham et al., 
2006). Three therapies that block IL-17 signalling are currently in stage 3 clinical 
trials (Kirkham et al., 2013). Th17 cells secrete IL-17, which can directly or 
indirectly exert effects on various cell types to induce chemokine and pro-
inflammatory cytokine expression and angiogenesis, which promotes the 
expansion of the synovium and osteoclastogenesis, which underpins bone 
resorption, and increased production of cartilage-degrading matrix 
metalloproteinase (MMPs) (Kirkham et al., 2013). 
Given that the pathogenesis of RA is thought to occur as a result of a 
breakdown in immunological tolerance, the role of Treg in RA has been under 
intense investigation. It is well established that Treg play a protective role in RA 
and other autoimmune diseases and dysregulation of this tolerance either 
through altered Treg levels, reduced suppressive function, or resistance of cells 
to the suppressive function of Treg may be important in disease pathogenesis 
(Cooles et al., 2013). 
1.8.3 Other players in RA disease pathogenesis 
It is well established that pro-inflammatory cytokines are involved in the 
pathogenesis of RA, in particular IL-6 and tumour necrosis factor (TNF)-α. 
Through complex signalling pathways, these cytokines trigger gene expression 
of inflammation-related proteins, including additional cytokines and proteases. A 
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selection of roles for TNF-α includes increased monocyte activation and 
subsequent pro-inflammatory cytokine release, and induction of acute-phase 
protein production, which exacerbate the immune response. IL-6 has important 
roles in osteoclast activation, neutrophil recruitment, B- and T-cell activation and 
differentiation and can also induce acute-phase protein production (Choy, 
2012). 
Over the past two decades, more interest in fibroblast-like synoviocytes (FLS) 
has developed, expanding on their original role in synovial architecture. RA FLS 
have long been known to express MHC class II which appears to be up-
regulated in the context of inflammation, but it is only more recently that IFN-γ 
treated RA FLS were shown to be able to extract and present auto-antigen 
candidates to antigen specific T-cell hybridomas (Leech and Morand, 2013). 
The cytokine secretion profile of RA FLS is notable for its ability to support the 
differentiation and activation of T-cells, specifically Th1 and Th17 subsets 
(Leech and Morand, 2013). 
1.9 Therapeutic Tolerance in RA 
Given the role for aberrant regulation of the immune system in the pathogenesis 
of RA, the ideal aim would be to re-instate tolerance as a disease cure. The 
traditional use of methotrexate for treatment of RA only induces remission in 
around 30 % of patients. In the 1990s, the development and subsequent 
approval of biological therapies that targeted pro-inflammatory cytokines or cell 
surface markers (Table 2) radically changed the course of RA disease. 
(Upchurch and Kay, 2012). These drugs relieve symptoms effectively but do not 
provide a cure and moreover, these drugs can increase the risk of serious 
infections. Preferably, tolerance should be induced in an antigen-specific 
fashion, possibly only aiming at the pathogenic cells and preserving physiologic 
defence.  
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Name Therapy type Site of action 
Abatacept CTLA-4 extracellular domain fused to Fc APC 
Adalimumab mAb TNF-α 
Etanercept Fusion Protein TNF-α 
Infliximab Chimeric mAb TNF-α 
Rituximab Chimeric mAb CD20+ B-cells 
Tocilizumab Humanised mAb IL-6R 
 
Table 2. Examples of biological therapies for the treatment of RA 
Adapted from Upchurch and Kay (2012). 
 
 
1.10 Identification of Tolerance Markers in T-cells 
The phenotypic link between anergy and RA (Carruthers et al., 1996, Ali et al., 
2001) initiated a study to determine gene expression profiles of anergic T-cells 
and T-cells from established RA patients. In order to help interpret some of the 
characteristic RA cellular defects, transcriptional similarities between anergic 
and RA synovial T-cells were explored using the CD4+ T-cell clone, HA1.7, 
developed by Lamb et al., (1983). This clone is responsive to the influenza virus 
HA1 peptide 306-329 and will differentially respond when stimulated with 
different concentrations of HA1 peptide. Stimulating this clone with low doses of 
peptide (1 μg/ml) induces T-cell proliferation, but increasing the dose (300 
μg/ml) stunts T-cell proliferation (Lamb et al., 1983), yet the cells remain viable 
as they respond to IL-2 (Figure 5). Comparison of the transcriptomes of T-cell 
anergy and RA synovium identified 11 transcriptional events that were common 
to both the anergic phenotype and the RA synovium. One example of this is the 
down-regulation of calmodulin seen in both anergy and the RA synovium, 
potentially linking the anergic state in HA1.7 with the hyporesponsiveness of RA 
T-cells. Calmodulin is a calcium-binding protein that binds [Ca]i and regulates 
other calcium-dependent proteins (Ali et al., 2001). 
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Figure 5. Induction of anergy in the human CD4+ T-cell clone, HA1.7 
(A) HA1.7 (   ), or HA2.61 (   ) were cultured in the presence of differing concentrations of peptides 20 or 11, respectively and proliferation 
was measured by 3HTdR incorporation after a 72 hour culture. Results are expressed as mean counts per minute (CPM) ± SEM of 
triplicate cultures. Figure taken from Lamb et al., (1983). (B) HA1.7 was incubated with peptide HA 306-318 for 24 hours (anergy) or with 
medium alone (control). The anergic state of the cells was subsequently tested by an immunogenic challenge for 48 hours of stimulation, 
measured as 3HTdR incorporation. Viability was confirmed by responsiveness to exogenous IL-2. Figure adapted from Ali et al., (2001). 
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To further investigate the different signalling mechanisms in activated and 
anergic T-cells, comparisons were made between the gene expression profiles 
of the activated and anergised CD4+ T-cell clone, by differential display (Isaacs, 
J.D., unpublished data), and identified 37 differentially regulated gene 
transcripts 2hr or 24hr post-manipulation (Figure 6). Several of the identified 
genes have subsequently been validated for playing a role in anergy. For 
example, src-like adaptor protein (SLAP), which was not documented to be 
expressed by T-cells at the time of the original work, has been shown by others 
to be important in down-regulating thymocyte and T-cell responses (Myers et 
al., 2006, Loreto et al., 2002). In our group, interest was drawn to one gene 
which was differentially expressed between these two states, CLDND1. At a 2hr 
time-point, the levels of CLDND1 were similar in the anergic state compared to 
the resting state but fell dramatically in the activated state (Figure 6A). By 
24hrs, the levels of CLDND1 were slightly elevated in the anergic state, but still 
remained low in the activated cells compared to the resting state (Figure 6B). 
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Figure 6. Gene expression profiling in the HA1.7 CD4+ T-cell clone identified CLDND1 to be differentially regulated between 
activation and anergy 
The HA1.7 clone was either activated or anergised with the influenza virus HA1 peptide 306-329 (as described in Ali et al., (2001)) and 
differential display was performed to identify gene expression profile changes compared to GAPDH. (A) 2hr time-point, post induction. (B) 
24hr time-point, post induction. CLDND1 transcript is highlighted in red. 
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1.11 CLDND1 
1.11.1 Discovery of the CLDND1 gene 
CLDND1 was originally identified in the human brain, through the screening of 
an array of clones from the IMAGE Consortium cDNA library 1NIB from infant 
brain, followed by macro-array analysis of CLDND1 expression in a variety of 
tissues. These findings were then confirmed using northern blot analysis of 8 
human tissues (pancreas, kidney, skeletal muscle, liver, lung, placenta, brain 
and heart) showing the 2.8 kb CLDND1 transcript levels to be predominantly 
expressed in brain tissue and faint expression in the heart. Northern blot 
analysis of different regions of the human CNS identified signals of varying 
intensities in all the regions tested, with the most intense signals identified in 
areas corresponding to myelin-rich structures such as the corpus callosm, 
spinal cord and medulla. Based on these expression profiles, CLDND1 
expression in oligodendrocytes was identified by quantitative real-time PCR 
(qRT-PCR). The coding region of the CLDND1 gene was determined using the 
Netstart programme and ATGpr, resulting in a transcript of 880 nucleotide long 
5’ untranslated region (UTR), followed by a 759 nucleotide open reading frame 
(ORF) followed by a 3’ untranslated sequence of 1.2 kb (Fayein et al., 2002). 
1.11.2 Predicted CLDND1 protein characteristics 
C3orf4, which is now known as CLDND1, is the putative protein encoded from 
the identified coding region above. The CLDND1 protein sequence was 
processed by the BLAST 1 BEAUTY application, followed by Pfam HMM, 
TMHMM, ScanProsite and LALIGN (ExPASy) to analyse protein motifs and 
local alignment. Alternative splicing of the message can generate six transcript 
variants (variants 1-4, 6-7), from which 3 protein isoforms can be translated 
(isoforms A, B and D) (Figure 7). Transcript variants 1, 2, 3 and 6 encode the 
253 amino acid protein isoform A, while transcript variant 4 encodes protein 
isoform B: a 276 amino acid protein. Sequence alignments indicate a longer N-
terminus on isoform B than isoform A (Figure 7). Transcript variant 7 encodes a 
shorter 158 amino acid isoform D. The membrane topology was also described 
for each isoform, with the presence of four transmembrane domains at positions 
5–27, 141–163, 175–197 and 212–234 for isoforms A and B, and three 
transmembrane regions for isoform D. Transmembrane regions correlate with 
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hydrophobic stretches of amino acids as seen on a hydrophobicity chart. 
Several putative glycosylation and phosphorylation sites were also predicted 
(Figure 7). Local alignments were identified in the third transmembrane domain 
with similar sites in the domain of human and mouse peripheral myelin protein 
22-growth arrest specific protein (PMP-22), which identified a consensus 
sequence with the PMP-22/EMP/MP20/claudin superfamily (Fayein et al., 
2002). 
 
A -----------------------MDNRFATAFVIACVLSLISTIYMAASIGTDFWYEYRS 37 
B MGGDRLENKTSVSVASWSSLNARMDNRFATAFVIACVLSLISTIYMAASIGTDFWYEYRS 60 
D ------------------------------------------------------------ 
 
A PVQENSSDLNKSIWDEFISDEADEKTYNDALFRYNGTVGLWRRCITIPKNMHWYSPPERT 97 
B PVQENSSDLNKSIWDEFISDEADEKTYNDALFRYNGTVGLWRRCITIPKNMHWYSPPERT 120 
C ----------------------------------------------------------MG 2 
 
A ESFDVVTKCVSFTLTEQFMEKFVDPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALI 157 
B ESFDVVTKCVSFTLTEQFMEKFVDPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALI 180 
C ESFDVVTKCVSFTLTEQFMEKFVDPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALI 62 
************************************************************ 
 
A GLCACICRSLYPTIATGILHLLAGLCTLGSVSCYVAGIELLHQKLELPDNVSGEFGWSFC 217 
B GLCACICRSLYPTIATGILHLLAGLCTLGSVSCYVAGIELLHQKLELPDNVSGEFGWSFC 240 
D GLCACICRSLYPTIATGILHLLAGLCTLGSVSCYVAGIELLHQKLELPDNVSGEFGWSFC 122 
************************************************************ 
 
A LACVSAPLQFMASALFIWAAHTNRKEYTLMKAYRVA 253 
B LACVSAPLQFMASALFIWAAHTNRKEYTLMKAYRVA 276 
D LACVSAPLQFMASALFIWAAHTNRKEYTLMKAYRVA 158 
  ************************************ 
 
Figure 7. Sequence alignment of CLDND1 protein isoforms 
CLDND1 isoforms (A, B and D) were aligned using clustalW2. Transmembrane 
regions and potential post-translational modifications were taken from 
www.unitprot.org or www.phosphosite.org. * indicates identical amino acids 
between the isoforms. Underlined regions indicate transmembrane regions. Red 
residues indicate potential N-glycosylation sites, orange residues indicate 
potential ubiquitination sites, purple residues highlight the PMP-
22/EMP/MP20/claudin superfamily consensus sequence and blue residues 
indicate potential phosphorylation sites. 
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1.11.3 The PMP-22/EMP/MP20/claudin superfamily  
The PMP-22/EMP/MP20/claudin superfamily is comprised of a diverse range of 
proteins with a large variation in function. The major components of this 
superfamily are the clarin family (IPR026748), the PMP-22/EMP/MP20 family 
(IPR004032), the claudin family (IPR006187) and the voltage-dependent 
calcium channel, gamma subunit family (CACNG) (IPR008368). These 
superfamily members all share a similar tetraspanning transmembrane topology 
with intracellular N- and C-termini. The similarity of the functional motifs in the 
superfamily members are illustrated in Figure 8. 
1.11.4 The clarin family 
The clarin family consist of clarins -1, -2 and -3. Clarin-1 is also known as Usher 
syndrome type-3 protein as mutations in the gene coding for this protein cause 
Usher syndrome type 3 (USH3), which is a genetically heterogeneous condition 
characterised by the association of retinitis pigmentosa and sensorineural 
deafness (Aller et al., 2004). The functions of clarin-2 and clarin-3 are not clear. 
1.11.5 The PMP-22/EMP/MP20 family 
PMP-22 and epithelial membrane protein (EMP)-1, -2 and -3 are highly similar, 
while movement protein (MP)20 is more distantly related. The roles of PMP-22 
are still being investigated, but it is known to be involved in promoting and 
maintaining the myelin sheath: an important insulator of axons. PMP-22 also 
has a role in controlling cell proliferation, apoptosis and adhesion (Zoidl et al., 
1995, Roux et al., 2005, Fabbretti et al., 1995). Circular dichroism and nuclear 
magnetic resonance (NMR) show that PMP-22 has an alpha-helical secondary 
structure, with four transmembrane spanning regions, and the protein has 
strong tendencies to dimerise (Mobley et al., 2007). The PMP-22 deletion 
results in hereditary neuropathy with liability to pressure palsies (HNPP) 
(Mouton et al., 1999) and its duplication results in Charcot–Marie–Tooth 1A 
(CMT1A) disease (Birouk et al., 1997). PMP-22 is also regulated by N-
glycosylation in the first extracellular loop and this is required for its cell surface 
location (Brancolini et al., 2000).
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Figure 8. CLDND1 protein motif comparison to PMP-22/EMP/MP20/claudin superfamily members 
PMP-22/EMP/MP20/claudin superfamily proteins were grouped according to EBI classification. Transmembrane regions and potential 
post-translational modifications were taken from uniprot (http://www.uniprot.org/) or cell signalling phosphosite plus 
(http://www.phosphosite.org). Individual family members with specific motifs are labelled. 
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The EMP family members bind to a family of ATP-gated ion channels and also 
play a role in inducing apoptosis in cell culture models (Wilson et al., 2002). The 
EMPs are expressed in a wide range of tissues, including heart, placenta, lung, 
skeletal muscle, kidney and small intestine and blood leukocytes (Chen et al., 
1997, Taylor and Suter, 1996). A positive role for EMP-1 in proliferating cells 
has also been suggested (Ben-Porath and Benvenisty, 1996), while EMP-2 also 
has a suggested role in cell adhesion (Wadehra et al., 2002).  
MP20, subsequently renamed to lens intrinsic membrane protein (LMIP), is 
expressed at extremely high levels in the mammalian eye lens. LMIP has a 
suggested role in signal transduction as it is phosphorylated by cyclic adenosine 
monophosphate (cAMP)-dependent kinases (Galvan et al., 1989), and a 
proposed function as a barrier protein in the eye (Grey et al., 2003), yet its exact 
role is still to be elucidated. 
1.11.6 The claudin family 
There are 23 members of the claudin family in humans, ranging from 20 to 34 
kDa in size (Lal-Nag and Morin, 2009). Immunofluorescence studies have 
identified claudins to be located at tight junctions (TJ) (Furuse et al., 1998) and 
their role in TJ function to be important (Tsukita and Furuse, 2000). TJ are 
found at the most apical regions of polarised epithelial and endothelial cells and 
function as a barrier to prevent paracellular transport of solutes and to maintain 
cellular polarity by preventing lateral diffusion of membrane lipids and proteins 
(Lal-Nag and Morin, 2009). 
Claudin family members show the most heterogeneity in their C-terminal tail, yet 
all claudins contain a PDZ-domain-binding motif that enables claudins to 
interact directly with cytoplasmic scaffolding proteins such as the zona 
occludens (ZO) family (Itoh et al., 1999). The C-terminal tail is also a site of 
various post-translational modifications that can alter claudin localisation and 
function (Van Itallie et al., 2005, D'Souza et al., 2005, Aono and Hirai, 2008, 
Ishizaki et al., 2003, Ikari et al., 2006). The functions of claudins have been 
determined through the over-expression or down-regulation of claudin genes in 
a variety of epithelial cell lines and generally they determine the selectivity of 
paracellular transport of small ions. Specific functions of claudin family 
members vary depending on the ion and the system in which it is studied 
(Angelow et al., 2008). 
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Various human diseases have shown the importance of the claudin family 
members in TJ function. Mutations of claudin-16 and -19 are associated with 
familial hypomagnesemia with hypercalciurea and nephroclacinosis (FHHNC), a 
rare magnesium wasting disorder as a result of loss of Mg2+ from malfunctioning 
kidneys (Simon et al., 1999, Konrad et al., 2006). Claudins are also 
dysregulated in different cancers which is consistent with TJ disassembly during 
tumourigenesis (Kramer et al., 2000, Resnick et al., 2005). 
1.11.7 The voltage-dependent calcium channel, gamma subunit family  
Voltage dependent calcium channels (VDCC) allow the coupling of electrical 
activity to [Ca]i signalling. The activity of the channel is regulated by four tightly 
coupled subunits: the pore forming α-1, an intracellular β, a disulphide-linked 
complex of an α-2 and δ and the CACNG (Catterall et al., 2003). The α, δ and β 
subunits act as the pore forming unit and aid channel function, while original 
studies identified the CACNG to regulate the channel (Eberst et al., 1997, Letts 
et al., 1998). Current understandings suggest a more diverse role for CACNG in 
the regulation of other channels as well (Chen et al., 2007). The suggested 
functional and phylogenetic attributes of CACNG have resulted in their division 
into three groups the γ-2, γ-3, γ-4 and γ-8 subunits are known to act as 
transmembrane 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
(AMPA) receptor regulatory proteins (TARP) (Osten and Stern-Bach, 2006), γ-1 
and γ-6 are known to regulate VDCC (Freise et al., 2000, Hansen et al., 2004), 
while γ-5 and γ-7, which have received the least attention, have been shown not 
to be important in AMPA receptor trafficking and have conflicting evidence for a 
role in VDCC signalling (Chen et al., 2007). 
All CACNG contain N-linked glycosylation sites in the first extracellular loop 
(Chen et al., 2007); yet other functional motifs are distinct within the subunit 
clusters. TARP contain a number of regulatory sites in their C-terminal domain, 
including a PDZ-binding domain, which is important for targeting AMPA 
receptors to the synapse and acts as a phosphorylation site for PKA, PKC and 
PKD, which is important for regulating the interactions between TARP and 
AMPA receptors (Choi et al., 2002) The PDZ-binding domain is lacking in the γ-
1 and γ-6 or γ-5 and γ-7 subunits. The C-terminal domain of γ-1 and γ-6 are 
very short and lack functional motifs.  
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The original identification of CACNG was the identification of CACNG2 in the 
stargazin mutant mouse model, which characteristically had spontaneous 
abnormal head movements and absence seizures with accompanying defects 
in the cerebellum and inner ear (Letts et al., 1998), yet its role in human disease 
is yet to be described. 
1.11.8 Potential CLDND1 function based on the PMP-22/EMP/MP20/claudin 
family 
Given the diverse functional roles of the PMP-22/EMP/MP20/claudin 
superfamily members in a range of cell types, it would be difficult to ascribe a 
specific potential function for CLDND1 in T-cells, from these members’ 
functions. There are, however, similar functional processes that are common 
between these family members that are also common to T-cells. A large 
proportion of the superfamily (all the claudins, PMP-22, LMIP and the EMP) 
have confirmed roles in barrier function or cell adhesion. This may suggest that 
CLDND1 may also play a role in inter-cellular contacts. Other family members 
have been identified to be important in controlling cell proliferation and 
apoptosis (PMP-22 and EMP), and also in the regulation of calcium signalling 
(CACNG), which both may be linked to the control of T-cell activation, as 
discussed throughout this chapter, and could potentially link to a function for 
CLDND1.  
1.11.9 CLDND1 gene function 
From the literature, there are only a handful of documented cellular expression 
data for the CLDND1 protein. Gene expression was first described in rat optic 
nerve cells, in particular on the oligodendrocyte population and so a role for 
CLDND1 in myelination of the central nervous system was suggested (Fayein et 
al., 2002). The increasing popularity of RNA microarray analysis of cell types 
has subsequently lead to the identification of CLDND1 gene expression in 
mouse hepatoma Hepa-1c1c7 cells (Hao et al., 2012) and within whole blood 
(Beineke et al., 2012), yet its detection in CD4+ T-cells remained elusive. 
CLDND1 has been found to be up-regulated in at least 80 % of lung squamous 
cell carcinomas (Liu et al., 2007), yet its role in these cells still needs to be 
determined. Advances in mass spectrometric techniques have recently 
identified CLDND1 protein on both HEK293 cells and human U2OS 
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osteosarcoma cells, yet no inference was made to its function; apart from the 
observation that CLDND1 protein can be ubiquitinated, and so is probably 
targeted for degradation in this manner (Kim et al., 2011, Wagner et al., 2011, 
Danielsen et al., 2011). There is currently no CLDND1-/- mouse available and so 
no function for CLDND1 can be determined from these types of studies. 
1.11.10 Pilot data indicating a function for CLDND1 in CD4+ T-cells 
Preliminary studies in the Isaacs’ lab looked at the effect of CLDND1 on CD4+ 
T-cell function (Isaacs, J.D., unpublished data). In primary human CD4+ T-cells, 
CLDND1 transcript was targeted for degradation using CLDND1 siRNA 
(siGENOME Smartpool), or over-expressed using two vectors: 
pcDNA3.2/GW/V5 (Life technologies, Paisley UK) or the pIRES2- H2Kk 
expression system (Tahvanainen et al., 2006). The use of the H2Kk expression 
vector system allowed for CLDND1 transfected cells to be sorted from the 
untransfected cells due to the co-expression of a truncated H2Kk mouse 
molecule with CLDND1. Silencing of the CLDND1 transcript was determined by 
qRT-PCR and was calculated at 70-75 %, while transfection efficiency for over-
expression was determined using an e-green fluorescent protein (GFP) 
expression vector (Amaxa, Lonza, Castleford, UK) and calculated at 50 %. 
Silencing of the CLDND1 gene resulted in an increase in transfected T-cell 
proliferation, compared to control cells (Figure 9A). The effect of CLDND1 over-
expression on T-cell proliferation was dependent on the vector used. Use of the 
pcDNA3.2/GW/V5 vector, in which only a proportion of the cells expressed 
CLDND1, resulted in an increase in transfected T-cell proliferation (Figure 9B), 
whereas use of the pIRES2- H2Kk vector (Figure 9C), where all the cells were 
both CLDND1 and H2Kk positive, showed that CLDND1 reduced T-cell 
proliferation. From these data, it was hypothesised that the differences in mixed 
and pure CLDND1-transfected CD4+ T-cell populations may be caused by 
paracellular homotypic interactions between CLDND1 molecules. Alternatively, 
the use of the different expression vectors may have resulted in different 
transfection efficiencies, or affected the viability of the cells. These preliminary 
results suggest a potential role for CLDND1 in inducing a hypo-proliferative T-
cell phenotype, however CLDND1 protein expression was not determined and 
cell viability was not measured in these limited experiments, and further 
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investigations are required to investigate these parameters and further elucidate 
a role for CLDND1 in T-cell tolerance. 
 
 
 
 
Figure 9. Preliminary work: targeting CLDND1 in primary human CD4+ T-
cells reveals a potential role for CLDND1 in the regulation of T-cell 
proliferation 
CLDND1 was silenced (A), or over-expressed (B and C) in primary human 
CD4+ T-cells. Over-expression was performed with two vectors (B) V5-tagged 
CLDND1 in pcDNA3.2 or (C) CLDND1 in pIRES-H2Kk. 24 hours after 
transfection, cells were stimulated with 1:1 ratio of α-CD3/CD28 expander 
beads for 3 days and T-cell proliferation was measured by 3HTdR incorporation. 
Data illustrate a single experiment. 
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1.12 Hypothesis and Aims of the Thesis 
T-cell activation is under tight regulation to prevent aberrant activation of self-
reactive T-cells. A consequence of a breakdown in immunological self-tolerance 
may lead to autoimmune diseases such as RA. An important therapeutic goal in 
RA is the reversal of the breakdown in tolerance in order to provide a potential 
cure. RA T-cell phenotyping revealed similarities to anergic cells and so 
identifying key players in anergy may yield a potential therapeutic target. 
CLDND1 expression was differentially regulated during T-cell anergy and 
activation and preliminary studies suggest a role for this protein in the regulation 
of T-cell activation. Thus it was hypothesised that CLDND1 may mediate a key 
mechanism in the regulation of T-cell proliferation and, given its cell surface 
location, may provide a novel therapeutic target. 
The main aims of this thesis were: 
 To generate polyclonal antibodies (pAbs) against CLDND1 in order to 
verify CLDND1 protein expression on CD4+ T-cells 
 Document CLDND1 expression during T-cell activation 
 Identify CLDND1 expression in early RA patients as both a potential 
biomarker of early disease and for a role in disease pathogenesis  
 Modulate CLDND1 expression by silencing or over-expressing CLDND1 
in primary human CD4+ T-cells, to strengthen its hypothesised function 
in the regulation of T-cell proliferation 
 To confirm a role for CLDND1 in anergy 
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Chapter 2. Methods 
2.1 List of Materials 
2.1.1 Stocks 
Stock solutions were prepared, aliquoted and stored as described below.  
4 % formaldehyde: paraformaldehyde (VWR International, Lutterworth, UK) was 
added to phosphate buffered saline (PBS) for a 4 % (w/v) solution and warmed 
between 55-60°C until dissolved. The stock was aliquoted and stored at -20°C. 
5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE): under aseptic 
conditions, CFSE (SIGMA Aldrich, Poole, UK) was reconstituted to 10 mM stock 
solutions with dimethyl sulfoxide (DMSO), aliquoted and stored at -20°C. 
Accell siRNA: under aseptic conditions, Accell siRNA (Thermo Scientific, 
Loughborough, UK ) was resuspended to 100 µM stocks with 1x Accell siRNA 
buffer (Thermo Scientific). Aliquots were stored at -20°C. 
ELISA standards: 2 µg/ml stock of recombinant human IL-2, IL-10, IFN-γ and 
TNF-α (all BD Bioscience, Oxford, UK) were prepared in PBS (Lonza) + 10 
mg/mL albumin from bovine serum (BSA) (SIGMA Aldrich) and stored at -80°C. 
Stocks were diluted 1/1000 in PBS + 1 % BSA for the top ELISA standard. 
Fetal bovine serum (FBS): FBS (Lonza) was thawed at 37°C then heat-
inactivated at 56°C in a water bath for 1 hour. Under aseptic conditions, the 
FBS was then aliquoted and re-frozen at -20°C. 
Glutamine solution: sterile glutamine solution [200 mM] (SIGMA Aldrich) was 
thawed at 37°C and was aliquoted and refrozen at -20°C. 
LB media: 20.6 g of LB broth EZMix Powder (SIGMA Aldrich) was dissolved in 1 
L deionised H2O and autoclaved. 
Methyl-3H thymidine (3HTdR): under aseptic conditions, 3HTdR (Perkin Elmer, 
Massachusetts, USA) was added to RPMI-1640 (Lonza) to generate a working 
stock of 0.548 MBq/mL and stored at 4°C. 
o-Phenylenediamine dihydrochloride (OPD): each OPD tablet (SIGMA Aldrich) 
was dissolved in 13 mL citrate phosphate buffer (25 mM citric acid, 50 mM 
disodium phosphate, 20 mM sodium phosphate dibasic dihydrate) before use, 
along with 6 µL 30 % hydrogen peroxide solution (SIGMA Aldrich). 
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Penicillin and streptomycin: sterile penicillin [10,000 units/mL] and streptomycin 
[10 mg/mL] solution (SIGMA Aldrich) was thawed at 37°C. Under aseptic 
conditions, the solution was aliquoted and re-frozen at -20°C. 
SB-505124: under aseptic conditions, lyophilised SB-505124 hydrochloride 
hydrate (SIGMA Aldrich) was reconstituted to 28.7 mM with DMSO (SIGMA 
Aldrich) and stored in aliquots at -20°C, for a maximum of 1 month. 
Tissue culture cytokines: the following reagents were prepared under aseptic 
conditions: 
IL-4 lyophilised powder (Miltenyi Biotech, Bergisch Gladbach, Germany) was 
resuspended to 50 µg/mL in RF-1 (RPMI-1640 medium, 2 mM L-glutamine, 100 
U/mL penicillin, 1 μg/mL streptomycin, 1 % FBS). Aliquots were stored at -20°C.  
Recombinant human granulocyte macrophage colony-stimulating factor (GM-
CSF) (Genzyme, Oxford, UK) was resuspended to 250 µg/mL in RPMI-1640 
then further diluted to 5 µg/mL in RF-1, aliquoted and stored at -20°C.  
Dexamethasone (SIGMA Aldrich) was reconstituted to 1 mg/mL (2.55x10-3 M) in 
ethanol then further diluted 25.5x in RPMI-1640 to give a 1x10-4 M stock 
solution. Aliquots were stored at -20°C.  
Calcitrol (vitamin D3) (Tocris Bioscience, Abingdon, UK) was resuspended to 
2.4x10-3 M in ethanol then diluted further in ethanol to 1x10-4 M and stored in 
aliquots at -20°C. For use, ethanol was added to each stock to make a 1x10-6 M 
solution, then this was diluted 1/100 to give a 1x10-8 M solution in RF-10 (RPMI-
1640 medium, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin, 10 
% FBS) and used immediately.  
LPS from Escherichia coli 0111:B4 (SIGMA Aldrich) was reconstituted to 1 
mg/mL in RF-1. Aliquots were stored at -20°C. From this, a working stock of 10 
µg/mL was prepared in RF-1 and kept for 1 month at 4°C.  
Recombinant human TGF-β1 (Peprotech, London, UK) was reconstituted to 1 
µg/mL in RF-1 and aliquots were stored at -20°C. 
Trypsin: sterile trypsin solution (SIGMA Aldrich) was thawed at 37°C. Under 
aseptic conditions, the solution was then aliquoted into 5 mL volumes and re-
frozen at -20°C until required for tissue culture media. 
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2.1.2 Antibodies 
Primary antibody Manufacturer Clone Catalogue Dilution 
Alexa Fluor® 647 α-human Foxp3 BioLegend 206D 320114 1/50 
Annexin V- allophycocyanin BD Bioscience - 550474 3 μL/test 
α-human CD3- allophycocyanin eBioscience UCHT1 17-0038-43 1/200 
α -human CD3- fluorescein isothiocyanate BD Bioscience HIT3a 555339 1/10 
α-human CD3- peridinin chlorophyll protein  BD Bioscience SK7 345766 1/20 
α-human CD4- fluorescein isothiocyanate eBioscience RPA-T4 11-0049-42 1/200 
α-human CD4- phycoerythrin cyanin7 eBioscience SK3 25-0047-42 1/50 
α-human CD4- peridinin chlorophyll protein  BD Bioscience SK3 345770 1/20 
α-human CD8- allophycocyanin BD Bioscience RPA-T8 555369 1/20 
α-human CD8- peridinin chlorophyll protein  BD Bioscience SK1 345774 1/20 
α-human CD14- fluorescein isothiocyanate BD Bioscience M5E2 555397 1/20 
α-human CD19- allophycocyanin BD Bioscience HIB19 555415 1/20 
α-human CD25- fluorescein isothiocyanate BD Bioscience M-A251 555431 1/20 
α-human CD25-phycoerythrin BD Bioscience M-A251 555432 1/20 
α-human CD28- fluorescein isothiocyanate BD Bioscience CD28.2 555728 1/20 
α-human CD45RA- fluorescein isothiocyanate BD Bioscience HI100 555488 1/20 
α-human CD56- fluorescein isothiocyanate BD Bioscience NCAM16.2 345811 1/10 
α-human CD80- fluorescein isothiocyanate BD Bioscience L307.4 557226 1/50 
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Primary antibody Manufacturer Clone Catalogue Dilution 
α-human CD83- allophycocyanin BD Bioscience HB15e 551073 1/20 
α-human CD86- allophycocyanin BD Bioscience 2331 (FUN-1) 555660 1/50 
α-human CD282 (TLR2)- allophycocyanin eBioscience TL2.1 17-9922 1/10 
α-human HLA-DR- peridinin chlorophyll protein  R&D Systems L203 FAB4869C 1/20 
α-human LAP (TGF-beta 1) phycoerythrin R&D Systems 27232 FAB2463P 1/10 
     MACSelect control fluorescein isothiocyanate Miltenyi Biotech Polyclonal 130-090-326 1/10 
Mouse α- H2Kk -phycoerythrin Miltenyi Biotech H100-27.R55 130-094-867 1/10 
Via-Probe™ BD Bioscience - 555815 5 μL/test 
 
Table 3. Directly-conjugated antibodies 
A list of the directly-conjugated antibodies, along with the manufacturer and clone of antibody, used for flow cytometry. The quantity of 
antibody used for each reaction is expressed as a dilution of the antibody stock, or a set volume per reaction. 
  
 
 
 
 
 
Katherine L. Crossland                                                                                                   Chapter 2. Methods 
36 
Primary antibody Manufacturer Clone 
Dilution 
Flow cytometry Western blot Immunofluorescence 
α-CLDND1 (in-house) UCB Celltech Polyclonal 1 μg/test 1 μg/mL - 
α-CLDND1 pre- and anti-sera UCB Celltech Polyclonal 1/100, 1/2000 1/100 1/100 
Goat α-human-CLDND1 Santa Cruz Polyclonal 5 μg/mL 1 μg/mL - 
Mouse monoclonal α-FLAG® M2  SIGMA Aldrich M2 - - 1/100 
Mouse monoclonal α-α-tubulin SIGMA Aldrich B-5-1-2 - 1/1000 - 
Rabbit α-human-CLDND1 ProSci Polyclonal 5 μg/mL 1 μg/mL - 
Rabbit α-human-CLDND1 Abcam Polyclonal 5 μg/mL 1 μg/mL - 
Rabbit α-human-CLDND1-SIGMA 1 SIGMA Aldrich Polyclonal 1 μg/mL 1 μg/mL - 
Rabbit α-human-CLDND1-SIGMA 2 SIGMA Aldrich 
Cell Signaling 
Technology 
Polyclonal 1 μg/mL 1 μg/mL - 
- 
Rabbit α-DYKDDDDK tag  
ll i li  
c l y 
Polyclonal - 1/1000 - 
Rabbit α-GAPDH  XP® 
Cell Signaling 
Technology 
D16H11 - 1/10000 - 
 
Table 4. Primary antibodies 
A list of the primary antibodies, along with the manufacturer and clone of antibody where applicable, used for flow cytometry, Western 
blot and immunofluorescence techniques. The quantity of antibody used for each reaction is expressed as a dilution of the antibody 
stock, or a set concentration or amount per reaction.
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Secondary antibody Manufacturer 
Dilution 
Flow cytometry Western blot Immunofluorescence 
Alexa Fluor® 488 goat α-rabbit IgG (H+L) Molecular Probes - - 1/750 
Alexa Fluor® 594 goat α-mouse IgG (H+L)  Molecular Probes - - 1/750 
Alexa Fluor® 594 goat α-rabbit IgG antibody, 
ReadyProbes™ reagent   
Molecular Probes - - 1/750 
α-mouse IgG (H+L) HRP-linked Cell Signaling Technology - 1/3000 - 
α-rabbit IgG (H+L) HRP-linked Cell Signaling Technology - 1/3000 - 
Fluorescein isothiocyanate-affinipure F(ab')2 
fragment goat α-rabbit IgG, Fc fragment 
specific 
Jackson ImmunoResearch 1/100 - - 
Goat serum SIGMA Aldrich 2 % - 2 % 
Human IgG (138.5 mg/ml) Gift from Sophie Hambleton 0.2 μg/test - - 
R-phycoerythrin-affinipure F(ab')2 fragment 
goat α-rabbit IgG (H+L) 
Jackson ImmunoResearch 1/200 - - 
 
Table 5. Secondary antibodies 
A list of secondary antibodies, along with the manufacturer, used to detect the primary antibodies used in flow cytometry, Western blot or 
immunofluorescence techniques. The quantity of antibody used for each reaction is expressed as a dilution of the antibody stock, a 
percentage of the final reaction volume, or a set amount per reaction. 
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2.1.3 Buffers 
 
Buffer alias Components 
T
is
s
u
e
 c
u
lt
u
re
 
RF-10 RPMI-1640 medium, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin, 10 % FBS 
RF-5 RPMI-1640 medium, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin, 5 % FBS 
RF-1 RPMI-1640 medium, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin, 1 % FBS 
RF-0 RPMI-1640 medium, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin 
Amaxa culture medium RPMI-1640 medium, 4 mM L-glutamine, 10 % FBS 
SW1353 culture medium DMEM, high glucose, 2 mM L-glutamine, 100 U/mL penicillin, 1 μg/mL streptomycin, 10 % FBS 
Rab-9 culture medium RPMI-1640 medium + 10 % FBS + 1 mM L-glutamine +100 µg/mL normacin (InvivoGen) 
MACS Buffer PBS pH 7.2, 0.5 % BSA, 2 mM EDTA 
D
N
A
 1xTAE 40 mM tris-acetate pH 8, 1 mM EDTA 
TAE-agarose loading buffer 0.125 M tris pH 6.8, 2% (w/v) SDS, 10 % (v/v) glycerol, 0.001 % bromophenol blue 
P
ro
te
in
 
id
e
n
ti
fi
c
a
ti
o
n
 RIPA lysis buffer 
50 mM tris HCl pH 8, 150 mM NaCl, 1 % (v/v) triton-X 100, 0.5 % (v/v) sodium deoxycholate, 
0.1 % SDS (w/v), protease inhibitor cocktail (Roche) 
Triton-X permeabilisation 
buffer 
PBS pH 7.2, 0.5 % (w/v) BSA, 1 % (v/v) fish skin gelatin, 0.5 % (v/v) triton-X 100  
Coomassie brilliant blue 
R250 staining buffer 
45 % methanol, 10 % glacial acetic acid, 45 % water, 3 g/L coomassie brilliant blue R250 
Coomassie destaining buffer 45 % methanol, 10 % glacial acetic acid, 45 % water 
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 Buffer alias Components 
5x laemmli loading buffer 
0.1 M tris HCl, pH 6.8, 0.35 M SDS, 20 % (v/v) glycerol, 0.01 % bromophenol blue and 5 % 
(v/v) β-mercaptoethanol 
Transfer buffer 20 mM tris HCL, 0.65 M glycine, 20 % (v/v) methanol 
TBS-T 10 mM tris pH 7.5, 150 mM NaCl, 0.1 % tween 20 (v/v) 
Red blood cell lysis buffer 0.1 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA 
10X Annexin V binding buffer 0.1 M HEPES, pH 7.4, 1.4 M NaCl, 25 mM CaCl2 
FACS buffer PBS pH 7.2, 3 % (v/v) FBS, 100 μM (v/v) EDTA, 0.01% (v/v) sodium azide 
E
L
IS
A
 
Citrate phosphate buffer 25 mM citric acid, 50 mM disodium phosphate, 20 mM sodium phosphate dibasic dihydrate 
Coating buffer 15 mM disodium phosphate, 20 mM monosodium phosphate sodium phosphate monobasic 
ELISA wash buffer PBS pH 7.2+ 0.1 % (v/v) tween 20 
Blocking buffer PBS pH 7.2 + 1 % (w/v) BSA 
Diluent PBS pH 7.2 + 1 % BSA + 0.1 % (v/v) tween 20 
 
Table 6. Buffers 
Alias and composition of the buffers used for tissue culture, molecular biology (DNA), protein identification and ELISA techniques.
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2.2 Vector Generation 
The CLDND1-autofluorescent protein (AFP) vector was pre-made by Kerry 
Tyson (UCB Celltech). All vector information can be found in Table 7. 
2.2.1 PCR amplification of DNA inserts 
The human CLDND1 (UCB) fragment, stuffer fragment and immunoglobulin κ 
light chain fragment were pre-amplified and digested with HindIII and EcoRI 
restriction enzymes by Kerry Tyson (UCB Celltech). CLDND1 cDNA was 
purchased from abgene (MHS1010-58003). The CLDND1 (UCB) fragment and 
CLDND1 abgene sequences differ in their nucleotide composition.CLDND1 
(UCB) was codon-optimised for mammalian expression (performed by Kerry 
Tyson, UCB Celltech) yet both translated proteins have the same protein 
sequence. All vectors generated from UCB Celltech (PIMMS2011, pQBI25-fN1, 
pVSV40E-ELF, pVSV40E-FerL, pVSV40E-hCMV and pKH10) utilised the 
CLDND1 (UCB) insert, whereas the remaining vectors contained the abgene 
CLDND1 sequence. Amplification of the CLDND1 abgene cDNA sequence was 
required to generate CLDND1-FLAG and CLDND1-H2K. CLDND1 (UCB) 
sequence amplification was required to generate human CLDND1 (UCB)-
truncated, human CLDND1 (UCB)-GPI1 and human CLDND1 (UCB)-GPI2 
sequences. 
For CLDND1 abgene cDNA sequence amplification, the following 20 µL 
reaction mix was created, according to manufacturer instruction: 2 ng of 
CLDND1 cDNA, 0.1 U Phusion hot start II high-fidelity DNA polymerase 
(Thermo Scientific), 500 nM forward and reverse primers. The sample mix was 
subjected to the following cycle conditions in a PCR thermocycler: 98°C for 30 
seconds; then 25 cycles of 98°C (10 seconds), 69-80°C (30 seconds) and 72°C 
(90 seconds), followed by a final extension time at 72°C for 5 minutes. 
For human CLDND1 (UCB)-truncated, human CLDND1 (UCB)-GPI1 and 
human CLDND1 (UCB)-GPI2 sequence generation, 50 ng of human CLDND1 
(UCB) sequence was used as a template and amplification was performed 
using 1 U Platinum® Taq DNA polymerase high fidelity (Thermo Scientific) with 
400 nM forward and reverse primers in a 50 µL reaction mix according to 
manufacturer instruction. The samples were subjected to the following cycle 
conditions in a PCR thermocycler: 94°C for 60 seconds; then 40 cycles of 94°C 
Katherine L. Crossland                                                                                    Chapter 2. Methods 
41 
(30 seconds), 68-75°C (30 seconds) and 68°C (60 seconds), followed by a final 
extension time at 68°C for 5 minutes. 
A 5 µL aliquot of each PCR reaction was run on a 1 % (w/v) tris-acetate-
ethlenediamine tetraacetic acid (TAE) (tris-acetate 40 mM pH 8, 1 mM EDTA)-
agarose gel, in loading buffer (0.125 M tris pH 6.8, 2 % (w/v) sodium dodecyl 
sulphate (SDS), 10 % (v/v) glycerol, 0.001 % bromophenol blue). Bands were 
visualised with 0.02 % ethidium bromide (SIGMA Aldrich) on a G:BOX Chemi 
system (Syngene, Cambridge, UK) to confirm construct sizes. The PCR 
products were then purified from the remaining sample using the QIAquick PCR 
purification kit (Qiagen, Crawley, UK), according to manufacturer instruction and 
eluted in 50 µL DNase and RNase free H2O (SIGMA Aldrich) 
2.2.2 Restriction digests  
PCR products and vectors (5 µL) were digested with 10 U of the each restriction 
enzymes (see Table 7) (all Thermo Scientific) in a total volume of 20 µL. Vector 
digests were run on a 1 % TAE-agarose gel as described above to verify correct 
digestion. The digested vector was incubated with 1 U FastAP thermosensitive 
alkaline phosphatase (Thermo Scientific) at 37°C for 10 minutes to remove 5’ 
phosphate groups in order to prevent vector ends from re-joining. The vectors 
were re-purified using commercially available kits (Qiagen) as described in 
Section 2.2.1. 
2.2.3 Ligations and transformations 
Ligations were performed using 1 U T4 DNA ligase (Thermo Scientific) with a 
3:1 molar ratio of DNA to vector for at least 1 hour at room temperature (RT), 
according to manufacturer instruction. Following ligation, 3 µL of the reaction 
was transformed into 100 µL of JM109 cells (Promega, Madison, USA) or 30 µL 
of XL1-blue competent cells (Agilent, Wokingham, UK). Cells were incubated on 
ice for 10 minutes, or 20 minutes respectively. The cells were heat shocked for 
45-50 seconds at 42°C before transferring to ice for 2 minutes. 900 µL LB 
medium or 125 µL of SOC medium (Life technologies) was added, respectively 
and cells were incubated at 37°C for 90 minutes. 100-150 µL of the cell mixture 
was plated onto a 30 µg/mL kanamycin (SIGMA Aldrich) or 50 µg/mL ampicillin 
(SIGMA Aldrich) 1.5 % LB-agar plates. The next day, several colonies were 
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selected and incubated, in 5 mL LB supplemented with 30 µg/mL kanamycin or 
50 µg/mL ampicillin, at 37°C and 200 rpm overnight in an orbital shaker. 
2.2.4 In-house minipreps 
Following overnight culture, the bacteria were pelleted, resuspended in 100 µL 
P1 resuspension buffer, lysed with 200 µL P2 lysis buffer and neutralised with 
150 µL P3 neutralisation buffer (all Qiagen). The DNA-containing supernatant 
was then precipitated in 1 mL 100 % (v/v) ethanol, vortexed and centrifuged at 
13,000 x g for 10 minutes. The pellet was air dried and resuspended in 50 µL 
DNase and RNase free H2O. A 5 µL aliquot was digested using the appropriate 
restriction enzymes, as described above and run on a 1 % 1xTAE-agarose gel 
to verify the plasmids had the correct inserts. 
2.2.5 DNA sequencing  
Vector sequences were confirmed by DNA sequencing performed either by 
Genome Enterprise Limited (commercial service, Norwich, UK) using Life 
Technologies 3730XL sequencers or by UCB Celltech. At UCB Celltech, DNA 
sequencing reactions were performed using the Big Dye® Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, catalogue no. 4336921), by Kerry Tyson, 
UCB Celltech. The reactions were run on a 3130xL Genetic Analyzer 
automated sequencer (Applied Biosystems), and sequencing data were 
analysed using the Vector NTI Advance (Version 11) ContigExpress program 
(Life Technologies). 
2.2.6 Qiagen maxi and giga preps 
Following identification of correct vector inserts, DNA was transformed as 
described in Section 2.2.3. After an 8 hour culture in 5 mL LB medium, the 
culture was transferred to 250 mL LB medium supplemented with 30 µg/mL 
kanamycin or 50 µg/mL ampicillin and cultured at 200 rpm in an orbital shaker 
at 37°C overnight. Following overnight culture, the bacteria were pelleted and 
DNA was extracted using the endoFree plasmid maxi kit or the QIAfilter plasmid 
giga kit (both Qiagen), as per manufacturer’s instruction. DNA concentration 
was determined using the NanoDrop ND-1000 spectrophotometer. 
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Vector 
alias 
Vector 
Inserted 
sequence 
Primers to amplify inserted 
sequence 
Digest 
sites 
Promoter 
Resistance 
gene 
Protein 
encoded 
Use 
CLDND1
-trunc 
PIMMS
2011 
CLDND1 
(UCB)-
truncated  
Fwd: 5’ ACGAAGCTTGCCACCA  HindIII 
hCMV-MIE Kanamycin 
CLDND1 
(UCB)-
truncated 
Rab-9, 
primary CD4+ 
T-cell Rev: 5’ CCCGAATTCTCATTCCT 
TCCGATTTGTATGGGCAGC 
EcoRI 
CLDND1
-GPI1 
PIMMS
2011 
CLDND1 
(UCB)-
GPI1 
Fwd: 5’ ACGAAGCTTGCCA 
CCATGGACAACCGTTTTGCC 
HindIII 
hCMV-MIE Kanamycin 
CLDND1 
(UCB)-
GPI1 
Rab-9, 
primary CD4+ 
T-cell  
Rev: 5’ CCCGAATTCCTATATCA 
GAGCCACCCTGGCCAGCACTC
CAATCGTGATGCCGACGGTGG
CCACAGCTGAGAGGACCGGT
GCACTTCCAGATTCTCCGGAA
ACATTGTCAGGGAG 
EcoRI 
CLDND1
-GPI2 
PIMMS
2011 
CLDND1 
(UCB)-
GPI2 
Fwd: 5’ ACGAAGCTTGCCACC 
ATGGACAACCGTTTTGCC 
HindIII 
hCMV-MIE Kanamycin 
CLDND1 
(UCB)-
GPI2 
 
Rab-9, 
primary  
CD4+ T-cell 
Rev: 5’ CCCGAATTCCTATATCA 
GAGCCACCCTGGCCAGCACTC
CAATCGTGATGCCGACGGTGG
CCACAGCTGAGAGGACCGGT
GCACTTCCAGATTGGCATCTC
CAAAGATATGTGCG 
EcoRI 
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Vector 
alias 
Vector 
Inserted 
sequence 
Primers to amplify inserted 
sequence 
Digest 
sites 
Promoter 
Resistance 
gene 
Protein 
encoded 
Use 
CLDND1
-FLAG 
modified 
pcDNA4
/myc-
His B 
CLDND1-
FLAG 
Fwd: 5’ TGCAAGATCTCACCAT 
GGATAACCGTTTTG 
BglII 
CMV Ampicillin CLDND1 
FreeStyle293-
F, SW1353  Rev: 5’ TACGCTGCAGATGCCA 
CACGATATGCCT 
PstI 
CLDND1
-AFP 
pQBI 
25-fN1 
CLDND1 
(UCB)-
AFP 
UCB Celltech made 
HindIII 
CMV Ampicillin 
CLDND1 
(UCB)-
AFP 
SW1353, Jurkat  
NheI 
CLDND1
-PIMMS 
PIMMS
2011 
CLDND1 
(UCB) UCB Celltech made 
HindIII 
hCMV-MIE Kanamycin 
CLDND1 
(UCB) 
Rab-9, primary 
CD4+ T-cell 
EcoRI 
CLDND1
-Elf 
pV 
SV40E-
ELF 
CLDND1 
(UCB) UCB Celltech made 
HindIII 
SV40E-
ELF 
Kanamycin 
CLDND1 
(UCB) 
Rab-9, primary 
CD4+ T-cell 
EcoRI 
CLDND1
-FerL 
pV 
SV40E-
FerL 
CLDND1 
(UCB) UCB Celltech made 
HindIII 
SV40E-
FerL 
Kanamycin 
CLDND1 
(UCB) 
Rab-9, primary 
CD4+ T-cell 
EcoRI 
CLDND1
-HCMV 
pV 
SV40E-
hCMV 
CLDND1 
(UCB) UCB Celltech made 
HindIII 
SV40E-
hCMV 
Kanamycin 
CLDND1 
(UCB) 
Rab-9, primary 
CD4+ T-cell 
EcoRI 
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Vector 
alias 
Vector 
Inserted 
sequence 
Primers to amplify inserted 
sequence 
Digest 
sites 
Promoter 
Resistance 
gene 
Protein 
encoded 
Use 
PIMMS-
non-
coding 
PIMMS 
2011 
Stuffer 
fragment UCB Celltech made 
HindIII 
hCMV-MIE Kanamycin 
Stuffer 
fragment 
Primary CD4+ 
T-cell 
EcoRI 
PIMMS-
coding 
PIMMS
2011 
Immunoglo
bulin κ light 
chain 
UCB Celltech made 
HindIII 
hCMV-MIE Kanamycin 
Immunoglo
bulin κ light 
chain 
Primary CD4+ 
T-cell 
EcoRI 
CLDND1
-Screen 
pKH10 
Human 
CLDND1 
(UCB) 
UCB Celltech made 
HindIII 
hCMV-MIE Kanamycin 
CLDND1 
(UCB) 
FreeStyle293-
F 
EcoRI 
CLDND1
-H2K 
pIRES2- 
H2Kk (1) 
Human 
CLDND1 
(H2K) 
Fwd: 5’ CGCAGCTAGCATGGA 
TAACCGTTTTGC 
NheI 
CMV Kanamycin CLDND1 
Primary CD4+ 
T-cell 
Rev: 5’ TGCAGGATCCTCATGC 
CACACGATAT 
BamHI 
 
Table 7. DNA vectors 
Throughout the thesis, vectors are referred to by the ‘Vector alias’. The vector backbone and inserted sequences are detailed for each 
vector, along with the primer sequences required for inserted sequence amplification, where required. Restriction digest sites are listed 
along with the type of promoter present within the vector backbone and antibiotic resistance gene. The CLDND1 protein sequence 
translated from each vector is also described, along with the technique each vector was used for. (1) vector information (Tahvanainen et 
al., 2006).
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2.3 Antibody Generation 
2.3.1 Peptide generation 
The peptide generation work was performed by Terry Baker, UCB Celltech. 
Human (NP_001035289.1) and mouse (NP_741968.1) CLDND1 protein 
sequences were aligned to the PMP-22/EMP/MP20/claudin superfamily 
members and regions of exclusivity in the extracellular loops of the mouse and 
human CLDND1 homologues were identified. Four peptides were generated 
from these exclusive regions, utilising the most immunogenic amino acids in the 
available sequences (Table 8). Peptides were made cyclic and attached to one 
of three hapten carriers: keyhole limpet hemocyanin (KLH), ovalbumin (OVA) or 
human serum albumin (HSA), through a maleimide structure. 
 
Peptide 
number 
Loop 
position 
Peptide sequence Immunisation 
number 
CLE11 1st cyclo[cys*KSIWDEFISDEADEKTY] 2675, 2676 
CLE12 1st cyclo[cys*ITIPKNMHWYSPPER] 2677, 2678 
CLE13 1st cyclo[cys*VSFTLTEQFMEK] 2679, 2680 
CLE21 2nd cyclo[cys*[ELLHQKLELPDNVSG] 2681, 2682 
 
Table 8. Immunisation peptides 
Name of peptide, along with extracellular loop position, sequence and 
immunisation number are shown. Cyclo[cys] indicates where the peptides were 
made cyclic and linked to the haptens, through the maleimide structure of the 
cysteine residue. 
 
 
2.3.2 Immunisation strategy  
The immunisation group at UCB Celltech performed the immunisations. Five 
immunisations were performed at 3 week intervals alternating the peptide-
conjugate as follows; KLH, OVA, HSA, KLH, then OVA, using 100 µg antigen 
per immunisation in HsdIF:NZW rabbits along with Imject Freund’s complete 
(FCA) or Freund’s imcomplete (FIA) adjuvant. Immunisations were performed 
subcutaneously. 10 mL bleeds were taken prior to the first immunisation and at 
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subsequent immunisations. Prior to immunisation, a preserum bleed was 
performed, for use as a negative control. At the end of the immunisation 
protocol, blood was drawn for antibody assessment and spleen and bone 
marrow cells were collected and stored at -80°C. Serum was prepared from the 
blood. An aliquot of serum was taken for antibody validation and the remaining 
serum was stored at -80°C.  
2.3.3 Antibody purification 
Antisera was centrifuged at 4000 x g for 10 minutes and filtered through a 
Whatman 0.22 µm bottle-top filter (GE Healthcare, Chalfont St Giles, UK). The 
serum was passed over a NHS-activated column (GE healthcare) loaded with 
streptavidin (SA) containing the biotinylated peptide: 
CTLESIMNTLESEEDFRYKY (Terry Baker, UCB Celltech) to remove any non-
specific antisera binding. 400 µL of 10 mM CLE11, the immunisation peptide, 
was added to 2676 antiserum and incubated overnight at 4°C. 
2.3.4 Affinity purification column generation 
130 mg SA (Terry Baker, UCB Celltech) was dissolved in 0.2 M NaCHO3 and 
purified using a disposable PD-10 column (GE healthcare), to remove low 
molecular weight contaminants. The NHS-activated HP 5 mL column (GE 
healthcare) was activated with 1 mM HCl according to manufacturer instruction, 
loaded with SA (NHS load) and re-circulated for 30 minutes. Unbound SA was 
eluted (NHS eluate) with 0.2 M NaHCO3. The SA coupling efficiency was 
measured as follows, according to manufacturer instruction: 
                   
   
 
     
 
where:                                                  
   
                                                        
                               
 
and was calculated at 95.4 %. The SA-NHS column was de-activated according 
to manufacturer instruction and a mock elution performed, using 0.1 M 
glycine/HCl pH 2.7, 20 % glycerol, followed by 0.58 % acetic acid then PBS. 
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2.3.5 Affinity purification 
The 2676 antiserum containing biotinylated CLE11 was loaded onto the SA-
NHS-CLE11 column, and washed in PBS. The bound antibodies were eluted in 
5 mL fractions using 0.1 M glycine/HCl pH 2.7, 20 % glycerol into a bijoux 
containing 0.5 mL 1 M tris pH 8, 0.5 M NaCl, to neutralise the acidity of the 
eluate. Absorbance at 280 nm was measured for each fraction. The purification 
process was repeated for 2675 antiserum. 2675 and 2676 antisera were chosen 
for purification due to their most convincing α-CLDND1 binding data. 
2.3.6 Antibody concentration and buffer exchange 
Fractions from the affinity purification containing functional antibody were 
pooled and concentrated using an Ultra-15 centrifugal filter unit with ultracel-30 
membrane (Merck Millipore, MA, USA) and buffer exchanged into PBS. 
Absorbance was measured at 280 nm and protein concentration was 
determined. Concentrated antibody was aliquoted into 1 mg/mL fractions and 
stored at -20°C. 
2.4 Cell Line Culture 
2.4.1 SW1353 cells 
The SW1353 cell line was initiated from a primary grade II chondrosarcoma in 
the right humerus of a 72 year old Caucasian female. Full details of the cell line 
can be found at the ATCC company website (www.atcc.org). Cells were 
purchased from ATCC (catalogue HTB-94). The cell line was cultured in 
SW1353 culture medium (DMEM, high glucose, 2 mM L-glutamine, 100 U/mL 
penicillin, 1 μg/mL streptomycin, 10 % FBS). Cells were plated into vented T75 
cm2 flasks, grown at 37°C in 5 % (v/v) CO2/humidified air until approximately 80 
% confluent. Cells were detached with trypsin and split into the appropriate 
culture vessel for experimentation or into further T75 cm2 flasks for continuation 
of the line every 2-3 days. Experiments were performed on cells between 
passage 3 and 25. 
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2.4.2 FreeStyle™ 293-F cells  
Cells were grown and maintained by Ashley Hudson, UCB Celltech. The 
FreeStyle™ 293-F cell line (Life Technologies) is derived from the 293 cell line 
and is adapted for suspension culture. The cells were maintained in Gibco® 
FreeStyle™ 293 expression medium (Life Technologies) and passaged at 1-
2x105 cells/mL every 3-4 days at 37°C in 5 % (v/v) CO2/humidified air. Cells 
were maintained in suspension by culturing cells with shaking and used until 
passage 30.  
2.4.3 E6-1 Jurkat cells 
The Jurkat cell line was established in the late 1970s from the peripheral blood 
of a 14 year old boy with T-cell leukemia. The E6-1 Jurkat cells are a clone of 
the Jurkat-FHCRC cell line, a derivative of the Jurkat cell line. Full details of the 
cell line can be found at the ATCC company website (www.atcc.org). Cells were 
purchased from ATCC (catalogue TIB-152). The cell line was cultured in vented 
T75 cm2 flasks, grown at 37°C in 5 % (v/v) CO2/humidified air in RF-10. Cells 
were passaged into the appropriate culture vessel for experimentation or into 
further T75 cm2 flasks for continuation of the line every 2-3 days. 
2.4.4 Rab-9 cells 
Cell maintenance was performed by Sophie Shaw, UCB Celltech. The Rab-9 
cell line is a rabbit fibroblast cell line from an adult female Oryctolagus 
cuniculus. Full details of the cell line can be found at the ATCC company 
website (www.atcc.org). Cells were purchased from ATCC (catalogue CRL-
1414). Cells were cultured in Rab-9 culture medium (RPMI-1640 medium + 10 
% FBS + 1 mM glutamine +100 µg/mL normacin (InvivoGen)) and passaged 
when confluency was reached. Cells were harvested with Accutase® (PAA 
Laboratories Ltd, Yevil, UK) and passaged to continue the stock. 
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2.5 Cell Line Transfections 
2.5.1 SW1353 cell transfections 
For chamberslide transfections for immunofluorescence, SW1353 were 
harvested, as described in Section 2.4.1 and resuspended to 5x104/mL in 
DMEM. 1.5x104 cells were added per well of a chamberslide and cultured 
overnight at 37°C in 5 % (v/v) CO2/humidified air prior to transfection with 
Fugene® HD (Promega) or ExGen 500 in vitro (Thermo Scientific) transfection 
reagents, in order to determine the transfection reagent with the highest 
transfection efficiency. 
FuGENE® HD transfection reagent: vector DNA was added to 11 µL of DMEM, 
to which FuGENE® HD transfection reagent was added, at differing ratios 
(Figure 10A). The mixture was vortexed and incubated at RT for 20 minutes 
then added to the cells. Cells were incubated for 24 hours at 37°C in 5 % (v/v) 
CO2/humidified air. The ExGen 500 in vitro transfection reagent resulted in 
higher transfection than the FuGENE® HD transfection reagent, so no optimal 
conditions were chosen for this transfection reagent. 
ExGen 500 in vitro transfection reagent: the volume of vector DNA was 
increased to 33 µL in 150 mM NaCl, to which varying concentrations of ExGen 
500 in vitro transfection reagent was added (Figure 10B). The mixture was 
incubated at RT for 10 minutes before removing the SW1353 culture medium 
and adding 33 µL of the DNA/ExGen 500 in vitro transfection reagent mixture 
per chamberslide well. 300 µL of SW1353 culture medium was added to the 
cells and the chamberslide was incubated at 37°C in 5 % (v/v) CO2/humidified 
air for 24 hours. From the optimisations, 0.5 µg vector DNA with a 1:3.8 ratio of 
ExGen 500 in vitro transfection reagent was chosen as this conditions resulted 
in the highest transfection efficiency, observed visually by AFP fluorescence. 
To generate cell lysates for Western blotting, the ExGen 500 in vitro transfection 
reagent transfection method was used with the following modifications: SW1353 
cells were resuspended to 1.15x105/mL in SW1353 culture medium and added 
to a 6-well plate at a final density of 3.5x105 cells/well. 2 µg vector DNA and 13 
µL of ExGen 500 in vitro transfection reagent was used in 300 µL of 150 mM 
NaCl. 300 µL of the mixture was added to the cells and 3 mL SW1353 culture 
medium was added.
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Figure 10. SW1353 transfection optimisations: CLDND1-AFP 
SW1353 cells were transfected with the CLDND1-AFP vector using transfection reagents: (A) FuGENE® HD transfection reagent or (B) 
ExGen 500 in vitro transfection reagent. The µg values represent the amount of DNA used and the ratios represent DNA quantity to 
transfection reagent ratios. Transfection efficiencies were visualised by the amount of AFP fluorescence detected. Nuclear staining was 
performed with DAPI and is illustrated by the blue fluorescence.
Katherine L. Crossland                                                                                    Chapter 2. Methods 
52 
2.5.2 FreeStyle™ 293-F cell transfections 
FreeStyle™ 293-F cells were harvested and washed in PBS. Cells were 
resuspended to a density of 1x106/mL in NM6 medium (SIGMA Aldrich) and 5 
mL was added per well of a 6-well plate. 5 µg of vector DNA was diluted into 
170 µL of Opti-PRO medium (Life Technologies) in polycarbonate tubes. 10 µL 
of 293fectin (Life Technologies) was diluted into 170 µL of Opti-PRO medium in 
polycarbonate tubes and incubated for up to 5 minutes. The DNA and 293fectin 
mixtures were combined and incubated for 20 minutes at RT before adding to 
the FreeStyle™ 293-F cells. Cells were incubated with shaking at 37°C in 5 % 
(v/v) CO2/humidified air for 24 hours. 
2.5.3 E6-1 Jurkat cell transfections 
E6-1 Jurkat cells were nucleofected using the Neon® transfection system (Life 
Technologies). Initially, optimisations were performed (Table 9), varying the 
nucleofection parameters. Based on cell viability and transfection efficiency, the 
following parameters were chosen for subsequent experiments: 1600 V pulse 
voltage, 10 pulse width, 3 pulse number (Table 9A). The transfection protocol 
was optimised further by varying the number of cells transfected and the 
amount of CLDND1-AFP vector used (Table 9B).  
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Voltage Width Number Efficiency (%) Viability (%) 
1400 20 1 2.95 84 
1600 20 1 13.9 72 
1100 30 1 0.77 91.97 
1300 30 1 5.69 86 
1000 40 1 0.88 93 
1200 40 1 7 85 
1200 20 2 3 87 
1400 20 2 19.5 76 
950 30 2 0.81 93 
1150 30 2 7.58 81 
1400 10 3 6.39 86 
1600 10 3 23.5 81 
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(B) 
Cell Number Vector DNA (µg) Efficiency (%) Viability (%) 
1x105 0.5 35 71 
1x105 
1x105 
1 48.6 69.5 
5 1.5 42.2 56.7 
1x105 3 27.6 34.39 
2x105 0.5 27.4 67.2 
2x105 1 44.3 68.5 
2x105 1.5 49.2 66.7 
2x105 3 31.7 39.15 
 
Table 9. Jurkat transfection optimisations 
Jurkat cells were transfected with the CLDND1-AFP vector and cultured for 18 
hours before determining transfection efficiency and cell viability by flow 
cytometry. Transfection efficiency was determined by AFP fluorescence and 
viable cell numbers were obtained from cells staining negative for Via-Probe™. 
(A) Nucleofection pulse parameters were varied, using 0.5 µg DNA and 1x105 
cells. (B) Using the nucleofection parameters: 1600 V, pulse width 10 and pulse 
number 3, cell number and amount of DNA was varied. 
 
 
For all subsequent transfections, 2x105 cells and 1 µg of CLDND1-AFP vector 
was used using the transfection method below: 
Two days prior to electroporation, Jurkats were harvested and passaged at 1:20 
dilution in RF-10. On the day of transfection, 500 µL of RF-10 was pre-
equilibrated in a 24-well plate at 37°C in 5 % (v/v) CO2/humidified air. Cells 
were harvested, centrifuged at 400 x g and washed in PBS. Cells were 
resuspended in resuspension buffer R at a final density of 1x107/mL. The 
Neon® transfection system was set-up to manufacturer instruction. Briefly, 3 mL 
electrolytic buffer E was added to the Neon™ pipette station and the 
nucleofection conditions were entered. 1 µg of CLDND1-AFP vector was 
transferred to a sterile 1.5 mL microcentrifuge tube and the cells were added 
and gently mixed. The cell/DNA mix was taken into the nucleofection pipette 
and the nucleofection was carried out. Post nucleofection, the pipette was 
emptied into the 24-well plate and the plate was gently rocked to assure even 
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distribution of the cells. The plate was incubated at 37°C in 5 % (v/v) 
CO2/humidified air, for 24 hours. 
H2Kk transfected Jurkats were purified against the H2Kk tag using MACSelect 
Kk microbeads (Miltenyi Biotech), according to manufacturer instruction. Prior to 
selection, dead cells were removed using the dead cell removal kit (Miltenyi 
Biotech), to prevent dead cells from binding the Kk microbeads. Dead cell 
removal was performed according to manufacturer instruction. Briefly, 1x107 
cells were resuspended in 100 μL of dead cell removal microbeads, mixed and 
incubated for 15 minutes at RT. An MS column was placed in the MACS 
separator and prepared by rinsing with binding buffer (Miltenyi Biotech). The 
sample was added to the column and effluent was collected as live cells. For 
dead cell fraction analysis, the column was removed from the MACs separator 
and dead cells were eluted in binding buffer. 
The effluent was prepared for MACSelect Kk microbead selection, according to 
manufacturer instruction. Cells were resuspended in 320 µL of buffer PBE (PBS 
pH 7.2 supplemented with 0.5 % BSA, 5 mM EDTA) per 1x107 cells, to which 
80 µL of MACSelect Kk microbeads were added and incubated at 4°C for 15 
minutes. The volume was adjusted to 2 mL in buffer PBE. An MS column was 
prepared by placing in a MACS separator and rinsed with 500 µL of buffer PBE. 
The cell suspension was applied to the column and unlabelled cells were 
collected in the effluent. The column was washed 3 x 500 µL in buffer PBE 
before the column was removed from the MACS separator and positively 
selected cells were eluted in 1 mL if buffer PBE. Cells were analysed for viability 
with Via-Probe™ (BD Bioscience) and H2Kk positivity using mouse anti- H2Kk-
phycoerythrin and MACSelect control FITC antibody (both Miltenyi Biotech), as 
the MACSelect Kk microbeads bind to the same epitope as the mouse anti- 
H2Kk-phycoerythrin and so could have masked binding. 
2.5.4 Rab-9 cell transfections 
Cells were harvested according to Section 2.4.4, upon confluency. The cells 
were washed with PBS by centrifugation at 400 x g. Cells were resuspended at 
5x107/mL in Earles solution (SIGMA Aldrich). 250 µg DNA at 1 mg/mL was 
added to 600 µL of cells and the cells were electroporated with a using the 
conditions 8.4 A, 20 ms in an in-house electroporator (UCB Celltech). Cells 
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were transferred to warm Rab-9 culture medium and cultured for 24 hours at 
37°C in 5 % (v/v) CO2/humidified air. 
2.6 Primary Cell Culture 
2.6.1 Ethics 
All research was performed under favourable ethical opinion for the Newcastle 
autoimmune inflammatory rheumatic diseases research biobank (NAIRD) and 
healthy controls and RA patients gave informed consent. The study has been 
reviewed by the South West 3 Research Ethics committee and by the 
Newcastle upon Tyne Hospitals NHS Foundation Trust Research and 
Development Department.  
2.6.2 Blood collection and culture 
Peripheral blood was collected into spray-coated K2EDTA or sodium heparin 
vacutainers (BD Bioscience). Peripheral blood was cultured in 24 well plates, 
with 1 mL blood per well. Where dilutions were required, RPMI-1640 was used. 
2.6.3 Buffy cone collection 
Buffy cones were bought from the national blood bank. Cells were removed 
from the cone using Hanks balanced salt solution (HBSS) supplemented with 2 
mM EDTA to a final volume of 50 mL. 
2.6.4 Peripheral blood mononuclear cell isolation 
Peripheral blood or processed buffy cone was diluted 1:1 with HBSS 
supplemented with 2 mM EDTA and layered onto Lymphoprep™ according to 
manufacturer’s instruction. Blood was centrifuged at 895 x g for 30 minutes at 
RT with no brake. Peripheral blood mononuclear cells (PBMC) were collected 
from the sample/medium interface. Two wash steps were performed with HBSS 
supplemented with 1 % FBS: 600 x g for 7 minutes at 4°C then 250 x g for 7 
minutes at 4°C to remove platelets. Cells were counted using a Burker 
haemocytometer. 
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2.6.5 CD4 T-cell isolation: positive selection 
The EasySep™ human whole blood CD4 positive selection kit (StemCell 
Technologies, Grenoble, France) and human CD4 microbeads (Miltenyi 
Biotech) specifically target the CD4 protein. CD4 is a 55 kDa cell surface protein 
highly expressed on T-cells, with lower expression on monocytes and dendritic 
cells. On T helper cells, CD4 acts as an accessory molecule for the recognition 
of MHC class II/peptide complexes by the TCR. Both systems utilise α-CD4 
antibody and magnetic bead complexes which allow for labelled cells to be 
isolated through magnetic separation. The EasySep™ human whole blood CD4 
positive selection kit uses a tube held within a magnet to maintain the positively 
selected cells whereas the human CD4 microbeads utilise a column held within 
a magnet to positively select for cells. 
EasySep™ human whole blood CD4 positive selection: peripheral blood was 
incubated with a 1/40 dilution of RosetteSep™ human monocyte depletion 
cocktail (StemCell Technologies) for 15 minutes at RT. This product couples 
CD36 expressing monocytes to red blood cells resulting in large aggregate 
formations. Blood was then inverted with 1/5 dilution of Hetasep™ solution 
(StemCell Technologies), a density centrifugation medium, prior to 
centrifugation at 50 x g for 5 minutes at RT. The blood was incubated at RT for 
10 minutes, to allow for the red blood cell/monocyte aggregates to settle. CD36 
expressing monocytes would therefore be eliminated prior to CD4 positive 
selection to reduce monocyte contamination in the purified fraction. The upper 
fraction was collected and washed in HBSS supplemented with 1 % FBS. Cells 
were resuspended with HBSS supplemented with 1 % FBS to 1/5 of the total 
volume of whole blood. CD4 expressing T-cells were isolated automatically with 
the RoboSep (StemCell Technologies) using the EasySep™ human whole 
blood CD4 positive selection kit. Purified cells were resuspended to 1x106 
cells/mL in X-vivo-15 medium (Xv15) (Lonza) unless otherwise specified. 
Human CD4 microbead positive selection: CD4 positive selection was carried 
out using human CD4 microbeads (Miltenyi Biotec) according to manufacturer 
instructions. Briefly, PBMC (see Section 2.6.4 for isolation method) were 
resuspended in 80 μL of MACS buffer (PBS pH 7.2, 0.5 % BSA, 2 mM EDTA) 
and 20 μL of human CD4 microbeads per 1x107 cells and refrigerated for 15 
minutes. Cells were washed in MACS buffer then resuspended in 2 mL MACS 
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buffer. The MS column (Miltenyi Biotech) was prepared by placing it in the 
magnetic field of a MACS separator (Miltenyi Biotech) and by rinsing with 500 
μL of MACS buffer. The cell suspension was applied onto the column and 
unlabelled cells were eluted. The column was washed prior to removing the 
column from the MACS separator and eluting the CD4 labelled cells in 1 mL of 
MACS buffer. Positively selected cells were washed and resuspended in the 
appropriate culture medium. 
2.6.6 CD4 T-cell isolation: enrichment 
RosetteSep™ human CD4+ T-cell enrichment involves the depletion of other 
cell types than CD4 expressing cells through antibody targeted depletion of the 
surface antigens CD8, CD16, CD19, CD36, CD56, CD66b and TCRγδ. The 
antibodies crosslink these surface antigens to red blood cells through 
glycophorin A, resulting in immunorosette aggregates. These rosette cells have 
a greater density and so pellet faster than unrosetted cells when centrifuged 
over a buoyant density medium. 
Non-CD4 expressing cells were depleted from whole blood or buffy cone using 
the RosetteSep™ human CD4+ T-cell enrichment cocktail (StemCell 
Technologies) using 50 μL or 75 μL per mL of blood or cone, respectively. Cells 
were incubated for 20 minutes at RT before diluting in PBS supplemented with 
2 % FBS at a 1:1 ratio. 20 mL of diluted cells were layered onto 15 mL of 
Lymphoprep™ (Axis-Shield, Dundee, Scotland), a density centrifugation 
medium, according to manufacturer’s instruction and centrifuged at 895 x g for 
30 minutes at RT with no brake. Cells were collected from the sample/medium 
interface and washed twice in PBS supplemented with 2 % FBS prior to use. 
2.6.7 Monocyte isolation 
PBMC were isolated from processed buffy cone according to Section 2.6.4. 
Monocytes were isolated using human CD14 microbeads (Miltenyi Biotech), 
according to revised manufacturer’s instruction. Briefly, cells were resuspended 
in 80 µL MACS buffer and 10 µL CD14 microbeads per 10x106 cells. Cells were 
incubated at 4°C for 15 minutes. Cells were washed and resuspended in 2 mL 
ice cold MACS buffer. The LS column (Miltenyi Biotech) was placed in the 
MACs separator and pre-rinsed with 3 mL ice-cold MACs buffer before the 
PBMC were added. LS column was washed 3 times with ice-cold MACs buffer. 
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The effluent fraction contained unlabelled cells. The LS column was removed 
from the magnet and the positively selected cells were flushed from the column 
with 5 mL of ice-cold MACS buffer. Cells were washed and resuspended in cold 
culture medium.  
2.6.8 nTreg isolation 
CD4+ T-cells were isolated according to Section 2.6.6. CD4+CD25high T-cells 
were isolated using human CD25 microbeads II (Miltenyi Biotech) according to 
revised manufacturer instruction. Briefly CD4+ T-cells were resuspended in 98 
µL MACS Buffer per 1x107 cells in with 2 µL of CD25 microbeads II, in order to 
obtain only the highest CD25 expressing cells, and refrigerated for 15 minutes. 
Volumes were scaled up as required. Cells were washed and resuspended in 
500 µL MACS buffer. The LS column was prepared by placing it in the magnetic 
field of a MACS separator and rinsing with 3 mL of MACS buffer. The cell 
suspension was applied onto the column and unlabelled cells were eluted and 
stored as effector T-cells (Teff). The column was washed prior to removing the 
column from the MACS separator and eluting the CD4+CD25high expressing 
cells in 5 mL of MACS buffer. Purity was determined by flow cytometry using 
CD3-FITC, CD4-PerCP, CD25-PE (all BD Bioscience) and Foxp3-AF647 
(BioLegend, San Diego, USA). 
2.6.9 Platelet rich and platelet poor plasma preparation 
K2EDTA sprayed vacutainers containing peripheral blood were centrifuged at 
2000 x g or 200 x g for 10 minutes at RT. The upper layer was collected as 
platelet poor (PPP) or platelet rich plasma (PRP), respectively. Where dilutions 
were required, RPMI-1640 was used. 
2.6.10 Serum preparations 
Peripheral blood was drawn into serum vacutainers (BD Bioscience) and 
incubated for 30 minutes to allow the blood to clot. Vacutainers were 
centrifuged at 1500 x g for 15 minutes and upper layer was collected as serum. 
Where dilutions were required, RPMI-1640 was used. 
2.6.11 Monocyte differentiation 
Monocytes were differentiated into DC using a 7 day differentiation protocol 
(Anderson et al., 2008). Monocytes were isolated and cultured according to 
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Section 2.6.7. Cells were seeded at 0.5x106 /mL in RF-10. IL-4 and GM-CSF 
were added at a final concentration of 50 ng/mL and cultured at 37°C in 5 % 
(v/v) CO2/humidified air. At day 3, the culture medium was refreshed by 
removing 450 μL medium and replacing with a 500 μL mastermix containing 
RF-10 supplemented with 50 ng/mL final concentrations of IL-4 and GM-CSF 
for mature DC (matDC) and IL-4, GM-CSF and 10-6 M dexamethasone for 
tolDC. At day 6, LPS at a 0.1 µg/mL final concentration was added to each well 
for matDC and a 0.1 µg/mL final concentration of LPS, 10-6 M dexamethasone 
and 10-10 M calcitriol were added for tolDC. At day 7, cells were incubated on 
ice for 1 hour prior to harvesting by pipetting and scraping the well with a pipette 
tip. Cell were washed extensively in HBSS + 1 % FBS prior to use. A recovery 
rate of 20-40 % was expected. 
2.6.12 Cell cryopreservation and thawing of cryopreserved cells 
Freezing: surplus cells were resuspended in 1 mL in FBS containing 10 % 
DMSO at 2x107 cells for T-cells or 1x106 for DC and transferred to cryovials. 
Cells were frozen at -80°C in polystyrene boxes then transferred to liquid 
nitrogen for longer term storage.  
Thawing: cells were removed from liquid nitrogen and gases were allowed to 
equilibrate by incubating the vial on ice for 5 minutes. Vials were thawed at 
37°C and immediately transferred to warm cell culture medium. Cells were 
washed twice in cell culture medium before counting in a 0.2 % trypan blue 
solution (final concentration) (SIGMA Aldrich) to assess cell viability. 
2.7 Primary Cell Transfections 
2.7.1 Accell siRNA original protocol 
CD4+ T-cells were isolated according to Section 2.6.5 “EasySep™ human 
whole blood CD4 positive selection” and rested overnight at 1x106/mL in Xv15 
at 37°C in 5 % (v/v) CO2/humidified air. Cells were harvested in PBS and plated 
at 1x105 per well of a 96 well plate, to which a 1 µM final concentration of Accell 
siRNA (Table 10) was added. Cells were incubated for 72 hours at 37°C in 5 % 
(v/v) CO2/humidified air.
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siRNA alias Reference Sequence 
NT1 D-001910-01 UGGUUUACAUGUCGACUAA 
NT2 D-001910-02 UGGUUUACAUGUUUUCUGA 
NT3 D-001910-03 UGGUUUACAUGUUUUCCUA 
NT4 D-001910-04 UGGUUUACAUGUUGUGUGA 
C1 A-020682-13 UUGUUAUGUUGCUGGAAUU 
C2 A-020682-14 CCGGUGAAUUUGGAUGGUC 
C3 A-020682-15 CUGGUGUGUAUCAACAUUA 
C4 A-020682-16 CCAGGGTTATTAAAAGTGT 
CD4SMARTpool E-005234-00 
UCCUUUUCCUUCAAGCCUA 
CCUUUGACCUGAAGAACAA 
GGAGGAGGUGCAAUUGCUA 
CCCCUGAGCUGAAAUAAAA 
 
Table 10. Accell siRNA 
Accell siRNA are referred to by the “siRNA Alias” throughout the thesis. 
 
 
2.7.2 Accell siRNA literature recommended protocol (72hrsiBead) 
CD4+ T-cells were isolated according to Section 2.6.5 “EasySep™ human 
whole blood CD4 positive selection”. nTreg were isolated according to Section 
2.6.8. Isolated cells were rested overnight at 1x106/mL in Xv15 at 37°C in 5 % 
(v/v) CO2/humidified air. Cells were harvested in PBS and plated in a 96-well 
flat bottom plate at 1x105 cells/well. α-CD3/CD28 expander beads (Life 
Technologies) were added to the cells at a 1:10 ratio, to make a final volume of 
100 µL. Accell siRNA was also added to give a final concentration of 1 µM per 
well. Cells were incubated for 72 hours at 37°C in 5 % (v/v) CO2/humidified air. 
As minimal differences were seen in cell viability between the NT siRNA 
samples, for proliferation assays, a selection of NT siRNA was chosen. 
Cells were then either taken for 3HTdR incorporation (see Section 2.8.5), or 
harvested for RNA extraction, protein analysis or for further culture. For further 
culture, cells were harvested in PBS and α-CD3/CD28 expander beads were 
removed using a magnet. Cells were cultured at 1x106/mL in Xv15 to rest for 72 
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hours. Cells were harvested and 1x105 cells were added per well of a 96-well 
plate in Xv15. A 1:10 ratio of α-CD3/CD28 expander beads were added to the 
cells to create a final volume of 100 µL per well. Cells were cultured for 72 
hours at 37°C in 5 % (v/v) CO2/humidified air. 
2.7.3 T-cell nucleofection: Amaxa 
CD4+ T-cells were isolated according to Section 2.6.6 from buffy cone. Cells 
were resuspended to 47.6x106/mL in RPMI-1640 medium. Master mixes were 
prepared containing 5 µg vector DNA and 5x106 CD4+ T-cells per condition. 
Cells were nucleofected using program U-14 on the Amaxa Nucleofector™ II 
Device (Lonza). Cells were immediately transferred to pre-equilibrated Amaxa 
culture medium (RPMI-1640 medium, 4 mM L-glutamine, 10 % FBS). Cells 
were cultured for 18 hours at 37°C in 5 % (v/v) CO2/humidified air.  
Cells were harvested and washed in PBS + 2 % FBS. Cells were resuspended 
in HBSS supplemented with 1 % FBS and layered over an equal volume of 
Lymphoprep™. Cells were centrifuged at 895 x g for 30 minutes RT in order to 
remove dead cells. Cells were washed twice with PBS + 2 % FBS. Cells were 
resuspended to 2x106/mL in RF-10 for T-cell activation studies. 
2.8 Cellular Assays 
2.8.1 T-cell stimulation 
For isolated CD4+ T-cell proliferation assays, a 1:10 ratio of stimulus to T-cells 
was used. Stimuli were matDC, tolDC or α-CD3/CD28 expander beads. CD4+ 
T-cell numbers varied depending on the type of assay: 
For CLDND1 over-expression studies, 2x105  transfected CD4+ T-cells were 
cultured in a flat bottom 96-well plate in RF-10 at 37°C in 5 % (v/v) 
CO2/humidified air for 3 or 6 days. For re-stimulations, 5x10
4 transfected CD4+ 
T-cells were cultured in a flat bottom 96-well plate in RF-10 at 37°C in 5 % (v/v) 
CO2/humidified air for 3 days. 
For CLDND1 kinetics experiments, 1x106 enriched CD4+ T-cells were cultured 
in a 24-well flat bottom plate in Xv15 or with RF-10 for the DC co-culture 
experiments, in a final volume of 1 mL. Where PBMC were used, 1x106 PBMC 
were cultured in 1 mL RF-10 in a 24-well plate with a final concentration of 1 
µg/mL LEAF purified anti-human CD3 (BioLegend) and 1 µg/mL of LEAF 
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purified anti-human CD28 (BioLegend). Cells were cultured at 37°C in 5 % (v/v) 
CO2/humidified air for the time-points specified. 
2.8.2 Anergy induction 
CD4+ T-cells were isolated according to Section 2.6.6. The in vitro anergy 
protocol attempted was based upon similar experiments performed (Safford et 
al., 2005). A 24-well tissue culture plate was coated with 1 µg/mL LEAF purified 
anti-human CD3 in PBS and incubated for 1 hour at 37°C. Solution was 
removed from each well, to which 1x106 CD4+ T-cells were added with 1 µg/mL 
LEAF purified anti-human CD28 in RF-10 medium. Cells were incubated 
overnight at 37°C in 5 % (v/v) CO2/humidified air. Cells were harvested and 
washed in HBSS + 1 % FBS and rested for 7 days at 1x106/mL in RF-10. Cells 
were harvested and 2x105 cells were added to a 96-well plate pre-coated, as 
before, with 1 µg/mL LEAF purified anti-human CD3. 1 µg/mL LEAF purified 
anti-human CD28 was added in RF-10 medium and cells were cultured for 3 
days at 37°C in 5 % (v/v) CO2/humidified air. 
2.8.3 nTreg suppression assay 
Suppression assays were set up using the following ratios of cells: 1 allogeneic 
matDC: 40 Teff: 20 nTreg cells in a final volume of 200 µL RF-10 in a 96-well 
round bottom plate. The following wells were prepared for each experiment: 
1. 5x104 Teff + 1.25x103 matDC 
2. 5x104 Treg + 1.25x103 matDC 
3. 5x104 Teff + 2.5x104 Teff + 1.25x103 matDC 
4. 5x104 Teff + 2.5x104 Treg + 1.25x103 matDC 
Cultures were incubated for 5 days at 37°C in 5 % (v/v) CO2/humidified air. 
2.8.4 CFSE staining 
A 1 µM 2x working solution of CFSE was prepared in PBS + 0.1 % FBS 
immediately before use. Transfected CD4+ T-cells were washed twice in RPMI-
1640. The third wash step was performed in PBS + 0.1 % FBS at 800 x g for 10 
minutes. All supernatant was aspirated and cells were resuspended to 
20x106/mL in PBS + 0.1 % FBS, or to 1 mL if fewer cells were used. 1x107 cells 
were incubated for 5 minutes at 37°C in 0.5 M CFSE. 5 mL cold RF-10 was 
added to the mixture to terminate the staining and cells were incubated on ice 
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for 5 minutes. Cells were washed twice at 800 x g in cold RF-10 and 
resuspended in RF-10 for use. 
2.8.5 3HTdR incorporation 
20 µL of the 0.548 MBq/mL methyl-3H thymidine working stock was added to 
each well of a 96 well plate and plates were incubated for 8 hours at 37°C in 5 
% (v/v) CO2/humidified air. Plates were harvested onto A, GF/C filtermats 
(Perkin Elmer) and air-dried overnight. Filters were placed in MicroBeta® Trilux 
sample bags (Perkin Elmer) and 5 mL of scintillation fluid (Perkin Elmer) was 
added. Filters were read on the Microbeta TriLux 1450 LSC luminescence 
counter (Perkin Elmer). 
2.9 RNA and Protein Quantification: Flow Cytometry 
2.9.1 Peripheral blood: immune cell subset staining 
200 µL of whole blood was used per stain. Cell surface marker antibodies were 
added directly to whole blood (at the concentrations listed in Table 3) and 
incubated at RT for 30 minutes in the dark. 800 µL of pre-warmed red blood cell 
lysis buffer (0.1 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA) was added and 
samples were incubated at 37°C for 5 minutes. Cells were centrifuged at 400 x 
g for 5 minutes and washed twice in FACS buffer (PBS pH 7.2, 3 % (v/v) FBS, 
100 μM EDTA, 0.01 % (v/v) sodium azide). Cells were then stained for CLDND1 
according to Section 2.9.3. Cell populations were identified by lineage marker 
during flow cytometric analysis according to Section 2.9.9.  
2.9.2 Cell populations: immune cell subset staining 
For cell surface marker staining on PBMC, PBMC were resuspended in FACS 
buffer and non-specific antibody binding was blocked by pre-incubating the cells 
with 2 % human IgG (kind gift from Sophie Hambleton, Newcastle University). 
Directly conjugated cell surface markers were added to the cell populations at 
the dilutions described in (Table 3) for 30 minute at 4°C. Cells were washed 
twice prior to acquisition, or further stained for CLDND1. Cell surface marker 
abundance was measured as geometric mean fluorescence intensity (GMFI) or 
comparatively by over-laying histograms of the fluorescence. 
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2.9.3 CLDND1 cell surface staining 
For CLDND1 staining, cell surface marker staining was performed if required 
(lineage markers were not used on isolated cell populations). Apart from where 
indicated in the antisera binding chapter, cells were fixed in 4 % formaldehyde 
for 30 minutes at RT. Cells were washed twice in FACS buffer. Cells were 
blocked in 2 % goat IgG (SIGMA Aldrich) and 1 µg α-CLDND1, or pre- or anti-
sera was added for 30 minutes at RT (at 1/100 or 1/2000 dilutions), in the dark. 
Cells were washed twice in the appropriate buffer before incubation with 1:200 
dilution of R-phycoerythrin-affinipure F(ab')2 fragment goat anti-rabbit IgG (H+L) 
(Jackson ImmunoResearch, PA, USA) for 30 minutes at RT in the dark. Cells 
were washed twice, resuspended in FACS buffer and stored at 4°C, if required, 
before acquisition. 
2.9.4 CLDND1 intracellular staining 
Cells were stained according to Section 2.9.3, with the following addition: post 
cell fixation, cells were permeabilised. Two different permeabilisation buffers 
were used depending on the type of staining. For staining of cells for 
commercial antibody and pre- and antisera analysis, cells were permeabilised in 
permeabilization buffer (10X), diluted to 1X (eBioscience, San Diego, UK). The 
permeabilisation buffer (10X) was diluted in deionised H2O, according to 
manufacturer instruction. All other flow cytometry staining that required 
permeabilisation used triton-X permeabilisation buffer (PBS pH 7.2, 0.5 % (w/v) 
BSA, 1 % (v/v) fish skin gelatin, 0.5 % (v/v) triton-X 100). The sample was 
incubated in either buffer for 30 minutes at RT. All subsequent staining steps 
were also performed in each permeabilisation buffer. 
2.9.5 Viability staining 
Where viability staining was required, post lineage marker staining, cells were 
resuspended in 100 µL of Annexin V binding buffer (diluted from a 10X stock 
(0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM CaCl2) in deionised H2O). Annexin 
V antibody (BD Bioscience) and Via-Probe™ (BD Bioscience) were added 15 
minutes prior to acquisition, according to manufacturer instruction. 
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2.9.6 CLDND1 antibody blocking 
CLE11, CLE12, CLE13 and CLE21 peptides were incubated at a final 
concentration of 1 µg/mL with a 1/200 dilution of α-CLDND1 pre- or anti-sera in 
PBS, overnight at 4°C. The mixture was added at a 1/20 dilution to the cells, at 
the equivalent step as the CLDND1 or sera staining in Section 2.9.3. 
2.9.7 Determining nTreg purity. 
Purified CD4+ T-cell and corresponding purified nTreg cell populations were 
stained for CD3, CD4 and CD25 according to Section 2.9.2. Cells were then 
fixed and permeabilised with Foxp3 fixation/permeabilization concentrate and 
diluent (eBioscience), according to manufacturer instruction. Alexa Fluor® 647 
anti-human Foxp3 antibody (BioLegend) was added and samples were 
incubated for 30 minutes at 4°C, in the dark. Cells were washed twice and 
resuspended in FACS buffer before acquisition. Sample purity was determined 
according to the strategy outlined in Figure 11. 
 
Figure 11. Gating strategy to determine nTreg purity 
CD4+ T-cells or purified nTreg were stained for CD3, CD4, CD25 and Foxp3. 
CD3/CD4 double positive cells were gated on and from this, CD25high Foxp3 
positive cells were determined, as identified by the boxed cells. The average 
number of cells identified in the box was 59 %. 
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2.9.8 Acquisition 
Samples were acquired in a FACSCanto II (BD Biosciences) with 2 lasers 
(488nm, 635nm) using FACSDiva software (BD Bioscience). Data was 
analysed with FlowJo software (Tree Star, OR, USA). 
2.9.9 Gating strategy 
For analysis of T-cells, a lymphocyte gate was drawn from the whole 
population. Cells were then selected for CD3 expression and from this gate, 
CD4+ or CD8+ T-cells were selected (Figure 12A). For analysis of monocytes 
and B-cells, a PBMC gate was drawn from the whole population and cells were 
then either selected for CD14 or CD19 expression, respectively (Figure 12B). 
The large population of cells present in the centre of the plots probably 
represent granulocytes. 
CLDND1 staining was determined by two methods: the percentage of CLDND1 
positive cells (Figure 12C) or by GMFI. Both methods required the negative 
control of cells stained with phycoerythrin-affinipure F(ab')2 fragment goat anti-
rabbit IgG (H+L) detection antibody only (detection only). For determining the 
percentage of CLDND1 positive cells, a CLDND1 positive gate was set above 
the staining profile in the “detection only” population of cells and transferred to 
the CLDND1 stained cells to determine CLDND1 positivity. The GMFI was also 
calculated for both the detection only sample and the CLDND1 stained sample 
and the detection only value was subtracted from the CLDND1 stained GMFI 
value to obtain a GMFI value for CLDND1 staining intensity. 
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Figure 12. Gating strategy to determine cell subsets and CLDND1 positivity 
Staining from whole blood is shown, and a similar gating strategy was applied to PBMC populations. Whole blood was stained for CD3, 
CD4, CD8, CD14 and CD19. (A) Identification of T-cells. The lymphocyte population was gated and T-cells were selected based on CD3 
positivity. CD4+ and CD8+ T-cell were separated. (B) Identification of B-cells and monocytes. The PBMC population was gated around 
and B-cells or monocytes were selected based on CD19 or CD14 staining (C) CLDND1 staining was determined using FMO analysis. 
Cells were stained with secondary detection antibody only and a gate was drawn above the population of cells. When the gate was 
transferred to CLDND1 antibody stained cells, the cells within this gate related to CLDND1 positive cells.
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2.10 RNA and Protein Quantification: Western Blotting 
2.10.1 Lysate generation 
For adherent cells: after desired cell incubation, cell culture medium was 
removed and cells were rinsed with cold PBS. The PBS was then removed and 
replaced with 100 µL ice-cold RIPA lysis buffer (50 mM tris HCl pH 8, 150 mM 
NaCl, 1 % (v/v) triton-X 100, 0.5 % (v/v) sodium deoxycholate, 0.1 % SDS (w/v), 
protease inhibitor cocktail (Roche, Burgess Hill, UK)). To detach the cells they 
were scraped and then transferred into an eppendorf on ice.  
For suspension cells: after desired cell incubation, cells were washed in PBS 
and then pelleted. 50-100 µL ice-cold RIPA lysis buffer was added to the cells, 
depending on the number of cells.  
Samples were incubated on ice for 30 minutes with periodic vortexing. Samples 
were centrifuged at 10, 000 x g for 3 minutes and the supernatant was 
transferred into a new eppendorf and frozen at -20°C. 
2.10.2 Bradford protein assay 
A 0.4 mg/mL BSA protein stock was prepared in PBS and was diluted to 
produce a range of standard from 0 - 0.4 mg/mL in 0.04 mg/mL increments and 
added to a flat bottom 96-well plate. Cell lysates and equal quantities of cell 
lysis buffer were added to act as blanks. BradfordUltra (Expedeon, Harston, 
UK) assay reagent was then added to the wells containing the standards and 
the samples, according to manufacturer instruction. The samples were gently 
mixed and left to stand for 5 minutes before the absorbance was read at 595 
nm using a Tecan Sunrise microplate absorbance reader. 
2.10.3 SDS-PAGE 
Cell lysates were thawed on ice and dilutions were made to correct for protein 
concentration. 5x laemmli loading buffer (0.1 M tris HCl, pH 6.8, 0.35 M SDS, 
20 % (v/v) glycerol, 0.01 % bromophenol blue and 5 % (v/v) β-mercaptoethanol) 
was added at 1/5 of the lysate volume. The resulting mixtures were heated to 
100°C for 5 minutes, cooled and then electrophoresed on a 12.5 % SDS-
polyacrylamide gel. For SDS-PAGE analysis, gels were stained with 
SilverQuest™ silver staining kit (Life Technologies), according to manufacturer 
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instruction or transferred into coomassie brilliant blue R250 staining buffer (45 
% methanol, 10 % glacial acetic acid, 45 % water, 3 g/L coomassie brilliant blue 
R250). Gels were destained in coomassie destaining buffer (45 % methanol, 10 
% glacial acetic acid, 45 % deionised H2O). Samples for western blot were then 
transferred to polyvinylidene fluoride (PVDF) membrane by electroblotting in a 
Scie-Plas V20-SDB 20X20 cm semi-dry blotter for 1.5 hours at 1 mA/cm2 in 
transfer buffer (20 mM tris HCl, 0.65 M glycine, 20 % (v/v) methanol). 
Membranes were covered in blocking buffer (TBS-T (10 mM tris pH 7.5, 150 
mM NaCl, 0.1 % tween 20 (v/v)), 5 % non-fat dry milk powder (w/v)) for 1 hour 
at RT. Membranes were washed 3 times for 5 minutes in TBS-T. Washed 
membranes were incubated overnight at 4°C with primary antibody or sera, 
diluted in TBS-T, 5 % BSA with gentle agitation. Following incubation, 
membranes were washed 3 times for 5 minutes with TBS-T and then incubated 
with anti-mouse IgG (H+L) HRP-linked  or anti-rabbit IgG (H+L) HRP-linked 
antibody (both Cell Signaling Technology, MA, USA) in TBS-T, 5 % milk for 1 
hour at RT with gentle agitation, then washed a further 3 times in TBS-T. Blots 
were visualised using ECL detection reagents (Merck Millipore) and the G:BOX 
Chemi system. 
2.11 RNA and Protein Quantification: Immunofluorescence 
Medium was removed from the chamberslide and the wells were washed twice 
with PBS. Cells were fixed in 4 % formaldehyde for 15 minutes at RT. Cells 
were washed once in PBS before permeabilisation using triton-X 
permeabilisation buffer for 15 minutes at RT. Samples were blocked with 2 % 
goat serum for 15 minutes before primary antibody or α-CLDND1 sera and 
mouse monoclonal anti-FLAG® M2 (SIGMA Aldrich) was added a 1/100 final 
dilution. Samples were incubated for 1 hour at RT before washing twice in 
triton-X permeabilisation buffer. Alexa Fluor® 488 goat anti-rabbit IgG (H+L), 
Alexa Fluor® 594 goat anti-mouse IgG (H+L) and Alexa Fluor® 594 goat anti-
rabbit IgG (all Life Technologies) secondary antibodies were added and cells 
were incubated for 30 minutes at RT, in the dark. Samples were washed twice, 
the final wash in PBS. The chambers were removed from the slide. Cells were 
mounted with VECTASHIELD mounting media with 4',6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Orton Southgate, UK) and 
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fluorescence was detected with a LEICA DMLB fluorescent microscope and 
associated SPOT RT camera and software. 
For confocal microscopy, analysis was performed using a Zeiss Axio Imager II 
and associated AxioVision software. Between 8 and 12 z-stacks were taken for 
each analysis, and one of these images were presented. 
2.12 RNA and Protein Quantification: RNA Analysis 
2.12.1 RNA extraction 
1x105 CD4+ T-cells were pelleted and RNA extracted using the RNeasy plus 
micro kit (Qiagen), according to manufacturer instruction, eluting in 14 µL 
DNase and RNase free H2O. For transfected CD4+ T-cells, an additional on 
column DNAse I treatment was performed using RNase-Free DNase set 
(Qiagen) as follows: after cell lysate was loaded onto the Qiagen spin 
purification column, 30 Kunitz units of DNase I was added to the column for 15 
minutes at RT. DNase was eluted from the column with RW1 buffer as part of 
the RNeasy plus micro kit protocol and the remaining RNA purification steps 
were performed according to manufacturer protocol. 
2.12.2 Reverse transcription 
For reverse transcription, 8 µL of eluted sample was transferred to a 96-well 
PCR plate. Following this, 0.375 mM dNTPs (Bioline, London, UK) and 0.2 µg of 
random hexamers p(dH)6 (GE healthcare) (final concentrations) were added to 
each well and the plate incubated at 70°C for 5 minutes. Samples were then 
placed on ice followed by the addition of a reaction mix consisting of 10 mM 
DTT (final concentration), 200 U MMLV-RT and the appropriate volume of 5X 
first strand buffer (all Life Technologies) to each well and the plate was 
incubated at 37°C for 50 minutes followed by 70°C for 15 minutes. The stable 
cDNA was then diluted 1.5 times in DNase and RNase free H2O and stored at -
20°C for further use. 
2.12.3 qRT-PCR 
Fluorescence-based, qRT-PCR was used to measure mRNA expression in 
cells. When analysed with a stably expressed ‘housekeeping’ gene, such as 
pol2a, a subunit of RNA polymerase II, the relative expression of a gene was 
determined. 
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Forward and reverse primers were designed with the universal ProbeLibrary 
(Roche) (Table 11) or CLDND1 was detected with the CLDND1 TaqMan® gene 
expression assay (Hs00219886_m1, Life Technologies). To prevent 
amplification of any residual genomic DNA present, the primers were placed to 
span an intron/exon boundary. 
 
Gene Primers Probe library 
Pol2a 
Fwd 5’ TTGTGCAGGACACACTCACA 
1 
Rev 5’ CAGGAGGTTCATCACTTCACC 
CD4 
Fwd 5’ GGCAGTGTCTGCTGAGTGAC 
18 
Rev 5’ GACCATGTGGGCAGAACC 
CLDND1 (UCB) 
Fwd 5’ AATTCATGGCCTCTGCACTT 
26 
Rev 5’ GGGTGTATTCCTTCCGATTTG 
CD25 
Fwd 5’ ACGGGAAGACAAGGTGGAC 
54 
Rev 5’ TGCCTGAGGCTTCTCTTCA 
 
Table 11. qRT-PCR primers for Taqman based assay 
Primers were designed using the universal ProbeLibrary assay design centre 
(Roche Diagnostics) to complement existing Roche probes for analysis of the 
genes listed by qRT-PCR. 
 
 
For qRT-PCR, 15 µL of a master mix containing 100 nM universal ProbeLibrary 
probe (Roche), 200 nM of each primer (SIGMA Aldrich) and 7.5 µL TaqMan® 
gene expression master mix (Life Technologies) was added to 5 µL of cDNA, or 
for the CLDND1 TaqMan® gene expression assay, 5 µL cDNA was mixed with 
20x CLDND1 TaqMan® gene expression assay to a final volume of 15 µL. 
mRNA expression was determined using a TaqMan 7900HT fast-real time PCR 
system (Life Technologies)  with the thermal cycler set to 50°C x 2 minutes, 
95°C x 10 minutes, then (95°C x 15 seconds, 60°C x 1 minute) X 40. CLDND1 
cDNA levels were normalised to the level of pol2a using the calculation 2e−ΔCT, 
where ΔCT represents CT(target gene) – CT(pol2a). Results were analysed 
using SDS 2.4 software (Life Technologies). 
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2.13 RNA and Protein Quantification: Immunoprecipitation 
2.13.1 CLDND1 antibody immunoprecipitation 
Several different methods to couple antibody to resin for immunoprecipitation 
(IP) are available. The Pierce direct IP kit (Thermo Scientific) was chosen as the 
antibody can be directly coupled to the resin through the interaction of lysine 
epsilon-amines on the antibody with aldehyde groups on the resin, stabilised by 
cyanoborohydride. 
IP were carried out according to manufacturer protocol. Briefly, 10 µg of α-
CLDND1 antibody was coupled to 20 µL of the AminoLink plus coupling resin in 
the presence of 75 mM sodium cyanoborohydride solution for 2 hours at RT. 
The column was washed and IP was performed. 
Cells were pelleted, lysed in 500 µL ice-cold IP lysis/wash buffer per 50 mg of 
wet cell pellet and incubated on ice for 5 minutes. Cell debris was removed by 
centrifugation at 13000 x g for 10 minutes and supernatant concentration was 
determined by Pierce BCA protein assay (Thermo Scientific), according to 
manufacturer instruction. The lysate was pre-cleared using 80 µL of control 
agarose resin per 1 mg of lysate. 1000 µg of pre-cleared lysate was added to 
the α-CLDND1 antibody coupled resin and incubated overnight at 4°C with 
rotation. The column was washed and the eluted fractions were kept as 
flowthrough (FT) fractions. CLDND1-antibody specific proteins were eluted from 
the IP matrix using 100 µL of elution buffer. Fractions were collected in 8 µL of 1 
M tris pH 9.5, to neutralise the acidity of the eluate. 
For the addition of SDS, 0.1 % SDS (w/v) was added to the IP lysis/wash buffer 
prior to cell lysis. For scale-up experiments, 50 µg of α-CLDND1 antibody as 
coupled to 200 µL of AminoLink plus coupling resin with other solution volumes 
and concentrations scaled-up accordingly. 
2.13.2 FLAG IP 
FLAG IP was performed using the FLAG IP kit (SIGMA Aldrich) according to 
manufacturer instruction. Briefly, transfected cells were pelleted and 
resuspended in 106-107 cells/mL and incubated for 15 minutes on a shaker. To 
remove cellular debris, cell lysates were centrifuged at 12000 x g for 10 
minutes. 500 µL of supernatant was added to 40 µL of anti-FLAG M2 affinity gel 
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resin and incubated for 2 hours at 4°C. Unbound proteins were washed from the 
column and kept as column FT. FLAG-proteins were eluted from the column by 
competitive binding with FLAG peptide. A 150 ng/µL FLAG peptide solution was 
prepared, 100 µL of this solution was added to the resin and the samples were 
incubated for 30 minutes at 4°C. Samples were eluted using 100 µL elution 
buffer at RT. For scale-up experiments, all volumes used were doubled. 
2.14 RNA and Protein Quantification: ELISA 
ELISAs for IL-5 and IL-17 were bought as kits (Peprotech and eBioscience, 
respectively) and were performed according to manufacturer instruction. 
Individual IFN-γ, IL-2, IL-10 and TNF-α capture and biotinylated secondary 
antibodies (all BD Bioscience) were purchased and ELISAs were performed as 
described below. 
96-well high-affinity plates were coated with 4 µg/mL IL-2, 2 µg/mL IL-10 or 
TNF-α or 1 µg/mL IFN-γ capture antibodies in coating buffer (15 mM disodium 
phosphate, 20 mM monosodium phosphate sodium phosphate monobasic) and 
incubated overnight at 4°C. Wells were washed in ELISA wash buffer (PBS pH 
7.2 + 0.1 % (v/v) tween 20) before wells were blocked in PBS pH 7.2 + 1 % 
(w/v) BSA. Samples were diluted accordingly in PBS pH 7.2 + 1 % BSA + 0.1 % 
(v/v) tween 20 before adding to the plate. 2000 pg/mL standards were diluted 2-
fold in PBS + 1 % BSA + 0.1 % (v/v) tween 20 to create a standard curve. 
Plates were incubated overnight at 4°C. Plates were washed in ELISA wash 
buffer before biotinylated detection antibody was added at 1 µg/mL for IL-2, IL-
10, IFN-γ or 0.5 µg/mL for TNF-α. Samples were incubated for 1 hour at RT. 
Plates were washed again in ELISA wash buffer before a 1/1000 dilution of 
ExtrAvidin®−peroxidase (SIGMA Aldrich) was added for 30 minutes at RT. 
Plates were washed in ELISA wash buffer before OPD susbstrate was added. 
Plates were developed for 30-40 minutes before the reaction was stopped with 
3 M sulphuric acid. Absorbances were read at 490 nm using a Tecan Sunrise 
microplate absorbance reader. 
  
Katherine L. Crossland                                                                                    Chapter 2. Methods 
74 
2.15 Bioinformatics 
2.15.1 BLAST Search 
Sequence alignments were performed against the CLDND1 protein sequence 
(NP_001035289.1) with the basic local alignment search tool (BLAST) (NCBI) 
using the algorithm blastp against the human genome. The search parameters 
were ranked according to max score, query coverage and E-value. Max score 
ranks the highest alignment score between the query and the database 
sequence, with higher scores corresponding to a better alignment. This score 
covers alignment of similar or identical residues and any gaps introduced to 
align the sequences. Values are normalised so different alignments can be 
compared. The query coverage identifies the length of the aligned sequence 
matching the hit within the database. The E-value describes the number of hits 
expected to be seen by chance when searching the database of a particular 
size. The lower the E-value, the more significant the alignment.  
2.15.2 PMP-22/EMP/MP20/claudin superfamily sequence alignment and 
phylogenetic analysis 
Phylogenetic analysis was carried out on the same sequences as Maher et al., 
(2011) (Appendix Table 1). Sequences were aligned using clustalW2-MUSCLE 
(EBI), followed by phylogenetic analysis using the Seaview software, on 
observed distance, with gap sites ignored. Bootstrap proportions were used to 
assess the robustness of the tree with 10000 bootstrap replications. Clarin-1 
was used as an out group.  
2.16 Fold Change Calculations 
Several data are expressed as a fold change compared to a control value for 
qRT-PCR and flow cytometric analysis. Control values were set to a value of 1, 
through the division of the value by itself. Subject values were also divided by 
the control value to give a value expressed as fold change. A fold change of 1 
represents no change from the control, values above 1 represent an increase in 
read-out in the subject sample compared to the control and a value below 1 
represents a decrease in read-out value in the subject sample compared to the 
control value. 
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2.17 Statistical Analysis 
Various statistical analyses were performed on the data to determine whether 
the data collected represented changes between two populations, as apposed 
to natural variance within each population. Where applicable, data was tested 
for fit to the Gaussian distribution using D’Agostino and Pearson omnibus 
normality test, as recommended by GraphPad PRISM and parametric or non-
parametric tests were used accordingly. Statistical testing was applied to 
experiments where three or more replicates were performed.  
For parametric data, Student’s t-test analysis was performed on normalised 
data or paired Student’s t-test was performed on raw data values. Where more 
than three groups of raw data were analysed repeated-measures ANOVA was 
performed on dependent groups or a 1way ANOVA was performed on 
independent samples, with Bonferroni’s correction to account for generation of a 
statistically significant result by chance from testing multiple parameters.  
For non-parametric data, Wilcoxon matched paired t-test was used for 
comparison between two dependent samples or a man-Whitney U test was 
performed for independent data. Where samples were not large enough to test 
for normality, both statistical testing was performed. If p values less than 0.05 
were only determined with parametric tests, these values were shown, but 
where both parametric and non-parametric tests gave p values lower than 0.05, 
the non-parametric test was shown.  
Data illustrate the mean value of the data plus the standard error of the mean 
(SEM). Significance values are illustrated by *, ** or ***, which correspond to 
p<0.05, p<0.01 and p<0.001, respectively.
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Chapter 3. Generation of CLDND1 Antibodies 
3.1 Aims 
One aim of this chapter was to validate the commercially available antibodies 
against CLDND1 by firstly determining whether these antibodies definitely 
recognised CLDND1 and secondly whether they could be used to manipulate 
CLDND1 function. In addition, I sought to generate in-house antibodies against 
extracellular regions of CLDND1 which would be thoroughly validated. These 
latter antibodies would then be screened for functional effects to further 
elucidate a role for CLDND1 in the immune response. 
3.2 Introduction 
3.2.1 Antibody characteristics 
Antibodies are glycoproteins produced by B-cells, as the main effector of the 
humoral immune response. Belonging to the immunoglobulin superfamily, they 
typically conform to a basic “Y”-shaped structure, comprising two large heavy 
chains and two small light chains. The five heavy chains determine the class of 
antibody: γ for IgG, α for IgA, μ for IgM, δ for IgD and ε for IgE antibodies. The 
class of the antibody dictates the effector function of the antibody. The κ or λ 
light chains are found on any class of antibody, but are restricted to one isoform 
per antibody molecule. 
Both heavy and light chains have a variable and a constant region. The variable 
region determines antigen specificity through its complimentary determining 
regions (CDRs) and framework regions. The framework regions define the 
placement of the three CDRs for each chain, so when the heavy and light 
chains are joined, the six CDRs form a surface that serves as the antigen-
binding site, of which there are two per antibody molecule.  
Each antibody is specific for a single epitope and antibody gene 
rearrangements enable the generation of different antibodies that are estimated 
to recognise 109 distinct epitopes. Further diversity can also be introduced by 
somatic hypermutation of the variable regions, which introduces additional point 
mutations in the coding sequences (Janeway et al., 2001). 
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3.2.2 Antibody production for research 
Immunising animals with an antigen can result in the development of pAbs in 
the serum of the animal, or mAbs can be developed from the B-cells in the 
spleen. Antibodies can also be made through in vitro selection protocols, such 
as phage display (Uhlen and Ponten, 2005). 
3.2.3 pAbs 
pAbs are produced by a population of non-identical B-cells, so are comprised of 
a mixture of antibodies with varying affinities and recognising different epitopes. 
The antiserum collected from the blood from animal immunisations, typically 
contains 1 % of antigen specific antibodies. Epitope specific affinity purification 
can separate the antibody from the antiserum, to reduce interference by the 
non-specific antibodies (Uhlen and Ponten, 2005).  
pAbs are suited to many technical applications due to their ability to recognise 
several epitopes within a target protein. The polyclonality of antiserum is an 
advantage in techniques such as immunohistochemistry, where some epitopes 
can be destroyed by chemical fixation (Fritschy, 2008), however include the 
disadvantage of non-specific binding, as mentioned above. 
3.2.4 mAbs 
mAbs are also generated from animal immunisations with antigen, utilising the 
spleen cells. The B-cells from the spleen are fused with a myeloma cell line to 
create immortal hybridomas that secrete antibodies, whose specificity is 
determined by the B-cell fusion partner. Each hybridoma can produce large 
amounts of antibody and this population of hybridomas can be screened to 
allow selection of one or more that secrete antibody of requisite specificity 
(Kohler and Milstein, 1975). mAbs confer an advantage over polyclonal antisera 
as a preparation containing one specificity of antibody can consistently be re-
made, whereas different batches of antiserum can have different properties. 
3.2.5 Types of antigens for immunisation 
Immunisation protocols use different types of antigen, depending on the desired 
properties of the antibody. There are three main types of antigen: synthetic 
peptides that mimic protein sequences, full length protein, or recombinant 
protein fragments. 
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The use of synthetic peptides is technically simple and relatively straight 
forward, as pure peptides can be readily prepared. As the peptides are usually 
less than 40 amino acids in length they are not likely to resemble folded protein 
structures. If peptide epitopes are hidden within the folded protein structure, 
however, the antibodies generated could be non-functional, recognising only 
denatured antigen (Uhlen and Ponten, 2005). 
Immunisation with full length protein is a way of generating antibodies that 
recognise folded protein. Full length proteins can be expressed in eukaryotic 
systems provided the cells are equipped for correct protein manufacture. 
Alternatively, protein can be purified from the appropriate tissue, but the yield is 
usually low. Purification methods are most suited to soluble proteins, as 
obtaining pure transmembrane protein samples is technically challenging. The 
use of folded protein for immunisation has been questioned as proteins can be 
denatured during the immunisation protocol (Uhlen and Ponten, 2005). 
Protein fragments are portions of the full length protein and maintain the 
potential to retain structural features seen in the full length protein. The use of 
protein fragments is often more straightforward than generating full length 
protein, partly due to using affinity tags for protein purification. For example, a 
small histidine tag on either terminus of the protein fragment allows for quick 
purification using resin immobilised nickel. The use of protein fragments risk 
incorrectly folded protein structures, however this can be partially overcome by 
strategic selection of protein fragments with increased structural integrity and 
architecture (Uhlen and Ponten, 2005). 
3.2.6 Antibody design for CLDND1 structure 
CLDND1 is a hypothesised tetra-spanning transmembrane protein, consisting of 
intracellular N- and C-termini and two extracellular loops. The large first loop 
contains the conserved PMP-22/EMP/MP20/claudin superfamily motif and three 
cysteine residues, which are important for function by forming disulphide 
bridges in other superfamily members (Wen et al., 2004). The first loop also 
contains potential phosphorylation and glycosylation sites (Figure 7). The 
presence of these potential features within the CLDND1 molecule needs to be 
considered when designing immunisation strategies to ensure CLDND1 specific 
antibody generation.  
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3.3 Results 
3.3.1 Commercial antibody validation 
Five commercially available α-CLDND1 antibodies were available at the time of 
validation, so they were tested on CLDND1-transfected cells, to determine their 
CLDND1 binding characteristics, before the in-house antibodies were produced. 
CLDND1 folded protein binding was measured by flow cytometry and denatured 
protein binding was analysed by Western blot (Figure 13). The commercial 
antibodies had different CLDND1 staining patterns. Compared to each isotype 
control, positive cell surface staining was detected on all cell populations probed 
with the SIGMA 2 or the Santa Cruz antibody or in the CLDND1-transfected 
cells for SIGMA 1 antibody (Figure 13A). The CLDND1-transfected cell staining 
profile of SIGMA 2 and the Santa Cruz antibody was less compared to the 
mock-transfected cells stained with each commercial antibody, suggesting 
these antibodies were not specific to CLDND1, transfected CLDND1 behaved 
differently to native CLDND1, or transfected-CLDND1 levels were low. 
At the time the experiments were performed, the hypothesised location of 
CLDND1 was at the plasma membrane, but as this was not validated, 
commercial antibody binding to total CLDND1 was also assessed. For total 
CLDND1 expression, the transfected cells were fixed and permeabilised prior to 
staining (Figure 13B). Compared to each isotype control, CLDND1 staining 
mirrored the cell surface staining for the CLDND1-transfected cells probed with 
commercial antibody. A small shoulder was seen on the histogram of the 
CLDND1-transfected cells probed with the SIGMA antibodies, above any 
staining of the control cells. The Abcam, Santa Cruz and the Prosci antibodies 
had similar staining profiles between the CLDND1-transfected and the mock 
transfected samples. These data suggest that the two SIGMA antibodies were 
potentially recognising a small amount of CLDND1. These cells were prepared 
by UCB Celltech, but transfection efficiency was not determined and so the 
level of transfection remains unknown.
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Figure 13. Validation of commercial antibodies  
Mock-transfected (-) and CLDND1-transfected (+) FreeStyle™ 293-F cells were stained with each commercial antibody or isotype control 
before flow cytometry or Western blot analysis. Detection of native CLDND1 expression (A) on the cell surface or (B) total cellular 
CLDND1 expression by flow cytometry. (C) Western blot of total CLDND1 in cell lysates. Mk represents protein ladder marker. Data 
illustrate one experiment.   
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At the time these experiments were performed, there were conflicting datasets 
regarding CLDND1 RNA expression in HEK293 cells (www.genecards.org, 
www.biogps.org) and so we were uncertain whether the commercial antibodies 
were detecting native protein on mock-transfected cells. CLDND1 protein 
expression has subsequently been confirmed on HEK293 cells by mass 
spectrometry (Kim et al., 2011, Danielsen et al., 2011, Wagner et al., 2011), 
suggesting the staining identified by the SIGMA and Santa Cruz antibodies on 
mock-transfected cells may have been native CLDND1. If the staining with the 
Santa Cruz antibody was true CLDND1 staining, it may suggest that induced 
expression of CLDND1 may disrupt the detection of endogenous expression. 
Due to the conflicting RNA expression data, Western blotting validation of the 
commercial antibodies was also performed on CLDND1-transfected cell lysates. 
The molecular weight of CLDND1 is predicted at 28 kDa, yet a phenomenon is 
known to occur with helical transmembrane proteins where aberrant migration 
by up to 20 % of the predicted molecular weight of the protein is observed by 
SDS-PAGE relative to standard protein markers (Rath and Deber, 2013). Given 
this fact, bands between 34 kDa and 22 kDa were ascribed to CLDND1. 
No bands were visualised on the Western blots probed with either the Abcam or 
ProSci antibodies (Figure 13C). Bands were identified with the Santa Cruz 
antibody, yet these were nearly double the predicted molecular weight of 
CLDND1 and were present at similar intensities in both the mock- and 
CLDND1-transfected cell lysates. There was also an additional band present in 
the mock-transfected sample, around the predicted molecular weight of 
CLDND1, which wasn’t present in the CLDND1-transfected sample. Given the 
discrepancy in RNA expression profiling, it was difficult to determine whether 
the band present in the mock-transfected sample was true staining. Staining 
results were, however, expected to be more intense in the CLDND1-transfected 
sample, and so the bands identified with the Santa Cruz antibody were 
dismissed as non-specific interactions. 
Bands were also visualised in the CLDND1-transfected lysates using either 
SIGMA antibody. The SIGMA 1 antibody detected 5 main bands, two of which 
had the predicted molecular weight of CLDND1 and three of which migrated 
lower than predicted. There was also a faint band present around 50 kDa, 
similar to the one identified by the Santa Cruz antibody. Two main bands were 
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identified in the CLDND1-transfected lysate with the SIGMA 2 antibody, one of 
which was the correct molecular weight for CLDND1 and one of which migrated 
lower than predicted. Similar to the SIGMA 1 and the Santa Cruz antibody, a 
band around 50 kDa was also detected with the SIGMA 2 antibody. 
The data presented showed that two (SIGMA1 and SIGMA2) of the five 
commercial antibodies may detect CLDND1 by Western blot; however the 
binding of the antibodies to native CLDND1 was low. The quantity of CLDND1 
detected in the CLDND1-transfected cell lysates by Western blot was not 
reflected in the flow cytometry data, as a minimal difference in cell surface 
staining between mock-transfected and CLDND1-transfected cell populations 
was seen. It can be argued that there was a small amount of total CLDND1 
expression detected, yet as the antibodies were to be preferentially used for 
functional studies, the conditions (fixation and permeabilisation) required to 
obtain positive staining were not suitable. Additionally, as both antibodies 
highlighted several bands by Western blot, it is not known whether all these 
bands corresponded to CLDND1. The definitive way to assess specific binding 
would have been to block the epitope binding site of the antibody with specific 
substrate or peptide, but it was not feasible to perform this experiment, due to 
the lack of reagent availability. With the hope of generating an antibody which 
could be used for functional studies as well as for protein detection, in-house 
antibodies were generated and full antibody validation was performed to confirm 
specificity to CLDND1. 
3.3.2 In-house antibody generation 
Synthetic peptides were chosen for antibody immunisations as this method is 
the most straightforward way for generating antibodies and avoids the 
generation of overlapping specificities to other PMP-22/EMP/MP20/claudin 
superfamily members. Although antibodies generated in this manner may be 
non-functional, a tool to detect CLDND1 protein would be the first step in 
definitively identifying CLDND1 protein expression. Attempting to generate cells 
expressing CLDND1 protein to use for immunisation would be challenging 
without an antibody to detect whether cell surface protein expression was being 
achieved. 
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Four peptides were generated against CLDND1-specific extracellular regions of 
CLDND1, taking into account any potential functional motifs (Figure 7), and 
used in the immunisation protocol described (See Sections 2.3.1 and 2.3.2). 
Serum obtained from the rabbits, pre (preserum) and post (antiserum) 
immunisation, were tested for the presence of α-CLDND1 peptide antibodies. 
Each serum was tested for binding with its cognate or non-cognate peptide: 
2675-78 sera with CLE11 and CLE12 peptides (2675 and 76 cognate peptide is 
CLE11, 2677 and 78 cognate peptide is CLE12) and 2679-82 sera with CLE13 
and CLE21 peptides (2679 and 2680 cognate peptide is CLE13, 2681 and 82 
cognate peptide is CLE21) (Figure 14). All antisera bound to their cognate 
immunisation peptide in a dose dependent manner. There was minimal cross-
reactivity of 2675 and 2676 antisera with CLE12 (Figure 14B), 2678 antiserum 
with CLE11 (Figure 14A), 2679 antiserum with CLE21 (Figure 14D) and 2681 
and 2682 antisera with CLE13 (Figure 14C). Non-cognate peptide binding was 
seen with 2677 antiserum and CLE11 and 2680 antiserum with CLE21, 
suggesting some non-specific activity of those antisera. 
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Figure 14. CLDND1 peptide binding by immunisation serum 
Binding of (A) 2675-2678 antisera to peptide CLE11, where CLE11 is cognate 
peptide for 2675 and 2676, (B) 2675-2678 antisera to peptide CLE12, where 
CLE12 is cognate peptide for 2677 and 2678, (C) 2679-2682 antisera to peptide 
CLE13, where CLE13 is cognate peptide for 2679 and 2680, (D) 2679-2682 
antisera to peptide CLE21, where CLE21 is cognate peptide for 2681 and 2682. 
Arrows indicate increasing concentrations of serum used in the ELISA. Mean 
values were plotted with error bars illustrating SEM. Data illustrate one 
experiment performed in duplicate. 
 
 
After clarification that all antisera recognised cognate peptide, the ability of each 
antiserum to recognise native protein was assessed in CLDND1-AFP-
transfected cells. As the transfected CLDND1 is fused with the fluorescent AFP 
molecule, the fluorescence of AFP should mirror the antibody staining. The 
CLDND1-AFP-transfected cells were stained with each of the antisera and 
positive staining was assessed using fluorescence microscopy by merging the 
fluorescence of the antisera stain with the AFP fluorescence (Figure 15). Dual 
fluorescence was detected with all antisera except 2680 and 2682. However, 
only weak staining was detected with 2679 and 2681 antisera.
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Figure 15. Antisera binding to CLDND1 protein: CLDND1-AFP transfection 
SW1353 cells transfected with the CLDND1-AFP vector were fixed and permeabilised prior to staining with DAPI (blue) and antiserum 
followed by α-rabbit IgG-Alex Fluor® 594 (red). Cells were visualised via fluorescence microscopy and images were merged to assess for 
co-localisation with AFP fluorescence (green). Data illustrate one experiment.
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To confirm the staining wasn’t due to antisera binding to epitopes within the 
AFP molecule, a second construct was used for transfection, CLDND1-FLAG. 
The availability of robust α-FLAG antibodies allowed for the dual validation of 
antiserum CLDND1 binding by fluorescence microscopy and by Western blot 
(Figure 16). 2675, 2676, 2678 and 2681 antisera were tested owing to the most 
prominent staining with the CLDND1-AFP transfected cells. Additionally, the 
corresponding presera were also used to stain the western blots to look at non-
specific banding patterns.  
Immunofluorescence analysis revealed that the four antisera stained the 
CLDND1-FLAG-transfected cells in the same manner as the α-FLAG antibody, 
suggesting each antiserum recognised the CLDND1-FLAG protein (Figure 
16A). Western blot analysis showed a similar binding pattern of 2675, 2676 and 
2678 antisera to the α-FLAG antibody in the CLDND1-FLAG transfected cell 
lysates (Figure 16B). Interestingly, two bands were identified on the western 
blot with the α-FLAG antibody. Similar size bands were also identified in the 
CLDND1-FLAG transfected sample with the 2681 antiserum, yet these bands 
were present in different proportions to the α-FLAG control.  
A similar size band was also present on the 2678 and 2681 preserum blots, 
suggesting that the bands identified by 2678 and 2681 antiserum may not be 
CLDND1 specific, or the bands may be masked by non-specific staining at that 
size. There were no similar banding patterns on the presera blots of 2675 and 
2676 as the bands identified on the antiserum blots, strengthening the evidence 
that these two antisera recognised CLDND1. 
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Figure 16. Antisera binding to CLDND1 protein: CLDND1-FLAG  
(A) SW1353 cells transfected with CLDND1-FLAG vector were fixed and permeabilised prior to staining with antiserum followed by α-
rabbit IgG Alexa Fluor® 488 (green), α-FLAG antibody (red) and DAPI (blue). Cells were visualised by fluorescence microscopy. Images 
were merged to assess for co-localisation of CLDND1 and FLAG fluorescence (B) Mock transfected (-) or CLDND1-FLAG transfected (+) 
cell lysate blots were probed with preserum, antiserum or α-FLAG antibody. Protein loading was confirmed with GAPDH. Mk represents 
protein ladder marker. Data illustrate one experiment.  
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A definitive way to determine whether an antibody is binding specifically to the 
target of interest is to block antibody binding with the epitope specific peptide 
used for the immunisation. The Jurkat T-cell line was transfected with CLDND1-
AFP and stained with 2675 or 2676 antisera. Each antiserum was also pre-
incubated with CLE11 peptide or the non-epitope specific peptide, CLE12. As 
2681 antiserum binding appeared not to recognise CLDND1-FLAG protein, its 
staining pattern was used as a negative control. 
Figure 17 showed that both 2675 and 2676 antisera bound to CLDND1, as 
double positive staining was seen in the top right hand quadrant of the plot. This 
staining was not present in the presera samples. After pre-incubation of each 
antiserum with CLE11, the double positive staining was lost, but staining was 
still present when each antiserum was pre-incubated with the non-epitope 
specific peptide, CLE12, showing the specific blocking activity of the peptide. 
No CLDND1 staining was seen with the negative control antiserum 2681 
(Figure 17B), regardless of whether the antibody was pre-incubated with 
epitope specific peptide, or not. 
The double positive staining seen with 2676 antiserum was more pronounced 
than with 2675 antiserum. There was also an additional population identified 
with 2676 antiserum in the non-AFP-positive cells (Figure 17A*). An 
independent finding that CLDND1 is expressed on Jurkat cells (Wollscheid et 
al., 2009), suggests that the staining seen with the 2676 antiserum is due to 
native CLDND1 expression on Jurkats. Naturally, as both antisera were used at 
the same dilution, the differences in staining intensity could have arisen from 
differences in the proportions of CLDND1 specific antibodies in each antiserum.
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Figure 17. Antisera binding to CLDND1 protein: peptide blocking 
CLDND1-AFP transfected Jurkat cells were fixed and permeabilised prior to staining with 2675 or 2676 pre or antiserum (A) pre-
incubated with cognate CLE11 peptide or non-cognate CLE21 peptide. (B) 2681 pre and antiserum was used as a negative control and 
was also pre-incubated with peptide CLE12. AFP and CLDND1 dual staining was assessed by flow cytometry. * possible native CLDND1 
expression on Jurkats.
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The experiments described above investigated CLDND1 on fixed and 
permeabilised cells to increase the positive staining intensity therefore 
endogenous native CLDND1 surface expression was not determined. I 
therefore sought to determine whether the antisera recognised endogenous 
native CLDND1 on the surface of Jurkat cells. CLDND1 staining was seen with 
fixed Jurkat cells, so this population was used as a positive control to determine 
whether the antisera also bound to native CLDND1 (Figure 18). Fixed Jurkats 
stained with 2675 and 2676 antisera showed increased CLDND1 staining above 
each of the preserum, as expected (Figure 18A). No native staining was seen 
with any of the other sera (data not shown). Comparing the staining profiles of 
the non-fixed cells identified that although both antisera showed positive 
staining above the detection antibodies, the intensity of CLDND1 staining in the 
antisera populations were comparable to each of the presera stains, suggesting 
that the antisera did not recognise expression of endogenous native CLDND1. 
 
 
Figure 18. Antisera binding to CLDND1 protein: native versus fixed 
CLDND1 
CLDND1 expression was examined with 2675 and 2676 pre- or antiserum in 
Jurkat cells that were (A) fixed (B) or not, prior to CLDND1 staining. CLDND1 
staining was detected using α-rabbit IgG (H+L) PE conjugated antibody 
(detection). Staining was assessed by flow cytometry. Data illustrate one 
experiment. 
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From the data presented, 2675 and 2676 antisera consistently bound CLDND1 
by Western blot and on fixed cells, but not on non-fixed cells so both antisera 
were used to purify CLDND1 antibodies using a two-step affinity purification 
method, followed by buffer exchange and concentration. 
3.3.3 Purified antibody re-validation 
The CLDND1-specific antibodies present in 2675 antiserum were all captured 
during the affinity purification, as no CLE11 binding activity was detected in the 
non-column binding FT (Figure 19A). The column-eluted fractions (F1-6) 
retained α-CLDND1 antibody activity, as these antibodies bound CLE11 peptide 
in a dose dependent manner in an ELISA based assay (Figure 19B). The 
amount of CLDND1-specific antibody in the 2676 antiserum was greater than 
the 2675 antiserum, as CLDND1 peptide binding activity was still seen in the FT 
fraction (Figure 19A). Although binding activity was detected in the FT fraction, 
the highest affinity antibodies would have bound and been eluted from the 
affinity column. Again the eluted 2676 antiserum fractions also retained CLE11 
binding activity (Figure 19B).  
The purified antibody fractions were pooled, buffer-exchanged and 
concentrated before analysing antibody integrity by SDS-PAGE. Samples of 
each of the purified antibodies were loaded under reducing and non-reducing 
conditions. In the reduced fractions, ratios of the heavy (H) and light (L) chains 
of antibody are shown (Figure 19C). These proteins migrated to approximately 
55 kDa and 25 kDa, respectively (Lewis et al., 2008). The band intensity around 
25 kDa was higher in the 2675 purified fraction. As equal concentrations of each 
antibody were loaded, this suggests that the integrity of the antibodies in 2675 
was greater, as individual proteins less than 30 kDa would have been lost 
during the concentration process, due to the size of the filter. In both fractions, 
there was a contaminating band around 70 kDa. This molecular weight 
corresponded to SA monomers that could have disassociated from the affinity 
purification column. 
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Figure 19. Antisera purification 
2675 and 2676 antisera were purified by CLE11 affinity chromatography. (A) Binding of antisera and non-column bound FT to CLE11. (B) 
Binding of purified fractions (F1-6) to CLE11. (C) SDS-PAGE analysis of purified fractions, under reducing or non-reducing sample 
conditions. H2L2 represents intact antibody, HL represents half an antibody comprising one heavy chain and one light chain, H represents 
heavy chain monomer and L represents light chain monomer.  
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Comparison of the non-reduced samples showed that there was relatively little 
intact antibody (H2L2) in either of the purified samples. The low amount of full 
length antibody present in both the samples may be a consequence of the 
harsh elution conditions from the affinity purification. The large band that was 
present between 70-100 kDa may have represented half an antibody structure, 
comprising one heavy and one light chain (HL) (Beenhouwer et al., 2007). 
Further analysis of these samples by size exclusion chromatography followed 
by mass spectrometry would have clarified these bands. 
3.3.4 Antibody titrations for experimental techniques 
Both the purified antibody samples were re-validated for CLDND1 binding by 
flow cytometry and Western blot, as per the screening experiments (Figure 20). 
The intensity of CLDND1 staining was reduced in the presence of cognate 
peptide (Figure 20A), showing that the purified antibodies were specific to 
CLDND1, however not all the antibody binding was blocked, suggesting that the 
amount of CLDND1 antibodies present were greater than in the initial antisera. 
Western blot analysis identified that the purified antisera had more intense and 
a sharper staining pattern that the antisera, without emphasising the non-
specific bands detected outside the molecular weight range of CLDND1 (Figure 
20B). Throughout the antibody validation experiments, 2676 antisera and 
purified antibody had greater staining intensities and bound to both endogenous 
and over-expressed CLDND1, so purified 2676, herein referred to as α-
CLDND1 antibody, was taken forward for use in all characterisation 
experiments. 
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Figure 20. Antibody re-validation 
CLDND1-AFP transfected cells were fixed and permeabilised prior to staining with purified antibody (A), or antibody pre-incubated with 
cognate peptide CLE11 (B). The gate was set on the CLE11 blocked-stained cells for each purified antisera and was copied to the not 
blocked populations. (C) Western blot of CLDND1-FLAG transfected SW1353 cell lysates probed with antiserum or purified antibody.  
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Before CLDND1 expression characterisation experiments were performed, 
optimisations of CLDND1 and detection antibody concentrations were 
performed for Western blotting to determine the best signal ratio over 
background. The α-CLDND1 antibody was also pre-incubated with CLE11 prior 
to Western blot probing to confirm the specificity of the bands identified (Figure 
21 and Figure 22). Western blot titrations were performed on lysates from both 
CLDND1-FLAG-transfected SW1353 cells (Figure 21) and in CD4+ T-cells 
(Figure 22) as different staining patterns were seen between the two different 
lysates and confirmation of CLDND1 specificity was therefore required for both 
cell types. In the presence of a 5 times molar excess of peptide to antibody, all 
bands seen with the α-CLDND1 antibody were diminished, indicating that all 
bands identified by the α-CLDND1 antibody were specific to the CLDND1 
peptide. Based on the staining profiles seen, a concentration of 1:1000 α-
CLDND1 antibody and 1:3000 secondary antibody were chosen for subsequent 
experiments as these conditions resulted in high CLDND1 staining in both the 
CLDND1-FLAG-transfected SW1353 cell and CD4+ T-cell lysates, while 
minimising the excess use of reagents. CLDND1 and detection antibody 
titrations were also performed for flow cytometry staining (Figure 23). Based on 
the staining profiles observed, 1 µg of α-CLDND1 antibody and 1:200 dilution of 
secondary antibody were chosen for subsequent experiments. These conditions 
enabled the detection of CLDND1 from the secondary antibody only stained 
control, without using concentrations of both α-CLDND1 and secondary 
antibody surplus to requirements.
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Figure 21. Antibody Western blot titrations: transfected cell lysates 
CLDND1-FLAG transfected SW1353 cell lysate Western blots were probed with 
a 1:1000 dilution of 1 mg/mL α-CLDND1 antibody pre-incubated with none, 1:1 
or 1:5 molar ratio of cognate peptide CLE11, followed by differing dilutions of 
secondary antibody, respectively (A). 1:2000 or 1:5000 dilutions of 1 mg/mL α-
CLDND1 antibody were used to probe the Western blots, followed by 1:1000 or 
1:3000 dilutions of secondary antibody (B). Data illustrate one experiment.
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Figure 22. Antibody Western blot titration: CD4+ T-cell lysates 
48 hour α-CD3/CD28 expander bead activated CD4+ T-cell lysate Western blots were probed with 1:1000 dilution of 1 mg/mL α-CLDND1 
antibody pre-incubated with none, 1:1 or 1:5 molar ratio of cognate peptide CLE11, followed by either a 1:1000 or 1:3000 dilution of 
secondary antibody, respectively (A). A 1:2000 dilution of 1 mg/ml CLDND1 was used to probe the Western blot followed by either a 
1:1000 or 1:3000 dilution of secondary antibody. Data illustrate one experiment. 
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Figure 23. Antibody flow cytometry titrations 
FreeStyle™ 293-F cells were stained with varying concentrations of α-CLDND1 antibody (0.1, 0.5, 1 or 2 µg) and secondary antibody 
(1:50, 1:100 or 1:200 dilution). (A) Concentrations of secondary antibody only. (B) Varying concentrations of CLDND1 and secondary 
antibody. Data illustrate one experiment.  
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3.3.5 Immunoprecipitation 
IP is one way to potentially determine a function of CLDND1 (as discussed in 
Section 4.4.2), through the identification of binding partners. IP utilises target 
specific antibodies to purify out the target from a given preparation, for example 
a cell lysate. As a CLDND1 specific antibody has been generated, I could 
potentially use this antibody for IP. Classically, IP utilises the binding 
characteristics of Protein A or Protein G to IgG molecules, to capture antibody-
bait complexes. Since the α-CLDND1 antibody was purified by affinity 
chromatography, the proportions and activity of the antibody may not be 
restricted to the IgG subclass, and although the immunisation process will have 
been designed to maximise IgG production, there may be a possibility that 
selecting for antibodies using this method may impact negatively on findings. 
Alternatively, an antibody can be covalenty immobilised to aldehyde-activated 
agarose resin. Lysine molecules available on amino acid side chains of the 
antibody react with the aldehyde on the agarose resin, which can be stabilised 
in the presence of cyanoborohydride. This technique can be applied to any 
purified antibody sample regardless of species or class of antibody, and so was 
tested for the α-CLDND1 antibody. 
The potential of the α-CLDND1 antibody to bind to endogenous CLDND1 in 
activated CD4+ T-cell lysates was determined. The reactions were performed in 
SDS-free conditions, according to manufacturer recommendations. SDS can 
dissociate disulphide bonds present between antibody chains, so compromising 
the structural integrity of the antibody. No bands were detected in the fractions 
eluted from the IP column (Figure 24A, lanes 4 and 5), suggesting that CLDND1 
was not bound or eluted, at least not at high enough concentrations to be 
detected. If bands cannot be detected by Western blot, there wasn’t sufficient 
protein for sequencing analysis. Worryingly, the amount of CLDND1 detected in 
the cell lysate (Figure 24A, Lane 2) was low compared to other experiments at 
similar time-points (Section 5.3.1, Figure 39A), which were performed using 
SDS-containing RIPA lysis buffer. As the IP was performed in SDS-free 
conditions, there was a concern that CLDND1 may not be sufficiently 
dissociated from the cell membrane, explaining the low levels detected by 
western blot. 
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Figure 24. Antibody IP: Western blot analysis 
IP were performed on 48 hour α-CD3/CD28 expander bead activated CD4+ T-cell lysates or CLDND1-FLAG transfected FreestyleTM 
293-F cell lysates using α-CLDND1 antibody or α-FLAG antibody. (A) Blot probed with α-CLDND1 antibody for CLDND1 antibody IP on 
CD4+ T-cells under SDS free conditions. (B) Blot probed with α-CLDND1 antibody or (C) probed with α-FLAG antibody for FLAG IP on 
FreestyleTM 293-F  CLDND1-FLAG transfected cells under SDS free conditions. (D) Blot probed with α-CLDND1 antibody for CLDND1 
antibody IP on CD4+ T–cell lysates in 0.1% SDS. (E) Blot probed with α-CLDND1 antibody or (F) probed with α-FLAG antibody for 
scaled-up CLDND1 IP on FreestyleTM 293-F CLDND1-FLAG transfected cells in 0.1% SDS. 
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In order to determine whether SDS was required for CLDND1 extraction from 
the cell membrane, an alternative approach was adopted. Throughout this 
chapter, CLDND1-FLAG-transfected cell lysates have been used to identify the 
antiserum binding characteristics. FLAG based IP methods were readily 
available, so as a positive control, FLAG IP was performed on CLDND1-FLAG 
transfected cell lysates, under SDS-free conditions (Figure 24B). The quantity of 
CLDND1-FLAG identified in the whole cell lysate was quite low (Figure 24B, 
Lane 2), yet this population was substantially enriched after the IP (Figure 24B, 
Lane 4). Similar bands identified by the α-CLDND1 antibody were also detected 
on Western blots probed with α-FLAG antibody (Figure 24B and C). These 
findings suggested that SDS was not required for extraction of CLDND1 from 
cell membranes, and was a reflection of the binding properties of the α-
CLDND1 antibody during the IP. 
Three cysteines residues are present in the first extracellular loop of CLDND1, 
which, in other PMP-22/EMP/MP20/claudin superfamily members, form 
disulphide bridges (Wen et al., 2004). It was hypothesised that disulphide 
bridges were interfering with α-CLDND1 antibody recognition as the α-CLDND1 
antibody epitope lies within CLDND1s first extracellular loop. To try to enhance 
antibody recognition, 0.1 % SDS was added to the cell lysis buffer and CLDND1 
antibody IP was performed on the same activated CD4+ T-cell lysate. Four 
bands were detected in Western blot of the eluted fraction probed with α-
CLDND1 antibody (Figure 24D, lane 4). The two bands that were present at 55 
kDa and 25 kDa might have corresponded to α-CLDND1 antibody heavy and 
light chain monomers, while the band identified near 35 kDa could correspond 
to CLDND1. Unfortunately, not enough material was recovered to perform 
protein sequencing.  
The requirement for SDS in α-CLDND1 antibody mediated IP meant that the 
potential to identify CLDND1 binding partners was eliminated, as the SDS 
would have disrupted any potential interactions. It was still worthwhile 
performing the CLDND1 antibody IP to confirm the proteins identified by the α-
CLDND1 antibody were CLDND1. The CLDND1 antibody IP protocol was 
scaled up and repeated with CLDND1-FLAG transfected lysate in the presence 
of SDS (Figure 24E and F). Again, a band was detected at 55 kDa, in both the 
CLDND1 and FLAG antibody probed western blots. There were also 3 bands 
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detected on the Western blots in the eluted fraction probed by α-CLDND1 
antibody (Figure 24E, lane 4) and two bands in the eluted fraction detected by 
the α-FLAG antibody (Figure 24F, lane 4) which potentially corresponded to 
endogenous CLDND1 and transfected CLDND1-FLAG. However, when these 
samples were analysed by SDS-PAGE and detected using Silver Staining, 
there were a number of proteins in both the samples (Figure 25). It was not 
clear which bands corresponded to CLDND1 and so protein sequencing was 
not performed. 
 
 
Figure 25. Antibody IP: SDS-PAGE analysis 
Eluted CLDND1-FLAG protein IP fractions from the scaled-up CLDND1 and 
FLAG IP were analysed by SDS-PAGE with silver staining. 
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3.3.6 Post translational modifications of CLDND1 
Throughout this chapter, several bands have been identified around the 
predicted molecular weight of CLDND1. Some members of the PMP-
22/EMP/MP20/claudin superfamily, but not the claudins, have the potential to 
be N-glycosylated in the first extracellular loop (Maher et al., 2011), and such 
sites are present in the first extracellular loop of CLDND1 (Figure 7). Therefore 
the glycosylation status of CLDND1 was examined using PNGase F; an 
amidase that cleaves between the innermost N-Acetylglucosamine (GlcNAc) 
and asparagine residues of high mannose, hybrid, and complex 
oligosaccharides from N-linked glycoproteins (Maley et al., 1989). CLDND1-
FLAG transfected SW1353 cell lysates were incubated with PNGase F or with 
PBS prior to analysing protein banding patterns by Western blot (Figure 26). 
The three bands usually identified between 30-40 kDa were reduced to one 
band in lysates pre-incubated with PNGase F. This finding was consistent with 
CLDND1 being differentially glycosylated, but could only be confirmed through 
mutational analysis of the potential glycosylation sites.  
 
 
Figure 26. Analysis of glycosylation status of CLDND1 
CLDND1-FLAG transfected SW1353 cell lysates were incubated with PNGase 
F for 1 hour prior to Western blot analysis, probed with α-CLDND1 antibody. 
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3.3.7 Efforts to generate an antibody to native CLDND1  
Based on the data presented in this chapter, it was clear that the α-CLDND1 
antibody generated in response to peptide immunisation was not adequate for 
binding to native CLDND1, limiting the potential use of this antibody in 
functional studies. The advantages and disadvantages of using full length 
protein as an immunisation antigen have already been discussed but given that 
using synthetic peptides for immunisation did not produce antibodies with the 
correct characteristics, it was worth looking again at the potential to immunise 
with full length CLDND1 protein. Protocols using full length protein typically use 
artificially synthesised full length protein with adjuvant as the antigen. However, 
given the complications associated with isolating transmembrane proteins due 
to high hydrophobicity and lack of protein structure in the absence of the 
membranes, cellular immunisation using CLDND1-transfected fibroblasts 
seemed a better approach. Transfection of the cell surface immunogen into the 
fibroblasts would increase the likelihood of fully folded protein being expressed 
on the cell surface, and so produce a native protein conformation against which 
antibodies could be raised, as part of the humoral immune response. 
Four different CLDND1-expressing vectors were generated containing different 
promoters, with the idea to balance high CLDND1 expression with cell viability. 
The different vectors were transfected into the rabbit fibroblast cell line, Rab-9, 
and CLDND1 expression was examined (Figure 27). While there was a slight 
increase in cell surface expressed CLDND1 in all the transfected populations 
compared to the mock-transfected population, the increased level of protein 
expression would not have been substantial enough to generate a sufficient 
antibody response against CLDND1. On examination of total CLDND1 
expression (Figure 27B), there was an increase in CLDND1 expression with all 
the vectors, in a portion of the population. This staining profile indicated that 
CLDND1 was not trafficking appropriately to the cell surface.  
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Figure 27. Native CLDND1 immunisations: Rab-9 transfections 
The rabbit fibroblast cell line, Rab-9 was transfected with one of the four 
CLDND1 containing constructs; CLDND1-PIMMS, CLDND1-FerL, CLDND1-Elf 
or CLDND1-HCMV. 24 hour post transfection cells were fixed and cell surface 
expression was measured (A), or cells were fixed and permeabilised and total 
CLDND1 expression was measured (B), by flow cytometry. 
 
 
CLDND1 cell surface expression was not seen in the Rab-9 fibroblast cell line, 
so the transfected cells would not make a good immunisation tool. To try to 
overcome the problem of minimal cell surface CLDND1 expression, protein 
engineering strategies were approached. Transmembrane proteins can be 
internalised by clathrin- or caveolin- mediated endocytotic pathways (Lodish et 
al., 2000b). CLDND1 contains a clathrin-mediated endocytosis signal in its C-
terminal tail, suggesting it may be internalised in this manner. Previous studies 
have shown that protein truncation to remove the clathrin-mediated endocytosis 
signal allowed for high cell surface protein expression compared to the wildtype 
protein (Finney, H., UCB Celltech, unpublished data). 
Three truncated forms of CLDND1 were cloned into the PIMMS vector 
backbone (Figure 28A). The CLDND1-trunc construct had an introduced stop 
codon prior to the YTLM clathrin-mediated endocytosis motif and the CLDND1-
GPI1 and CLDND1-GPI2 constructs truncated after the second and first 
extracellular loops, respectively, and were fused directly to the 
glycosylphosphatidylinositol (GPI) sequence indicated. 
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Figure 28. Native CLDND1 immunisations: CLDND1 engineering 
Three truncated versions of CLDND1 were made: CLDND1-trunc (C-trunc), CLDND1-GPI1 (GPI1) and CLDND1-GPI2 (GPI2). (A) 
Mutated CLDND1 construct sequences. Underlined amino acids indicate transmembrane regions. The YTLM sequence is the clathrin-
mediated endocytosis signalling motif. Arrows indicate CLDND1 sequence termination for each CLDND1 construct.For C-trunc, a TGA 
stop sequence was inserted and for GPI1 and 2 the GPI sequence replaced the remaining amino acids. (B) CLDND1 cell surface 
expression in transfected CD4+ T-cells. (C) Total CLDND1 expression in transfected CD4+ T-cells lysates.  Western blot were probed 
with α-CLDND1 antibody. C2 represents CLDND1/C-trunc/GPI1 dimer, G2 represents GPI2 dimer. α-tubulin was used to control for 
protein loading. 
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Construct transfection into primary human T-cells effectively altered CLDND1 
cell surface expression (Figure 28B). Removal of the clathrin-endocytosis signal 
increased the CLDND1 cell surface expression when comparing CLDND1-trunc 
to full length CLDND1, but removal of both the clathrin-endocytosis signal and 
the second extracellular loop (CLDND1-GPI1) reverted the surface expression 
profile back to similar levels of full length CLDND1. Incorporation of a GPI 
anchor after the first extracellular loop resulted in a large cell surface expression 
of CLDND1. 
Total CLDND1 expression was also examined to determine whether the 
differences in cell surface expression were due to differences in total protein 
expression (Figure 28C). Comparable band intensities were seen between full 
length CLDND1 and CLDND-trunc but no loading control was detected in the 
full length CLDND1 sample. The reason for this is unknown. Total protein levels 
were normalised prior to loading on the gel and so may suggest CLDND1 
expression was greater with the full length CLDND1 expression vector based on 
these differences between the loading controls. Overall, the increased cell 
surface expression of CLDND1 in the CLDND1-trunc cells was not due to 
increased quantities of total CLDND1 protein in this sample.  
The predicted molecular weights for CLDND1-GPI1 and CLDND1-GPI2 are 24 
kDa and 16 kDa, respectively. There was marginal CLDND1 expression in 
CLDND1-GPI1 transfected cells but high expression in CLDND1-GPI2 
transfected cells. Two large bands were detected at the top of each lane for 
both GPI constructs, indicating protein aggregation. In the CLDND1-GPI2 
transfected cell lysates, two bands were present, suggesting protein 
glycosylation. Interestingly, in all the samples there was a band present at 
approximately double the molecular weight of CLDND1 (Figure 28C, C2) and 
also a band approximately double the molecular weight of CLDND1-GPI2 
(Figure 28C, G2), potentially suggesting dimer formation between CLDND1 
proteins. High cell surface CLDND1 expression has been achieved with the 
CLDND1-GPI2 vector in primary human CD4+ T-cells but in order to test the 
suitability of this vector for immunisations, transfections still need to be 
performed in the Rab-9 fibroblast cell line, which is an area for future 
investigation. 
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3.4 Discussion 
This chapter has followed the binding characteristics of both commercial and in-
house generated CLDND1 antibodies. Due to the unsuitability of the 
commercial antibodies, a decision was made to generate in-house antibodies, 
so full validation experiments could be performed. These experiments 
confirmed the generation of a CLDND1 specific antibody for use with Western 
blotting. The antibody was also suitable for the detection of CLDND1 cell 
surface expression by flow cytometry, provided the cells were fixed in 
formaldehyde prior to staining. The antibody has also revealed that CLDND1 
exists in a glycosylated state, yet mutational analysis would be needed to 
confirm the glycosylation sites.  The results obtained have given some insight 
into the potential structures and functional qualities of CLDND1. Both points will 
be discussed below. 
3.4.1 Formaldehyde fixation and CLDND1 structure 
A confounding finding in this chapter is the ability of the α-CLDND1 antibody to 
recognise CLDND1 in its fixed conformation but not in its native conformation. 
As the antibody was raised against a linear epitope, this would suggest that the 
extracellular loop in its native state is arranged in such a way that the epitope is 
not available for antibody binding; but on the addition of formaldehyde, this 
region becomes available for antibody binding. 
Formaldehyde is known to cause four different modifications on proteins: 
hydroxyl methyl (methylol) adducts, Schiff base adducts, 4-imidazolidinone 
adducts and methyl bridges. Formaldehyde can react with primary amines 
(lysine) and thiol groups (cysteine) to form metholyl groups. The methylol 
groups can then cross-link with the nucleophiles tyrosine, arginine, asparagine, 
glutamine, histidine, and tryptophan. 4-imidazolidinone adducts form at the N-
terminal site of proteins (Metz et al., 2004, Fowler et al., 2011), and so are 
unlikely to be involved in the α-CLDND1 antibody mechanism. The 
consequences of these reactions are well documented in immunohistochemistry 
leading to epitope masking and loss of antibody signal (Fritschy, 2008); yet 
conversely, the α-CLDND1 antibody binds in the presence of formaldehyde 
fixation, which is a less well documented phenomenon and indicates a 
mechanism that opens up the CLDND1 extracellular loop structure to allow for 
α-CLDND1 antibody binding.  
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Aqueous formaldehyde primarily exists in the form of methylene glycol, which 
alters protein tertiary structure by two mechanisms: promoting protein unfolding 
by weakening the hydrophobic stability of the protein core; or inducing β-sheet 
secondary conformation through interactions with the protein backbone, thus 
causing a collapse of the tertiary structure (Fowler et al., 2011). Either 
mechanism may explain CLDND1 epitope exposure during fixation. This 
information may also indicate a predominantly α-helical secondary structure in 
the first extracellular loop of CLDND1, yet to prove this, structural techniques 
such as x-ray crystallography would need to be performed. 
An alternative suggestion which enables α-CLDND1 antibody binding after 
formaldehyde fixation includes steric-hindrance or epitope sequestration by 
CLDND1-protein binding partners. Formaldehyde fixation may act on the 
CLDND1-binding partner(s), disrupting their conformation and allowing access 
for the α-CLDND1 antibody, although there is little evidence in the literature to 
support this model. 
3.4.2 CLDND1 glycosylation states 
Western blot analysis of CLDND1-transfected cell lysates confirmed CLDND1 
exists in different glycosylation states, which is consistent with several of the 
PMP-22/EMP/MP20/claudin superfamily members. The family member sharing 
the most homology to CLDND1, TMEM114, demonstrates glycosylation which 
is critical for cell surface location (Maher et al., 2011). The importance for 
glycosylation to help maintain TMEM114 protein stability and folding (Lodish et 
al., 2000a), was not addressed and, therefore may account for the phenotype 
observed. Mutational analysis of the sequence of CLDND1 would confirm 
whether glycosylation is important for its cellular distribution, but the effects of 
glycosylation on CLDND1 stability would need to be controlled for. 
A band of approximately double the molecular weight of CLDND1 was observed 
during Western blot analysis of CLDND1-transfected CD4+ T-cells, which was 
CLDND1 specific. These bands were also detected with the SIGMA and Santa 
Cruz antibodies during the commercial antibody validation. Independent studies 
in the PMP-22/EMP/MP20/claudin superfamily members, integral plasma 
membrane protein (IP) 39 and PMP-22, detected protein dimer formation by 
Western blot (Suzuki et al., 2013, Mobley et al., 2007), suggesting that CLDND1 
may also exist in dimers. 
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3.4.3 Rate-limiting factors for antibody generations 
One of the main limiting factors at the start of the project was the lack of 
evidence supporting CLDND1 protein expression in different cell types, which 
could have been used for the screening of both the commercial and in-house 
antibodies. At the time the experiments were undertaken, the choice to use 
CLDND1-transfected cells was most suited to assess for antibody binding. 
Alternatively, rat optic nerve cells or cultured oligodendrocytes (Fayein et al., 
2002) from where CLDND1 was originally discovered could have been used; 
yet protein expression was also not confirmed in these cells. The lack of 
experimental data assessing CLDND1 protein expression meant that robust 
validation techniques were required to identify true CLDND1 staining. The 
variety of techniques and experiments performed in this chapter has validated 
2676 antiserum as a CLDND1 binder. 
CLDND1-transfected cells were the most suited tool for screening α-CLDND1 
antibody specificity, but in the absence of a direct way to detect over-expressed 
CLDND1 protein, a CLDND1-AFP fusion protein was instead used to indirectly 
detect CLDND1, through AFP expression. The large AFP molecule shares a 
similar molecular weight to CLDND1 and raised potential issues with proper 
CLDND1 protein folding and trafficking to the cell surface membrane. 
Consequently, the CLDND-AFP transfected cells were fixed and permeabilised 
to help achieve the greatest intensity of staining over the high non-specific 
background binding of the preserum. Unfortunately, screening by this technique 
identified antibodies which only recognised fixed-conformation CLDND1. 
During the in-house α-CLDND1 antibody validation experiments, all antiserum 
binding was compared to the corresponding preserum, acting as a control. 
Upon purification of the CLDND1-specific antibodies, there was no equivalent 
isotype control as rabbit serum would contain a lot more non-specific binding 
properties than the purified antibody samples. Ideally, purification of antibodies 
from scrambled peptide sequence immunisations would have provided a similar 
preparation to the purified antibody to use as an isotype control. As a result, the 
percentage of CLDND1 positive cells was only determined by using 
fluorescence minus one (FMO) analysis. 
In retrospect, some of the commercial antibodies displayed similar binding 
properties as the in-house antibody, in particular the SIGMA antibodies, and 
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could potentially have been used as a positive control to screen for CLDND1 
binders. These antibodies however, were not used for this purpose as the 
quantities required for staining were large and not cost effective. 
For future immunisation strategies, it is a prerequisite to consider CLDND1 cell 
surface expression in Rab-9 rabbit fibroblast cells. The lack of cell surface 
CLDND1 expression seen may reflect the cell culture techniques: Rab-9 cells 
are an adherent cell line and require Accutase® treatment to remove them from 
tissue culture flasks. Accustase® treatment may have cleaved CLDND1 from 
the cell surface. Additionally, CLDND1 staining reflects one time-point, which 
may not represent normal CLDND1 expression profiles. The use of live cell 
imaging would resolve this issue, but would first require generation of a native-
CLDND1 binding antibody. Understanding this pathway could also infer 
mechanisms regarding CLDND1 regulatory mechanisms by cellular location. 
In conclusion, the generation of in-house antibodies has provided insight into 
potential CLDND1 extracellular loop structures and although these antibodies 
could not be used functionally, they have highlighted other strategies for 
production of functional antibodies, along with interesting features of the 
CLDND1 protein, which can be validated with further studies.
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Chapter 4.  Optimisation of CD4+ T-cell siRNA Transfection 
4.1 Aims 
The aim of this chapter was to identify a role for CLDND1 in the regulation of T-
cell activation by assessing the phenotype of CD4+ T-cells lacking endogenous 
CLDND1, targeted by short interfering RNA (siRNA). Firstly, a procotol for 
siRNA transfection needed to be optimised. At the time, due to a lack of a 
CLDND1-specific antibody, CLDND1 silencing was measured by qRT-PCR and 
protein silencing was assessed using siRNA and a monoclonal antibody against 
CD4. In CLDND1 silenced cells, T-cell proliferation was measured in response 
to α-CD3/CD28 expander bead stimulus along with their pro-inflammatory 
cytokine profile. 
4.2 Introduction 
CLDND1 function remains elusive owing to a lack of published evidence in any 
cell type. A regulatory function in CD4+ T-cells has been hypothesised from 
preliminary studies on the CD4+ T-cell clone, HA1.7, which showed lower levels 
of CLDND1 transcript in activated compared to anergic cells (Figure 6). Other 
suggestions for CLDND1 function have been predicted based on homology to 
the PMP-22/EMP/MP20/claudin superfamily. The claudins are important 
structural components of TJ, as well as mediating inter-cellular communication 
through signalling via the ZO protein family. Different claudins have been shown 
to interact homotypically and heterotypically with other claudin family members 
and these interactions impart specific function (Angelow et al., 2008). 
4.2.1 RNA interference 
RNA interference (RNAi) is evolutionary conserved in eukaryotes and has an 
essential role in the clearance of viral RNA. The effect of double stranded RNA 
(dsRNA) on the translational efficiency of messenger RNA (mRNA) was first 
described in Caenorhabditis elegans (Montgomery et al., 1998) and subsequent 
experiments unravelled the mechanism involved (Kurreck, 2009). In brief, 
dsRNA is processed by Dicer into siRNA around 21 nucleotides in length with 3’ 
unpaired ends. Once unwound, the siRNA duplex guides the RNA induced 
silencing complex (RISC) to complementary target mRNA. Site specific 
cleavage of the mRNA occurs 10 nucleotides from the 5’ end of the siRNA 
Katherine L. Crossland                      Chapter 4. Optimisation of CD4+ T-cell siRNA Transfection 
113 
strand by the catalytic component Argonaut 2 (Valencia-Sanchez et al., 2006). 
Post cleavage, the RNA is degraded by cellular exonucleases such as XRN1 or 
the exosome (Orban and Izaurralde, 2005). 
Early use of this technique in mammalian cells proved problematic as dsRNA 
sequences over 30 nucleotides in length mediated biological responses against 
the dsRNA, known as the interferon response, where general RNA degradation 
and shutdown of cellular processes occurs. The subsequent discovery that 21-
nucleotide siRNA could be transfected into cells while evading host responses, 
minimised off-target effects (Elbashir et al., 2001).  
4.2.2 Current CD4+ T-cell siRNA transfection techniques 
The prevalent transient transfection method of primary human CD4+ T-cells is 
electroporation: a transfection technique where the cell membrane phospholipid 
bilayer is disrupted by electrical pulses. Temporary pores are formed, through 
which small molecules such as DNA can pass into the cell. While nucleofection, 
a trade name for electroporation, is versatile and can be used with many cell 
subsets, it results in high cell toxicity and allows non-specific transport of 
material both in and out of the cell, which can lead to ion imbalance (Weaver, 
1995). 
4.2.3 Accell siRNA 
Dharmacon offer a variety of different siRNA and transfection moieties. Their 
Accell siRNA range is specifically designed for use with difficult to transfect cell 
types, such as primary human T-cells. Dharmacon claim Accell siRNA can 
achieve “delivery into difficult-to-transfect cells without additional reagents, 
virus, or instruments”. The modifications to the siRNA to facilitate transfection 
are novel and proprietary, but claim to facilitate siRNA stability and uptake while 
maintaining specificity and knockdown efficiency. 
Several recommendations are provided when using this product. Firstly, Accell 
siRNA works at a 1 µM working concentration, higher than conventional siRNA. 
Secondly, siRNA delivery may be inhibited by the presence of BSA in serum, so 
transfection with serum-free media formulations or less than 2.5 % serum in 
standard media are recommended. Dharmacon claim optimal mRNA silencing 
is typically achieved by 72 hours, or up to 96 hours for protein knockdown. 
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4.3 Results 
4.3.1 CD4+ T-cell isolation methods 
A highly pure isolated CD4+ T-cell population was required for the siRNA 
transfection experiments to prevent contaminating cells skewing any data 
interpretation. There are several methods for isolating CD4+ T-cells from whole 
blood, which fall under two categories: positive selection, where the cells of 
interest are selected using a specific cell surface marker; or cell enrichment, 
where undesired cells are depleted from the population, leaving an untouched 
cell population of interest. Three different CD4+ T-cell isolation protocols were 
therefore tested, monitoring CD4+ T-cell purity, CD14 contamination and cell 
viability (Table 12). CD14 contamination was monitored as monocytes express 
low levels of CD4, and so can be co-purified with CD4+ T-cells during positive 
selection. The highest percentage of CD3+/CD4+ cells (98.3%) were isolated 
using StemCell positive selection, followed by Miltenyi CD4 positive selection 
(94%). The lowest purity was obtained using StemCell CD4 enrichment 
(85.4%); however this protocol also had the lowest monocyte contamination 
(1.15%). The Miltenyi CD4 positive selection had the highest monocyte 
contamination (2.31%). Viability of the purified cell population was comparable 
between the different isolation methods. The StemCell CD4 positive selection 
method was chosen due to the high purity of the isolated CD4+ T-cell 
population. 
 
Isolation method 
CD3/4+ 
(%) 
CD4/14+ 
(%) 
Viable 
(%) 
StemCell CD4 positive selection 98.3 1.24 96.3 
Miltenyi CD4 positive selection 94 2.31 96.3 
StemCell CD4 enrichment 85.4 1.15 97.6 
 
Table 12. CD4+ T-cell isolation methods 
CD4+ T-cells were isolated from PBMC using Miltenyi CD4 positive selection, or 
from whole blood for StemCell positive selection and enrichment. Isolated 
populations were stained for CD3, CD4 and CD14 expression and viability 
determined with Annexin V and Via-Probe™. 
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4.3.2 Cell culture media optimisation 
After cell isolation but prior to transfection, Dharmacon recommend resting the 
cells by incubating them overnight. Two different cell culture media were tested 
for the rest incubation and the 72 hour transfection period: RPMI supplemented 
with 5 % FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-
glutamine, followed by RPMI supplemented as above but without FBS for the 
siRNA transfection period (RF-5/RF-0), against Xv15, a serum free T-cell 
medium. The RF-5/RF-0 media were used for comparison based on previous 
work (Crossland, K., 2010 Masters Dissertation).  
Transfection efficiencies for the RF-5/RF-0 and Xv15 media were examined 
using siGLO positive control siRNA (Figure 29). Dharmacon siGLO siRNA is a 
non-targeting (NT) positive control siRNA, labelled with Dy-547, a red 
fluorophore similar to PE. Transfection efficiencies using siGLO siRNA were 
equivalent with RF-5/RF-0 and Xv15 (Figure 29A). To determine the siRNA 
efficiency to silence protein, CD4 was used as a positive control and targeted 
using Accell CD4 SMARTpool siRNA (Figure 29B-E). Previous studies have 
shown that CD4 can be successfully targeted with siRNA in mouse CD4+ T-
cells (Mantei et al., 2008) and both CD4 mRNA and protein are easy to 
measure, due to high expression on CD4+ T-cells. 
CD4 mRNA levels were significantly reduced in both RF-5/RF-0 and Xv15 
media when normalised to the untransfected control (Figure 29B-C) (68 % in 
RF-5/RF-0 media compared to 50 % in Xv15). The reduction in CD4 mRNA also 
translated to a reduction in CD4 protein. Using GMFI to quantify CD4 protein, a 
61 % or 55 % decrease in CD4 was seen for RF-5/RF-0 or Xv15, respectively. 
Although there was a greater reduction in CD4 protein in RF-5/RF-0, the 
reduction in CD4 protein was more consistent between experiments in Xv15. 
Untransfected cells had a more uniform expression of CD4 in Xv15 compared to 
RF-5/RF-0, identified by the single peaked histogram (Figure 29D). 
T-cell recovery after culture in RF-5/RF-0 or Xv15 was better with Xv15, after 
the rest incubation (Figure 29E). Post 72 hour siRNA transfection, there were 
significantly more cells recovered in Xv15 than RF-5/RF-0. The presence of 
siRNA in either culture did not affect CD4+ T-cell recovery. Xv15 was chosen 
for all subsequent transfection experiments. 
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Figure 29. Accell siRNA transfection: cell culture media optimisation  
Positively isolated CD4+ T-cells were incubated in RF-5/RF-0 or Xv15 media in the presence of 1 µM Accell siRNA for 72 hours. (A) 
Histogram illustrating data from one siGLO siRNA transfection experiment. Cells were incubated with CD4 SMARTpool siRNA. (B) CD4 
mRNA levels were detected by qRT-PCR and normalised to pol2a. (C) CD4 protein levels were determined by GMFI. (D) Representative 
histogram of CD4 fluorescence on CD4 siRNA transfected cells or untransfected cells. (E) Cell recovery was assessed during the 
transfection protocol. Data illustrate  at least 3 independent experiments. Mean values were plotted with error bars illustrating SEM. 
Student’s t-test analysis was performed. *p<0.05, **p<0.01, ***p<0.001. 
Katherine L. Crossland                      Chapter 4. Optimisation of CD4+ T-cell siRNA Transfection 
117 
4.3.3 siRNA transfection protocol optimisation: manufacturer recommendations 
Although introduction of siRNA into immune cells is thought to bypass the 
interferon response, there have been reports that siRNA can actually trigger 
immune activation (Sioud, 2010). NT siRNA was therefore required to account 
for any off-target effects on T-cell function. Dharmacon offer four NT Accell 
siRNA. These siRNA were tested with CD4 SMARTpool siRNA (Figure 30). A 
significant reduction in CD4 mRNA was still achieved when normalising CD4 
mRNA levels in the NT 2, 3 and 4 siRNA samples. Contrary to the initial findings 
(Figure 29B), silencing was not reproduced using the no siRNA control (Figure 
30A), suggesting variability between experimental replicates. The reduction in 
CD4 mRNA seen in the CD4 siRNA sample compared to NT 2, 3 and 4 siRNA 
did not translate to an equivalent reduction in CD4 protein (Figure 30B), 
although protein levels were lower than control siRNA. The only significant 
reduction was found when normalising CD4 protein levels to the no siRNA 
control, indicating CD4 protein levels were lower in the NT siRNA samples 
compared to the no siRNA sample. 
All four NT siRNA and no siRNA were used as controls to validate the four 
CLDND1 Accell siRNA (C1-4). C1 and 2 siRNA bind within the CLDND1 ORF 
and CLDND1 siRNA 3 and 4 bind in the 3’ UTR (Appendix Figure 1). Post 
siRNA transfection, no consistent reduction in CLDND1 mRNA in the C1-4 
siRNA samples were seen when CLDND1 mRNA levels were normalised to any 
of the NT siRNA CLDND1 mRNA values (Figure 30C). There were large 
differences in relative CLDND1 mRNA expression in the C1-4 siRNA samples 
depending on the CLDND1 mRNA values used for normalisation from each 
control siRNA. 
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Figure 30. Accell siRNA transfection: manufacturer protocol 
Positively selected CD4+ T-cells were transfected with 1 µM Accell siRNA for 72 hours. All values are given as fold change in RNA 
compared to each control siRNA, after normalisation to pol2a mRNA. (A) CD4 SMARTpool siRNA: fold change in CD4 mRNA (B) CD4 
SMARTpool siRNA: fold change in CD4 protein MFI. (C) Accell C1-4 siRNA: fold change in CLDND1 RNA. Data illustrate at least four 
independent experiments. Mean values are plotted and error bars illustrate SEM. *p<0.05, **p<0.01, Student’s t-test.
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Due to the variation in relative CLDND1 gene expression, CD4+ T-cell viability 
was assessed post transfection, to determine whether gene expression profiles 
were being altered due to cell death (Table 13). There was no significant 
difference in T-cell viability post transfection with any of the Accell siRNA, 
suggesting the differences in CLDND1 mRNA levels were due to other factors.  
 
siRNA Viability (%) 
No siRNA 82 ± 10 
NT1 79 ± 6 
NT2 83 ± 7 
NT3 75 ± 8 
NT4 81 ± 6 
C1 81 ± 8 
C2 80 ± 8 
C3 80 ± 6 
C4 78 ± 6 
CD4 85 ± 5 
Table 13. Accell siRNA transfection cell viabilities: manufacturer 
recommended protocol 
CD4+ T-cells were transfected with 1 µM Accell siRNA for 72 hours. Post 
culture, cell viability was assessed using Annexin V and Via-Probe™. Values 
illustrate at least three independent experiments ± SD. 
 
 
4.3.4 siRNA transfection protocol optimisation: literature recommendations 
Two independent groups using Accell siRNA in human T-cells (Apetoh et al., 
2010, http://www.systemsimmunology.org/, no date), used the siRNA in the 
presence of TCR stimulation, so this approach was attempted with CD4 and 
CLDND1 siRNA. Initially, optimisations were performed using CD4 SMARTpool 
siRNA: CD4+ T-cells were stimulated with a 10:1 α-CD3/CD28 expander bead 
ratio for 72 hours in the presence of 1 µM CD4 SMARTpool or NT siRNA 
(Figure 31). This protocol will be referred to as the 72hrsiBead protocol. A 
significant reduction in CD4 mRNA and protein was seen in the CD4 siRNA 
sample compared to NT siRNA samples (Figure 31A-B): 54 ± 4 % for CD4 
mRNA and 36 ± 5 % for CD4 protein. 
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Figure 31. Accell siRNA transfection: modified protocol (72hrsiBead)  
Positively selected CD4+ T-cells were transfected with 1 µM Accell siRNA for 72 hours with 10:1 ratio of α-CD3/CD28 expander beads. 
Each bar illustrates the values of target mRNA levels in the given target siRNA sample, compared to the value in the given control siRNA 
or no siRNA sample (-), plotted as fold change. CLDND1 RNA values were first normalised to pol2a. (A) CD4 SMARTpool siRNA: fold 
change in CD4 mRNA. (B) CD4 SMARTpool siRNA: fold change in CD4 GMFI. (C) Accell C1-4 siRNA: fold change in CLDND1 RNA. 
Data illustrate at least 4 independent experiments. Mean values are plotted and error bars illustrate SEM. Student’s t-test analysis was 
performed. *p<0.05, **p<0.01, *** p<0.001. 
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CLDND1 gene silencing was assessed using C1-4 siRNA. A significant 
decrease in CLDND1 mRNA was achieved for C2-4 siRNA samples (35.9 %, 
69.7 % and 53.0 % respectively), when normalised to any NT siRNA CLDND1 
mRNA values, yet no reduction was seen in the C1 siRNA sample (6.3 %). The 
reduction in CLDND1 mRNA was consistent regardless of the NT siRNA used 
for normalisation (Figure 31C) and cell viability varied from 47 to 52% with the 
different CLDND1 siRNA (Table 14). 
 
siRNA Viability (%) 
No siRNA 46 ± 8 
NT1 55 ± 12 
NT2 51 ± 8 
NT3 50 ± 21 
NT4 52 ± 16 
C1 50 ± 11 
C2 47 ± 13 
C3 50 ± 5 
C4 52 ± 13 
CD4 42 ± 9 
 
Table 14. Accell siRNA transfection cell viabilities: literature 
recommended protocol 
CD4+ T-cells were transfected with 1 µM Accell siRNA for 72 hours with 10:1 
ratio of α-CD3/CD28 expander beads. Cell viability was assessed using 
Annexin V and Via-Probe™. Data illustrate two independent experiments ± SD. 
 
 
4.3.5 siRNA transfection: effect on T-cell function 
Post the 72hrsiBead protocol, T-cell proliferation was assessed. Based on 
higher CLDND1 expression in anergic cells compared to activated counter-parts 
(Section 1.10, Figure 6) a reduction in CLDND1 transcript should correlate with 
increased T-cell proliferation. Instead, a significant reduction in T-cell 
proliferation was seen in cells incubated with C4 siRNA compared to no siRNA 
and NT2 siRNA samples (51 % reduction, on average) (Figure 32).  
 
Katherine L. Crossland                      Chapter 4. Optimisation of CD4+ T-cell siRNA Transfection 
122 
 
Figure 32. CLDND1 gene silencing and T-cell function: 72hrsiBead 
Positively selected CD4+ T-cells were transfected with 1 µM Accell C2-4 siRNA 
for 72 hours with 10:1 ratio of α-CD3/CD28 expander beads. Proliferation was 
determined by 3HTdR incorporation. Data illustrate at least 5 independent 
experiments where each experimental replicate was normalised to one data 
value in the no siRNA control, for every independent experiment. Mean values 
are plotted and error bars illustrate SEM. Student’s t-test analysis was 
performed. *p<0.05.  
 
 
A reduction in proliferation was only seen for the C4 siRNA sample, and not in 
C2 and C3, where there was also a reduction in CLDND1 mRNA. One possible 
explanation is different levels of CLDND1 protein within the siRNA transfected 
cells, as a result of different CLDND1 transcript degradation rates of each 
siRNA. The lack of CLDND1 specific antibodies available at that time, and an 
unknown CLDND1 protein half-life meant protein levels could not be measured, 
so the protocol was further optimised to account for a lag time between reduced 
CLDND1 RNA levels resulting in reduced CLDND1 protein levels.  
After the 72hrsiBead protocol, the α-CD3/CD28 expander bead stimulus was 
removed; the cell medium was refreshed and the cells were rested for a further 
3 days (72hrsiBeadRest). CLDND1 mRNA levels were examined after the 3 day 
rest (Figure 33A), prior to re-stimulation. At this time-point, CLDND1 mRNA 
levels in the CLDND1 siRNA samples were starting to return to the CLDND1 
mRNA levels seen in the NT siRNA samples, but were still significantly reduced 
in C3 and C4 siRNA samples when normalised to the CLDND1 mRNA levels in 
the no siRNA and NT2 siRNA samples.  
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Figure 33. CLDND1 gene silencing and T-cell function: 72hrsibeadRest 
Positively selected CD4+ T-cells were transfected with 1 µM Accell C2-4 or NT 
2 or 4 siRNA for 72 hours with 10:1 ratio of α-CD3/CD28 expander beads. Cells 
were rested for 72 hours prior to re-stimulation with 10:1 ratio of α-CD3/CD28 
expander beads. (A) CLDND1 RNA levels relative to control siRNA. Each bar 
illustrates the CLDND1 mRNA level in the CLDND1 siRNA sample, compared 
to the value in the control siRNA or no siRNA sample (-), plotted as fold change. 
CLDND1 RNA values were first normalised to pol2a. (B) Proliferation was 
determined by 3HTdR incorporation. (C) IL-2 production or (D) IL-10 production 
measured by ELISA. For (B-D), data illustrate three independent experiments 
where values were normalised to one data point in the no siRNA control or NT4 
siRNA for (C) and (D), for each independent experiment. Mean values are 
plotted and error bars illustrate SEM. Student’s t-test analysis was performed. * 
p<0.05, *** p<0.001. 
 
 
Using the 72hrsiBeadRest protocol, the effect of CLDND1 silencing on T-cell 
proliferation was examined. A significant reduction in T-cell proliferation in cells 
pre-incubated with C4 siRNA was seen (Figure 33B). It is unclear whether there 
was a reduction in IL-2 and IL-10 production, due to the variability in the control 
siRNA values (Figure 33C and D) and no difference in IFNγ, IL-5 or IL-17 
production (data not shown). The reduction in proliferation was more subtle with 
this protocol than the 72hrsiBead protocol (Figure 32).  
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4.3.6 siRNA transfection: effect on nTreg function 
The 72hrsiBead protocol was tested in an isolated nTreg population and the 
ability of the nTreg to suppress Teff proliferation in a mixed lymphocyte reaction 
(MLR) was assessed. Post siRNA transfection, nTreg CLDND1 mRNA levels 
were significantly reduced in the C3 siRNA sample but the decrease in 
CLDND1 mRNA levels in the C4 siRNA sample was not significant (Figure 
34A). There was a trend for an increase in Teff proliferation when cultured with 
the nTreg that was pre-incubated with C4 siRNA (Figure 34B), yet this was very 
variable between experimental replicates. There was also variability in IFN-γ 
production between the siRNA samples (Figure 34C) and so it was difficult to 
draw a conclusion on a function for CLDND1 in nTreg. 
 
 
Figure 34. CLDND1 gene silencing: nTreg suppression assay 
nTreg cells were transfected using the 72hrsiBead protocol, prior to performing 
a suppression assay. (A) Fold change in CLDND1 RNA relative to control 
siRNA. Each bar illustrates CLDND1 mRNA levels in the CLDND1 siRNA 
sample, compared to the value in the control siRNA or no siRNA sample (-), 
plotted as fold change. CLDND1 RNA values were first normalised to pol2a. (B) 
Proliferation of Teff were determined by 3HTdR incorporation. (C) IFNγ 
production was measured by ELISA. Data illustrate four independent 
experiments. Mean values are plotted and error bars illustrate SEM. Student’s t-
test analysis was performed. *** p<0.001. 
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4.3.7 siRNA transfection: CLDND1 protein 
On completion of the in-house antibody validation (see Section 3.3.3), cell 
surface and total CLDND1 protein levels were determined in cells transfected 
with Accell siRNA, for both 72hrsiBead and 72hrsiBeadRest protocols. 
Correlating differences in CLDND1 protein levels to reduced T-cell proliferation 
in the C4 siRNA sample may allude to CLDND1 function. 
Characterising CLDND1 protein expression in CLDND1 siRNA transfected cells 
showed that regardless of the optimised protocol used, there was no consistent 
reduction in cell surface or total CLDND1 protein in the CLDND1 siRNA 
samples, when normalising CLDND1 protein levels to control siRNA (Figure 
35). A reduction in CLDND1 cell surface protein was observed in the CLDND1 
siRNA samples compared to a no siRNA control in the 72hrsiBeadRest protocol 
(Figure 35C), and indicates that the transfection protocol is altering CLDND1 
protein expression itself. Contrary to expected findings, there was a trend for a 
minimal increase in CLDND1 protein at the cell surface with C4 siRNA, and a 
total increase in CLDND1 protein with C3 and C4 siRNA (Figure 35A and B). 
The non-concordance of CLDND1 mRNA values to CLDND1 protein levels in all 
of the siRNA transfected cells has significantly affected the interpretation of my 
experimental series. Even though the reduction in CLDND1 mRNA was not 
reflected in a reduction in CLDND1 protein, there were still functional 
differences observed between the C4 siRNA sample and the control siRNA, 
albeit subtle. Instead of a reduction in CLDND1 protein in the C4 siRNA sample, 
there was a slight increase in CLDND1 protein, suggesting the increased 
CLDND1 protein expression in the C4 siRNA sample may account for the 
decrease in proliferation seen in this transfected sample, although the increase 
in CLDND1 protein is minimal. Overall, the results are still consistent with the 
hypothesis that CLDND1 acts as a negative regulator of T-cell proliferation, 
rather than a positive regulator of T-cell proliferation as suggested by the 
CLDND1 siRNA and mRNA data.
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Figure 35. Accell siRNA transfection: CLDND1 protein  
CD4+ T-cells were transfected with 1 µM Accell C2-4 or NT 2 or 4 siRNA using the 72hrsiBead protocol. Each bar illustrates CLDND1 
protein levels, determined by CLDND1 GMFI, in the CLDND1 siRNA sample compared to the value in the control siRNA or no siRNA 
sample (-), plotted as fold change. Data illustrate three independent experiments. (A) Surface CLDND1 GMFI. (B) Total CLDND1 GMFI. 
Cells were transfected using the 72hrsiBeadRest protocol. (C) Surface CLDND1 GMFI. (D) Total CLDND1 GMFI. Data illustrates five 
independent experiments. Mean values are plotted and error bars illustrate SEM. Student’s t-test analysis was performed. 
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4.4 Discussion 
This chapter has studied an alternative method of introducing siRNA into 
primary human CD4+ T-cells, omitting the need for nucleofection. However, 
although this method could silence the CLDND1 gene, no consistent effect was 
seen on CLDND1 protein and so a function for CLDND1 in the regulation of 
CD4+ T-cell proliferation could not be determined. Even though the Accell 
method was apparently not suitable for CLDND1, different Accell siRNA have 
since been successfully used in primary human T-cells (Gomez-Valades et al., 
2012), validating the Accell CD4 siRNA silencing performed in this chapter. 
Documented success with Accell siRNA would suggest an issue using the RNAi 
technique for CLDND1, rather than a problem with the Accell siRNA. There are 
numerous technical and theoretical considerations to explore to help explain the 
issues of silencing CLDND1 in primary human CD4+ T-cells, which will be 
addressed accordingly. 
4.4.1 Technical considerations 
It has been widely argued that isolating T-cells using CD4 positive selection 
may lead to altered function of the T-cell and skew data interpretation, due to 
the targeting of a co-receptor. Nonetheless, microarray data analysing positively 
and negatively selected T-cells suggests that gene expression profiling in each 
CD4+ T-cell population is comparable regardless of the T-cell isolation 
technique (Lyons et al., 2007). Additionally, the effects of T-cell function during 
CLDND1 silencing were compared to controls, which have also been subjected 
to the same isolation method. Any difference mediated through silencing 
CLDND1 should therefore remain identifiable. 
Evidence suggests that the siRNA silencing technique is applicable to primary 
human CD4+ T-cells, so discrepancies between the CLDND1 mRNA and 
protein data may be a due their detection techniques. Measuring siRNA 
mediated mRNA silencing using qRT-PCR has the potential to generate false 
positives and false negatives. An independent study identified how positive 
results can be missed due to inadequate primer design (Holmes et al., 2010). 
Designing primer sets downstream of the siRNA binding site may give false 
negatives due to primer binding to the 3’ mRNA degradation product even 
though the cleavage of RNA is sufficient to reduce RNA translation. In the case 
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of the CLDND1 silencing experiments, the design of CLDND1 primers could 
potentially have resulted in a false negative observation for C1 siRNA, as 
CLDND1 primer sites sit downstream of where this siRNA binds.  
Similarly, false positives can be generated when using qRT-PCR primers that 
flank the siRNA-mediated cleavage site. For in vivo siRNA mediated gene 
silencing in animal studies, higher concentrations of siRNA are required. Excess 
siRNA can be purified with cellular RNA and can interfere with RNA 
amplification during reverse transcription, lowering the perceived amount of 
target RNA during qRT-PCR (Herbert et al., 2011). As the Accell method 
requires higher concentrations of siRNA than other transfection methods, false 
positives could be a concern. In order to prevent detection of false negative and 
positives, it is proposed that qRT-PCR primers should be designed to bind 
upstream of the siRNA binding site (Herbert et al., 2011). In fact, analysis of the 
qRT-PCR primers used to detect CLDND1 transcripts reveals that the primers 
bind upstream of all the siRNA (Appendix Figure 1), and so excludes the 
possibility of detecting false positives and negatives in these experiments.  
Thus the likelihood of differences in CLDND1 protein and mRNA detection 
being due to the mRNA technique used is unlikely. Focus next falls on the 
method of detecting CLDND1 protein using the in-house antibody. The antibody 
specificity was confirmed by performing peptide blocking experiments (see 
Section 3.3.2) so it was improbable that the α-CLDND1 antibody generated 
bound to other proteins that mask any changes in the levels of CLDND1 protein. 
4.4.2 Theoretical considerations 
From the points discussed, technical errors to account for differences in 
detecting CLDND1 RNA and protein seem unlikely. Instead these discrepancies 
may represent a method of CLDND1 translational regulation. 
One possibility looks at the translation of CLDND1 transcript as its own 
regulatory mechanism for protein expression, independent of the level of mRNA 
in the cell. This type of regulation has been shown for another protein BiP, an 
ER-stress protein, where increased cellular RNA levels were not reflected by 
increased protein, which remained constant under steady state conditions. 
When ER stress was induced, transcript translation was disproportionally 
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increased from the same amount of transcript, compared to the steady state 
condition (Gulow et al., 2002). 
Similarly, the quantity of CLDND1 mRNA may not prove essential in the role of 
CLDND1 protein expression, if the position of CLDND1 within the cell is part of 
a mechanism to regulate protein function. For example, CTLA-4 is a potent 
negative regulator of CD4+ T-cell proliferation and its cell surface location is 
tightly regulated. CTLA-4 is not present on the surface of resting T-cells and is 
only up-regulated upon T-cell activation, where it can exert its effect. The CTLA-
4 protein is primarily localised to intracellular vesicles and cycles between there 
and the cell surface (McCoy and Le Gros, 1999).Whilst these two mechanisms 
could potentially explain my findings, there may also be additional reasons to 
explain the discrepancies between CLDND1 mRNA and protein observed 
during the siRNA silencing experiments.  
During the siRNA experiments, four different CLDND1 siRNA were used to 
target the CLDND1 transcript. I have shown that these four siRNA differed in 
their efficiency to down-regulate the CLDND1 transcript. Based on the sites the 
siRNA binds to within the CLDND1 mRNA, the efficiency of these siRNA could 
allude to potential regulation of the CLDND1 transcript post-transcriptionally, 
namely by microRNAs. MicroRNAs are endogenous double-stranded RNA 
sequences that have been shown to regulate protein expression through 
repressing translation of RNA transcripts. C3 and C4 siRNA showed the most 
efficient targeting of the CLDND1 transcript and these siRNA bind to the 3’UTR 
of the CLDND1 transcript. One group have reported that 3’ UTR targeting is the 
most effective way of targeting transcripts in primary T-cells, while ORF-binding 
siRNA was ineffective and this targeting was identified in several types of cells. 
Although their studies are limited and they admit that further screening may 
identify ORF siRNA repressors, they suggest that the 3’ UTR of genes that can 
be silenced by siRNA may also be targets for regulation by microRNAs 
(McManus et al., 2002). Also interestingly, genes that avoid microRNA 
regulation have transcripts that have varying 3’ UTR lengths (Cheng et al., 
2009). The CLDND1 siRNA that are most effective target the 3’UTR of the 
transcripts. In addition, all CLDND1 transcripts have the same length 3’UTR 
(Appendix Figure 1). These two factors may suggest that CLDND1 may be 
regulated by microRNAs.  
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The presence of the siRNA, a double stranded RNA molecule, may itself alter 
CLDND1 protein expression, as TLR signalling in the CD4+ T-cells may have 
been induced. It has been shown in PBMC that siRNA mediated silencing can 
induce immune activation through endogenous TLR triggering, as well as TLR-
independent mechanisms (Sioud, 2010). Most TLR are expressed on and in T-
cells and activation of TLR can induce co-stimulatory molecule expression 
(CD69) on T-cells (Simone et al., 2009). We have shown than CLDND1 is up-
regulated upon TCR-induced T-cell activation (Section 5.3.2, Figure 38) with a 
modest increase in CLDND1 RNA (Section 5.3.2, Figure 39). Therefore if Accell 
siRNA activated TLR in lymphocytes and induced CLDND1 translation, this 
could overcome the effects of siRNA silencing. Similarly the activation of CD4+ 
T-cells by α-CD3/CD28 expander beads during the siRNA transfection period 
could also over-ride any down-regulatory effects of the CLDND1 siRNA. These 
mechanisms may provide a useful insight into how CLDND1 protein function is 
regulated, however an extensive amount of research would need to be 
performed to verify any such mechanisms. 
This chapter has revealed that silencing the CLDND1 gene is not a suitable way 
of determining CLDND1 function. An alternative method to investigate the 
CLDND1 protein would be to over-express the protein. This would be the next 
step in trying to identify CLDND1 function. Failing this, it may be worthwhile 
visiting other methods of determining protein interactions to determine a 
function for CLDND1. As protein-protein interactions are critical for cellular 
function, there are several techniques that identify the interactions of a given 
protein in its environment. Two examples of these techniques are yeast-two 
hybrid screening systems, and co-IP.  
Yeast-two hybrid screening allows for large scale screening of potential protein 
binding partners. The basic principle of this technique utilises the binding and 
interaction characteristics of transcription factors. A bait protein is fused to the 
DNA binding domain of a transcription factor and the prey protein is fused to the 
transcriptional activation domain of that transcription factor. Expression and 
interaction of the two proteins results in the transcription of a transcription factor 
specific reporter gene (Ratushny and Golemis, 2008). This technique is 
performed in a host cell, such as yeast, that is predominately easier to 
manipulate than the cell subsets of interest and, as such, false positive 
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interactions may be highlighted, as cell-specific regulation of proteins is not 
accounted for. It has been recorded that non-specific interactions can account 
for up to half of the results collected (von Mering et al., 2002). Initial studies 
using the yeast-two hybrid screening approach were limited to soluble protein 
interactions and so may not be suited to identifying binding partners for 
CLDND1. However, a variant of this technique, termed the split-ubiquitin 
membrane-based yeast two-hybrid system, allows for integral membrane 
protein interactions to be studied (Thaminy et al., 2004). To determine CLDND1 
binding partners a high-throughput screen would be required, as potential types 
of interacting partners are unknown and therefore cannot be pre-selected for. 
Given the reported number of false positive results generated using this, it 
would be challenging to verify actual binders. The yeast two-hybrid system 
could be utilised after functional studies confirmed a role for CLDND1 in the 
regulation of CD4+ T-cell activation, to validate potential CLDND1 interactions. 
A different method for determining protein-protein interactions is to perform co-
IP experiments using cell lysates containing CLDND1. Lamentably, IP 
performed with either the α-CLDND1 antibody or using α-FLAG, to isolate 
binding partners to FLAG tagged CLDND1 over-expressed protein (see Section 
3.3.5), were unsuccessful to identify potential CLDND1 binding partners. 
Another method reliant on robust functional antibodies is to perform antibody 
blocking experiments to determine whether blocking potential interaction sites 
on CLDND1 may disturb its function, or alternatively act in an agonistic fashion 
and increase any function that CLDND1 may possess. With this approach, 
potential CLDND1 interaction sites would need to be identified along with a 
function for CLDND1 in order to have a read-out on the functional effects of the 
antibody. More immediately, functional antibodies would also have to be 
generated. In order to determine the function of CLDND1 in the absence of 
these reagents, over-expression studies would give the best insight into the role 
of CLDND1 in primary human CD4+ T-cells. 
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Chapter 5. CLDND1 Expression Profiling 
5.1 Aims 
The aim of this chapter was to identify a role for CLDND1 in primary human 
CD4+ T-cells through its expression profiling under a range of different stimuli. 
In order to understand roles of CLDND1 within the immune response as a 
whole, CLDND1 protein expression was also sought on a variety of different 
immune cell subsets. CLDND1 expression patterns were documented during 
CD4+ and CD8+ T-cell TCR-mediated activation and also in the presence of the 
immunoregulatory cytokine, TGF-β, as CLDND1 expression patterns could infer 
roles for CLDND1 in the regulation of the immune response. CLDND1 protein 
expression was identified with the in-house generated α-CLDND1 antibody 
using flow cytometry and, where individual subsets were isolated, CLDND1 
protein expression was confirmed by Western blotting and CLDND1 mRNA by 
qRT-PCR. Finally the expression of CLDND1 was determined in early arthritis 
(EA) patients, with focus on the early RA subgroup to determine a potential role 
for CLDND1 in arthritic disease progression. 
5.2 Introduction 
Characterisation of different immune cell subsets and functions has been aided 
through the division of these subsets by distinct cell surface protein expression 
profiles. These sub-divisions have allowed for separation between pro-
inflammatory immune responders and those involved in regulating immune 
responses. One type of regulatory immune response that has generated 
interest from an immunotherapeutic perspective is the hypo-responsive state of 
anergy. Although several proteins have been identified in the process of anergy, 
many of these proteins are present within the cytoplasm, and so are not ideal 
targets for biological therapy. Identification of a cell surface protein that can 
specifically modulate an aspect of the immune response would make a more 
tractable therapeutic target. 
5.2.1 Documented expression of CLDND1 to date 
CLDND1 is a tetraspanning transmembrane protein of unknown function. 
CLDND1 gene and protein expression has been documented on only a handful 
of cell types. Gene expression was first described in rat optic nerve cells, with 
Katherine L. Crossland                                                   Chapter 5. CLDND1 Expression Profiling 
133 
focus drawing on the oligodendrocyte population and so a role for CLDND1 in 
myelination of the central nervous system was suggested (Fayein et al., 2002). 
The increasing popularity of RNA microarray analysis of cell types has 
subsequently lead to the identification of CLDND1 gene expression in mouse 
hepatoma Hepa-1c1c7 cells (Hao et al., 2012) and within whole blood (Beineke 
et al., 2012), yet it’s detection in CD4+ T-cells remained elusive. Advances in 
mass spectrometric techniques has recently detected CLDND1 protein on both 
HEK293T cells and in human U2OS osteosarcoma cells, yet no inference was 
made to its function apart from the fact that CLDND1 protein can be 
ubiquitinated, and so is probably targeted for degradation in this manner (Kim et 
al., 2011, Wagner et al., 2011, Danielsen et al., 2011). The potential presence 
of CLDND1 on the cell surface of CD4+ T-cells, as well as its differential 
expression between activated and anergic CD4+ T-cell clones has sparked our 
interest in the function of CLDND1 in the CD4+ T-cell immune response. 
Elucidating a role for CLDND1 in the CD4+ T-cell immune response may open 
avenues of research into a novel therapeutic target. 
5.2.2 Expression of the PMP-22/EMP/MP20/claudin superfamily members in 
T-cell subsets 
CLDND1 shares homology to the PMP-22/EMP/MP20/claudin superfamily 
which contains a diverse population of proteins of differing cellular functions and 
distributions. One sub-group of this family, the claudins, are important structural 
and functional components of epithelial TJ. Based on shared homology, the 
documented expression of PMP-22/EMP/MP20/claudin superfamily members 
on T-cells was investigated. Expression of some claudins has been 
documented in different stages of T-cell development and function. 
Claudin-4 is expressed in CD4/CD8 double positive thymocytes and is diffusely 
distributed on the cell surface of these cells, independently of CD3 but in 
association with CD4 and lck (Kawai et al., 2011). Upon TCR engagement, 
claudin-4 recruits to the IS and co-ligates with CD3, resulting in a marked 
increase in T-cell activation. Claudin-4 is subsequently down-regulated in the 
thymocytes post TCR activation, leading to a theory that claudin-4 is important 
in thymocyte positive selection, independently of its known function in TJ. 
Claudin -10, -11, -12 and -20 transcript is also present in these thymocytes, 
their function remains unknown (Kawai et al., 2011).  
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Both claudin-1 and -5 are expressed on CD20+ B-cells, CD14+ monocytes and 
CD4+ and CD8+ T-cells and co-localise with the integral TJ proteins ZO-1 and 
ZO-2 (Mandel et al., 2012). In the presence of α-CD3 stimulus, claudin-1 protein 
levels increase on CD4+ T-cells by four times the resting levels. Claudin-5 
levels are not affected by T-cell stimulation (Mandel et al., 2012).  
5.2.3 TGF-β signalling in T-cells 
In the work that follows, CLDND1 cell surface expression was partially regulated 
by TGF-β and so it is important to understand the roles of TGF-β in the immune 
response. TGF-β signalling induces a diverse range of outcomes depending on 
the cell type studied and the environment in which TGF-β signalling takes place. 
There are three isoforms of TGF-β, of which TGF-β1 is expressed 
predominantly in haematopoietic cells. Even within T-cells, TGF-β signalling 
plays different roles depending on the stage of T-cell development and function. 
In brief, TGF-β is produced in an inactive form, which requires proteolytic 
cleavage before it can bind to the TGF-β receptor (TGFBR). The TGFBR is 
made up of two different polypeptides, TGRBR type I and II. TGF-β binds 
directly to TGFBRII, which results in TGFBRII mediated phosphorylation of the 
regulatory domain of TGFBRI. TGFBRI phosphorylation results in its activation 
and subsequent phosphorylation of SMAD (mothers against decapentaplegic 
homologue) proteins. These proteins, through an array of interactions, 
transduce signals to the nucleus. The regulation of TGF-β signalling can be 
modulated by many mechanisms, from the TGF-β ligand being sequestered in 
its latent form by latency associated protein (LAP), to post signalling regulation 
by SMAD specific E3 ubiquitin protein ligases (SMURFS), making TGF-β 
signalling difficult to predict. The activation of the TGF-β signalling pathway can 
prevent both naïve CD4, helper, and CD8 cytolytic T-cell responses, in part due 
to the inhibition of IL-2 production (Rubtsov and Rudensky, 2007, Gorelik and 
Flavell, 2002). 
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5.3 Results 
5.3.1 CLDND1 expression in immune cell subsets 
Gene expression analysis of the CD4+ T-cell clone, HA1.7, (Figure 6) identified 
CLDND1 transcript expression; the first record of CLDND1 expression in CD4+ 
T-cells. CLDND1 protein cell surface expression was confirmed in a selection of 
immune cells, as a result of generating the in-house CLDND1-specific antibody. 
PBMC were isolated from whole blood by density centrifugation and the cell 
populations were fixed prior to CLDND1 staining. The percentage of CLDND1 
positive cells was determined using FMO analysis, and the amount of CLDND1 
expressed on the cell surface was determined using CLDND1 GMFI (see 
Section 2.9.3 Figure 36). 
The profile of CLDND1 expression was similar between the different immune 
cell subsets, irrespective of the flow cytometry analysis used. Identification of 
CLDND1 protein on the CD4+ T-cell population, along with the CD8+ T-cell 
population, supported the RNA expression profiling data from the preliminary 
differential display experiment. Interestingly, CLDND1 was identified on only a 
subset of each of the cell types, as determined from the percentage of CLDND1 
positive cells. This finding was similar to the expression profiles identified for 
claudin-1 and -5 on immune cell subsets (Mandel et al., 2012). The CLDND1 
positive CD4+ T-cell subset did not correlate with antigen experience as 
CLDND1 levels were similar between the naïve and memory subsets. 
Natural killer (NK) T-cells had lower CLDND1 cell surface expression and 
percentage of CLDND1 positive cells than both the T-cell and the NK cell 
population, suggesting that CLDND1 may not play a substantial role in this 
subset, under resting conditions. The highest level of CLDND1 cell surface 
expression was detected on CD14+ monocytes, yet both the percentage of cells 
expressing CLDND1 and the quantity of CLDND1 was very variable between 
individuals.
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Figure 36. CLDND1 expression on immune cell subsets 
PBMC were isolated from whole blood by density centrifugation prior to surface staining for cell subsets. The CD markers relate to the 
following cell types; CD14: monocytes, CD19: B-cells, CD3/4: CD4+ T-cells, CD3/8: CD8+ T-cells, CD56: NK cells, CD3/56: NK T-cells. 
For naïve and memory CD4+ T-cells, CD45RA staining was used to segregate naïve (CD45RA+) and memory (CD45RA-) cells. Cells 
were fixed in 4 % formaldehyde prior to staining for CLDND1. Percentage of CLDND1 positive cells, using FMO analysis, and amount of 
CLDND1, using CLDND1 GMFI, was measured. Median values are indicated by the corresponding line for each subset. Data illustrate at 
least six independent experiments. 
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5.3.2 CLDND1 expression during T-cell activation 
The CLDND1 transcript is differentially expressed between activated, resting 
and anergic states of the CD4+ T-cell clone, HA1.7, and so to strengthen these 
data, CLDND1 protein expression was sought. Revival of the CD4+ T-cell clone 
was unsuccessful, as the clone did not respond to stimulatory activation (Amy 
Anderson, unpublished data), so no comparison between RNA and protein 
could be made. Instead, primary CD4+ T-cells were used as a model, however 
as a result, an anergic state could not be generated for comparison. There are 
several published methods claiming to induce non-clonal anergy (Hoves et al., 
2006, Davies et al., 2011, Heissmeyer et al., 2004), yet it is well documented 
different types of anergy are induced depending on the stimulus used, resulting 
in different phenotypic characteristics of the cells (Schwartz, 2003, Lechler et 
al., 2001). Due to the complexities of these interactions and differences in 
effects, these methods were not used as an alternative model for T-cell anergy. 
Additionally, a CD3-based anergy model was attempted, but proved 
unsuccessful in inducing an anergic state (Figure 37). 
 
 
Figure 37. CD3-based in vitro CD4+ T-cell anergy model 
CD4+ T-cells were incubated with no stimulus (-), 1 µg/mL plate-bound α-CD3 
or with 1 µg/mL plate-bound α-CD3 and soluble α-CD28 overnight, before 
resting for 7 days. Cells were re-stimulated with 1 µg/mL plate-bound α-CD3 
and soluble α-CD28 for 72 hours. (A) Proliferation was measured by 3HTdR 
incorporation. (B) IFNγ levels were measured in the supernatants of cultures by 
ELISA. Mean values were plotted with error bars illustrating SEM. Data illustrate 
one experiment performed in triplicate. 
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CD4+ T-cells were activated with α-CD3 and α-CD28, as part of a PBMC or 
isolated cell population, and CLDND1 cell surface protein levels, total CLDND1 
protein levels and CLDND1 RNA levels were measured. Non-activated (resting) 
T-cells were used as the control to assess for changes in CLDND1 protein and 
RNA expression in the activated cells.  
An increase in CLDND1 cell surface protein was seen in the activated 
population compared with the resting counterpart (Figure 38), peaking during 
day 2 of stimulation (6.0 ± 1.33 SEM fold change). The change in the amount of 
CLDND1 cell surface expression during the stimulation was more pronounced 
than the change in the percentage of cells expressing CLDND1. A substantial 
decrease in the amount of CLDND1 cell surface expression and number of 
CLDND1 expressing cells was seen during the first 24 hours of resting cell 
culture. The amount of CLDND1 remained low throughout the culture of the 
resting cells and although the number of CLDND1 positive cells started to 
recuperate, there were still less CLDND1 positive cells than in freshly isolated 
cells. 
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Figure 38. CD4+ T-cell CLDND1 protein expression during PBMC activation 
PBMC were rested or activated for 3 days with 1 μg/ml soluble α-CD3 and α-CD28 then stained for CD3 and CD4 expression prior to cell 
fixation in 4 % formaldehyde for CLDND1 staining. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 
positive cells, using FMO analysis, and by CLDND1 GMFI. Data illustrate six independent experiments. Mean values were plotted with 
error bars illustrating SEM. **p<0.01, repeated measures ANOVA with Bonferroni correction comparing unstimulated  to stimulated cells 
at each time-point, and day 0 values to day 1 and day 3 unstimulated values. 
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CLDND1 total protein was also up-regulated at day 2 and 3 during stimulation 
(Figure 39A). Modest amounts of CLDND1 protein were detected in the resting 
cells at day 0, day 2 and day 3, and CLDND1 protein was undetectable at day 
1, mirroring the cell surface expression flow cytometry data. These data 
suggested CLDND1 protein was being internalised and degraded or that 
CLDND1 was being cleaved, yet as there were no antibodies available against 
different epitopes, this theory could not be tested. 
To determine whether the increased CLDND1 protein expression was a result 
of increased gene transcription, CLDND1 RNA levels were compared between 
the resting and activated T-cell populations (Figure 39B). At 2 hours post-
stimulation, there was a marginal decrease in the amount of CLDND1 transcript 
in the activated cells compared to the resting counterparts and, although not 
significant, this showed a similar trend to the same time-point in the initial 
differential display study (Section 1.10, Figure 6). Post 2 hours, CLDND1 RNA 
levels increased significantly in activated cells, although the RNA levels never 
exceeded more than 1.9 ± 0.3 SEM fold more than the resting T-cell RNA 
values. 
The increase in CLDND1 cell surface expression on the T-cells was not linked 
to CD25 expression (Figure 40), as both CLDND1 positive and negative 
populations has comparable CD25 expression during T-cell activation. There 
was however a link between CD25 expression and CLDND1 cell surface 
expression in resting cells (Figure 40, day 0), as the CLDND1 positive cells 
were predominately also CD25 positive.
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Figure 39. CLDND1 expression during CD4+ T-cell activation  
CD4+ T-cells were rested or activated with 10:1 ratio of α-CD3/CD28 expander beads for 3 days. Cell lysates were prepared and (A) 
CLDND1 protein expression was examined by Western blot, using α-tubulin to account for total protein or (C) RNA was extracted and 
CLDND1 mRNA levels were determined by qRT-PCR, normalising to the housekeeping gene pol2a. Data illustrate three or six 
independent experiments, respectively Mean values were plotted with error bars illustrating SEM. **p<0.01, repeated measures ANOVA 
with Bonferroni correction comparing unstimulated  to stimulated cells at each time-point, and day 0 values to day 1 and day 3 
unstimulated values. 
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Figure 40. CLDND1 and CD25 expression during CD4+ T-cell activation 
PBMC were activated with 1 μg/mL soluble α-CD3 and α-CD28 for 3 days. At each time-point, PBMC were stained for CD3, CD4 and 
CD25 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. The CLDND1 gate was determined from the CD3/CD4 
positive gate, based on FMO analysis. The CLDND1 gated populations were analysed for CD25 expression. Data represent two 
independent experiments. 
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To further visualise CLDND1 expression in resting and activated T-cells, 
confocal microscopy analysis was performed, using CD3 staining to identify the 
cell surface plasma membrane, and DAPI staining to identify non-cytoplasmic 
regions (Figure 41). CLDND1 protein was present on the surface of resting 
CD4+ T-cells, post isolation, in agreement with the flow cytometry data. 
Interestingly, in some of the cells visualised, CLDND1 expression looked to be 
polarised (Figure 41, day 0 arrow). Intracellular CLDND1 localises to the 
cytoplasm. Post CD4+ T-cell activation, total CLDND1 levels increase and show 
punctate staining, indicative of localised pockets of CLDND1, yet further 
analysis would be required to determine whether these foci localise to 
intracellular vesicles. CLDND1 cell surface expression post activation looked 
polarised ( Figure 41, day 3 arrow). CLDND1 expression did not co-localise with 
CD3, suggesting CLDND1 has distinct functions from claudin-4 during T-cell 
activation, as this protein was shown to co-ligate with CD3 in the IS (Kawai et 
al., 2011). 
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Figure 41. CLDND1 expression during CD4+ T-cell activation: visualisation 
CD4+ T-cells were stained immediately, or stimulated for 3 days with α-
CD3/CD28 expander beads before fixation in 4 % formaldehyde and stained for 
CD3 expression. Cells were then stained for CLDND1 expression 
(unpermeabilised), or permeabilised prior to CLDND1 staining. Nuclear staining 
was performed with DAPI. Confocal microscopy analysis was performed and 
one cross-sectional image is displayed. Arrow indicates proposed polarisation 
of CLDND1. Data represent two independent experiments. 
 
The expression profiling of CLDND1 protein during T-cell activation was also 
investigated in the CD8+ T-cell population to determine whether increased 
CLDND1 protein expression occurred as part of generic T-cell activation events 
(Figure 42). Similar CLDND1 cell surface expression kinetics were seen in the 
activated CD8+ T-cell subset as for the CD4+ T-cell subset, however the 
change in CLDND1 cell surface expression was smaller (4.02 ± 0.96 SEM fold 
change). These findings suggested CLDND1 expression was modulated by 
generic T-cell activation events. The same pattern in CLDND1 cell surface 
expression as the CD4+ T-cells was seen in resting CD8+ T-cells during the 
first 24 hours in culture, suggesting a generic regulation of CLDND1 in response 
to in vitro culture. 
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Figure 42. CLDND1 expression during CD8+ T-cell activation 
PBMC were rested or activated with 1 μg/ml soluble α-CD3 and α-CD28 for 3 days. PBMC were stained for CD3 and CD8 expression 
prior to cell fixation in 4 % formaldehyde for CLDND1 staining. CLDND1 expression was determined from the CD3/CD8 positive gate. 
Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive cells, using FMO analysis, and amount of 
CLDND1, using CLDND1 GMFI. Data illustrate five independent experiments. Mean values were plotted with error bars illustrating SEM 
*p<0.05, repeated measures ANOVA with Bonferroni correction comparing unstimulated cells to stimulated cells at each time-point, and 
day 0 values to day 1 and day 3 unstimulated values.
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5.3.3 Effect of experimental parameters on CLDND1 expression 
As a distinct loss of CLDND1 protein expression was identified during T-cell 
culture, a couple of parameters were tested in order to see whether this was a 
direct effect of cellular manipulation and culture. Firstly, the cell density of the 
cultures was assessed as CLDND1 shares homology to proteins with roles in 
cell-cell interactions and so cell-to-cell proximity may have influenced CLDND1 
protein levels (Figure 43). No significant association was identified between cell 
culture density and CLDND1 cell surface expression, indicating cell culture 
density was not important for maintenance of CLDND1 cell surface expression, 
at least over the range of cell densities tested.
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Figure 43. The effect of cell density on CLDND1 expression 
PBMC were cultured at different cell densities for 24 hours. PBMC were stained for CD3 and CD4 expression prior to cell fixation in 4 % 
formaldehyde for CLDND1 staining. CLDND1 expression was determined from the CD3/CD4 positive gate. Cell surface CLDND1 protein 
expression was measured by percentage of CLDND1 positive cells, using FMO analysis, and CLDND1 GMFI. Data illustrate three 
independent experiments. Mean values were plotted with error bars illustrating SEM. 
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Secondly, all the preceding experiments used cells isolated from whole blood 
drawn into the anticoagulant EDTA, which acts as a chelating agent. Chelation 
of metal cations may have affected the expression of CLDND1, as specific 
claudins are known to be expressed where specific metal cation uptake occurs 
(Angelow et al., 2007). The anticoagulants EDTA and heparin sulphate, an 
antithrombin III activator which does not chelate metal ions, were compared. 
PBMC were isolated from the two blood preparations and were cultured for 24 
hours (Figure 44). A significant decrease in both the percentage of CLDND1 
positive cells and the amount of CLDND1 protein was detected after 24 hour 
culture in the cell preparations from EDTA-containing blood, as seen previously. 
A similar trend in CLDND1 cell surface expression was also seen in cell 
preparations from heparin sulphate-containing blood. These findings suggested 
that the anticoagulant was not the confounding factor in the reduction of 
CLDND1 cell surface expression during cell culture and that metal chelation is 
not important for CLDND1 cell surface expression. All subsequent experiments 
were performed using blood anticoagulated using EDTA. 
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Figure 44. The effect of anticoagulant of CLDND1 expression 
Whole blood was collected in EDTA based or Heparin based anticoagulant vacutainers. Blood was stained immediately or cultured for 24 
hours. Cells were stained for CD3 and CD4 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. CLDND1 
expression was determined from the CD3/CD4 positive gate. Cell surface CLDND1 protein expression was measured by percentage of 
CLDND1 positive cells, using FMO analysis, and CLDND1 GMFI. Data illustrate five independent experiments. Mean values were plotted 
with error bars illustrating SEM.*p<0.05, Wilcoxon matched pairs test. 
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A further possible factor underpinning loss of CLDND1 cell surface expression 
was the cell isolation methods used. Cell surface expression of various 
chemokines is irreversibly lost during the isolation of cell types from whole blood 
(Nieto et al., 2012). In light of this, CLDND1 cell surface expression was 
compared between CD4+ T-cells from whole blood and PBMC cultures (Figure 
45A). Comparison of day 0 and day 1 cultured CD4+ T-cells in whole blood 
showed no difference in the amount of cell surface CLDND1 or the percentage 
of CLDND1 expressing cells, whereas as previously shown the PBMC CD4+ T-
cells had reduced CLDND1 cell surface expression after culture (Figure 44). 
Additionally, comparison of CD4+ T-cells at day 0 in whole blood to the freshly 
isolated PBMC revealed that CLDND1 expression was significantly lower in the 
CD4+ T-cells of the isolated PBMC population even prior to cell culture (Figure 
45B).  
These findings suggested that either factors within whole blood maintained 
CLDND1 cell surface expression; or specific elements of PBMC isolation 
resulted in its loss. Understanding factors that regulate CLDND1 expression 
would facilitate in vitro study of this molecule. Components of blood were 
addressed individually to determine their importance in maintaining CLDND1 
cell surface expression. Blood is made up of a mixture of 45 % cellular and 55 
% soluble material. The soluble fraction is termed plasma and comprises a 
mixture of water, sugar, fat, protein, and salts. The cellular portion comprises 
red blood cells, which occupy approximately 40-45 % of the blood’s volume, 
leukocytes and platelets. 
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Figure 45. The effect of cell isolation on CLDND1 expression 
Whole blood was collected in EDTA based vacutainers. Blood or isolated PBMC were stained immediately, or cultured for 24 hours. Cells 
were stained for CD3 and CD4 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. CLDND1 expression was 
determined from the CD3/CD4 positive gate. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive 
cells, using FMO analysis, and CLDND1 GMFI. (A) Whole blood CLDND1 cell surface levels. (B) Day 0 (immediate) stain of whole blood 
and isolated PBMC. Data illustrate ten independent experiments. Mean values were plotted with error bars illustrating SEM.*p<0.05, 
**p<0.01, Wilcoxon matched pairs test. 
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Initially, whole blood was separated into its cellular and soluble fractions by 
centrifugation, to address the importance of soluble factors. Varying 
centrifugation speed enabled the separation of two different plasma 
preparations: low speed centrifugation for the separation of plasma which was 
rich in platelets (PRP) whereas higher speeds eliminated the platelet portion 
from the plasma (PPP). Visually, the clarity of the plasma post centrifugation 
confirmed the presence or absence of platelets. Both these preparations were 
compared with serum, the soluble fraction of blood obtained after blood clotting 
has taken place. These preparations differ in their levels of soluble factors 
(Ayache et al., 2006), which could influence CLDND1 cell surface expression. 
PBMC were cultured in varying concentrations of these plasma and serum 
preparations for 24 hours. PBMC were also maintained in cell culture media as 
a positive control and whole blood was cultured as a negative control. CLDND1 
cell surface expression was analysed pre- and post-culture (Figure 46). As the 
previous experiments have shown, isolation and culture of PBMC in culture 
medium resulted in a substantial decrease in CLDND1 cell surface expression 
whereas CLDND1 cell surface expression was maintained in all dilutions of 
cultured whole blood. Loss of CLDND1 cell surface expression was also seen in 
PBMC cultured in PPP or serum. There was however, maintenance of CLDND1 
cell surface expression in the PBMC cultured in the PRP, comparable to the 
CLDND1 levels identified in the whole blood samples. The differences between 
the two plasma preparations suggested that platelets or platelet related factors 
may play a role in the maintenance of CLDND1 cell surface expression in 
culture. Platelet-related effects could have been mediated through cell-platelet 
contact, or through soluble mediators released by the platelet, such as PDGF 
and TGF-β.
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Figure 46. The effect of plasma on CLDND1 expression 
Whole blood or isolated PBMC were stained immediately or cultured for 24 hours. Whole blood was cultured at 100 %, 50 % or 5 % 
concentrations and PBMC were cultured in 100 %, 50 % or 5 % concentrations of PRP (rich), PPP (poor) or serum. Cells were stained 
for CD3 and CD4 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. CLDND1 expression was determined from 
the CD3/CD4 positive gate. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive cells, using FMO 
analysis, and CLDND1 GMFI. Data illustrate at least four independent experiments. Mean values were plotted with error bars illustrating 
SEM. *p<0.05, **p<0.01, paired Student’s t-test.
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5.3.4 TGF-β and CLDND1 expression 
Within the CLDND1 promoter, potential binding sites for an array of different 
transcription factors exist, one of which is the binding element CAGACA, for the 
SMAD transcription factors (Jonk et al., 1998), major transcription factors 
downstream of TGF-β ligands. I therefore sought an effect of TGF-β on 
CLDND1 expression. 
PBMC were cultured and activated with α-CD3 and α-CD28 in the presence of 
TGF-β for 3 days (Figure 47). A significant increase in the percentage of 
CLDND1 positive cells was seen by day 3 in the resting CD4+ T-cells cultured 
with TGF-β compared to the no-TGF-β control. A more distinct change in the 
amount of cell surface CLDND1 was seen in the presence of α-CD3 and α-
CD28: in contrast to the finding that CLDND1 levels were increased in the 
presence of T-cell activation, the presence of TFG-β with α-CD3 and α-CD28 
stimulus reduced the amount of cell surface CLDND1 compared to no-TGF-β at 
the same time-point. Significance was determined through the use of a paired t-
test, and did not include a correction for multiple sample comparison. As twelve 
different parameters were compared in these experiments a Bonferroni multiple 
correction analysis was performed, to account for a type I error, where the null 
hypothesis is rejected when it is true. The p value threshold of <0.05 was 
adjusted to account for this. As 12 different variables were tested, the p value 
was adjusted to p<0.004 (=0.05/12), and so would yield these findings 
insignificant. There is much debate as to whether the Bonferroni correction is 
constructive in determining true statistical significance (Perneger, 1998).
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Figure 47. The effect of TGF-β on CLDND1 expression: T-cell activation 
Isolated PBMC were stained immediately or cultured for 24, 48 or 72 hours in the presence of 10 ng/ml TGF-β and 1 μg/ml soluble α-
CD3 and α-CD28. Cells were stained for CD3 and CD4 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. 
CLDND1 expression was determined from the CD3/CD4 positive gate. Cell surface CLDND1 protein expression was measured by 
percentage of CLDND1 positive cells, using FMO analysis, and CLDND1 GMFI. Data illustrate at least five independent experiments. 
Mean values were plotted with error bars illustrating SEM. *p<0.05, paired Student’s t-test.
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To validate further the effects seen with TGF-β, the TGF-β signalling pathway 
was targeted with the small molecule inhibitor SB-505124. This molecule 
selectively inhibits the TGFBRI, ALK-4, -5 and -7, preventing TGF-β dependent 
down-stream activation of SMAD2 and 3 signalling (DaCosta Byfield et al., 
2004). As the hypothesis for TGF-β involvement was predicted from the PRP 
and PPP preparation experiment, this experiment was performed again, in the 
presence of SB-505124 (Figure 48). As expected, CLDND1 cell surface 
expression was maintained in whole blood cultures and decreased in PBMC 
cultured in media. Contrary to the initial findings, the amount of cell surface 
CLDND1 was not maintained in platelet rich plasma, and the presence of SB-
505124 showed no difference in CLDND1 cell surface expression in these cells. 
As CLDND1 cell surface levels were maintained in whole blood, the effect of 
SB-505124 could be tested. A small decrease in the amount of CLDND1 cell 
surface expression was detected in the 100 % blood cultures in the presence of 
SB-505124; suggesting TGF-β signalling may be playing some role in 
maintaining CLDND1 expression, however the limited decrease suggests that 
TGF-β signalling may not be a major contributing factor to CLDND1 expression. 
Again, as multiple analyses were performed, application of a Bonferroni 
correction would re-adjust the p-value required for significance to <0.008 
(=0.05/6). As the PRP experiment did not maintain CLDND1 cell surface 
expression, these data were omitted from the statistical analysis. Again, 
application of the Bonferroni correction yielded an insignificant difference 
between the day 1 100 % blood samples in the absence or presence of SB-
505124. The underlying aim of these experiments was to determine optimal 
culture conditions for maintaining CLDND1 cell surface expression. This proved 
challenging with some inconsistencies potentially suggesting donor dependent 
factors.
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Figure 48.The effect of TGF-β on CLDND1 expression: SB-505124 
Whole blood or isolated PBMC were stained immediately or cultured for 24 hours with 1 μM SB-505124. Whole blood was cultured at 
100 % or 50 % concentration, diluting in RPMI and PBMC were cultured in 50% concentrations of PRP,PPP or serum. Cells were stained 
for CD3 and CD4 expression prior to cell fixation in 4 % formaldehyde for CLDND1 staining. CLDND1 expression was determined from 
the CD3/CD4 positive gate. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive cells, using FMO 
analysis, and CLDND1 GMFI. Data illustrate at least five independent experiments. Mean values were plotted with error bars illustrating 
SEM. *p<0.05, **p<0.01, paired Student’s t-test. 
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5.3.5 CLDND1 expression on CD4+ T-cell and DC co-cultures. 
The CLDND1 protein expression data obtained during T-cell activation used α-
CD3 and α-CD28 as a stimulus. Based on homology to the PMP-
22/EMP/MP20/claudin superfamily members and their roles in cell-cell 
interactions, I hypothesised a role for CLDND1 in the interaction between T-
cells and APC. DC are the archetypal APC, can be differentiated from blood 
monocytes and are widely used to activate T-cells in vitro. Depending on the 
differentiation process used, DC can be matured with LPS (matDC) or become 
tolerogenic (tolDC) with dexamethasone and calcitriol.  
These two DC subsets were generated to determine CLDND1 expression 
profiles on co-cultured CD4+ T-cells. Firstly, DC characterisation was performed 
to confirm mature and tolerogenic phenotypes (Figure 49). TolDC had lower 
CD80 and CD83 co-stimulatory molecule expression than matDC and 
marginally lower expression of CD86. TolDC had higher HLA-DR expression, 
suggesting they maintain the capability to present to T-cells, and higher TLR-2 
expression. Increased TLR-2 expression has been associated with a lower pro-
inflammatory immune profile (Chamorro et al., 2009, Harry et al., 2010). The 
tolDC had higher LAP expression, a marker for TGF-β, but no comparable 
difference in CLDND1 expression. 
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Figure 49. Characterisation of mat- and tolDC 
Mat- and tolDC were differentiated from CD14+ monocytes. (A) Post differentiation the DC were stained for the different cell surface 
markers shown. Data illustrate at least four independent experiments. Mean values were plotted with error bars illustrating SEM. *p<0.05, 
paired Student’s t-test. 
Katherine L. Crossland                                                   Chapter 5. CLDND1 Expression Profiling 
160 
CD4+ T-cells co-cultured with matDC or tolDC had different proliferation kinetics 
and cytokine expression profiles (Figure 50). The matDC stimulated T-cells had 
higher proliferation counts at day 3 than the T-cells stimulated with the tolDC 
(Figure 50A). Both proliferation values were lower than the value obtained with 
α-CD3/CD28 expander bead stimulus. The cytokine expression profile also 
mirrored the proliferation data, with less IFN-γ, TNF-α and IL-10 production by 
the T-cells stimulated with tolDC (Figure 50B). The day 6 data revealed that 
proliferation counts were comparable between the DC stimulated T-cells (Figure 
50C). The cytokine expression profiling showed that T-cells stimulated with 
tolDC secreted less IFN-γ (Figure 50D).
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Figure 50. Mat- and tolDC co-cultures with CD4+ T-cells: T-cell activation 
Mat- and tolDC were differentiated from CD14+ monocytes. CD4+ T-cells were cultured with DC or α-CD3/CD28 expander beads for (A) 
3 days, measuring proliferation by 3HTdR incorporation and (B) IFN-γ, TNF-α and IL-10 secretion by ELISA, or for 6 days (C) measuring 
proliferation by 3HTdR incorporation and (D) IFN-γ, TNF-α and IL-10 secretion by ELISA. Data illustrate at least four independent 
experiments. Mean values were plotted with error bars illustrating SEM *p<0.05, **p<0.01, paired Student’s t-test.
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CLDND1 expression on CD4+ T-cells co-cultured with mat- and tolDC was 
determined at day 3 and day 6 time-points, looking at both cell surface and total 
CLDND1 expression (Figure 51). The CLDND1 expression profiles mimicked 
the proliferation data, with higher CLDND1 cell surface expression at day 3 with 
matDC compared with tolDC but both T-cell populations having less CLDND1 
expression than when stimulated with α-CD3/CD28 expander bead stimulus 
(Figure 51A). Total CLDND1 expression on DC stimulated T-cells was 
comparable to unstimulated T-cells, suggesting the total amount of CLDND1 
protein did not change (Figure 51B), and differences seen on the surface may 
be linked to protein trafficking. At day 6, α-CD3/CD28 expander bead stimulus 
induced CLDND1 cell surface expression was comparable to levels of both the 
DC stimulated cells (Figure 51C). Again, total CLDND1 expression remained 
similar between the populations, suggesting no change in the total amount of 
CLDND1 (Figure 51D). All day 6 values were lower than at day 3, suggesting a 
transient activation-induced expression of CLDND1. 
Based on the findings above, CLDND1 cell surface expression correlated with 
the intensity of the activation stimulus. α-CD3/CD28 expander bead stimulus 
resulted in the highest proliferation, cytokine production and CLDND1 cell 
surface expression, at earlier time-points, followed by matDC. TolDC induced 
the lowest proliferation and cytokine production and had the lowest CLDND1 
cell surface expression, but at a later time-point the profile was similar to the 
matDC.
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Figure 51. Mat- and tolDC co-cultures with CD4+ T-cells: CLDND1 
expression 
Mat- and tolDC were differentiated from CD14+ monocytes. CD4+ T-cells were 
cultured with DC or with α-CD3/CD28 expander beads for 3 or 6 days. Cells 
were fixed in 4 % formaldehyde before CLDND1 staining. Cell surface CLDND1 
protein expression was measured by CLDND1 GMFI. Day 3 CLDND1 
expression of (A) cell surface, or (B) total protein. Day 6 CLDND1 expression of 
(C) cell surface, or (D) total protein. Data illustrate five independent 
experiments. Mean values were plotted with error bars illustrating SEM. 
*p<0.05, **p<0.01, paired Student’s t-test. 
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5.3.6 Analysis of CLDND1 expression in Early Arthritis (EA) Patients 
Previous studies have shown than RA CD4+ T-cells from synovium adopted a 
gene expression profile that shares characteristics with an anergic T-cell gene 
expression profile (Ali et al., 2001). Therefore, CLDND1 cell surface expression 
was measured in EA patients. EA patients are predominately drug naïve, 
removing a major confounder that could influence CLDND1 expression. Using a 
selection of EA patients also allowed for the separation of the arthritides to 
create control groups. These four groups were: non-inflammatory arthritis (N-
IA), osteoarthritis (OA), inflammatory non-RA (INRA) and RA. 
Whole blood cells from patients with different diagnoses attending an EA clinic 
were stained for CLDND1 expression. CLDND1 cell surface expression was 
measured on CD4+ and CD8+ T-cell subsets, CD14+ monocytes and CD19+ B-
cells in whole blood (Figure 52 and Figure 53). A significant increase in the 
amount of cell surface CLDND1 was detected in RA, compared to N-IA in the 
CD4+ and CD8+ T-cell subsets. An increase in the median amount of cell 
surface CLDND1 was also seen in INRA compared to N-IA. These patterns 
were also seen for the percentage of CLDND1 positive cells, wherein all cell 
subsets showed significant differences in RA compared to N-IA. 
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Figure 52. EA patients: disease classification: % CLDND1 positive cells  
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and 
CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 staining. Cell 
surface CLDND1 protein expression was measured by percentage of CLDND1 
positive cells, using FMO analysis. EA patients were grouped according to 
disease classification for each cell subset. Median values are illustrated by the 
line. *p<0.05, **p<0.01, 1way ANOVA with Dunn’s multiple comparison 
correction. 
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Figure 53. EA patients: disease classification: CLDND1 GMFI  
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and 
CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 staining. Cell 
surface CLDND1 protein expression was measured by CLDND1 GMFI. EA 
patients were grouped according to disease classification for each cell subset. 
Median values are illustrated by the line. *p<0.05, **p<0.01, 1way ANOVA with 
Dunn’s multiple comparison correction. 
Katherine L. Crossland                                                   Chapter 5. CLDND1 Expression Profiling 
167 
As CLDND1 cell surface levels were increased in RA, CLDND1 expression was 
correlated to markers of general inflammation or to disease activity to 
distinguish whether increased CLDND1 levels were due to a general increase in 
inflammation, or whether CLDND1 expression was associated with disease 
activity. Inflammation status was measured by the erythrocyte sedimentation 
rate (ESR) and by levels of C-reactive protein (CRP). No correlation was found 
between either ESR or CRP and the percentage of CLDND1 positive cells 
(Figure 54) or the amount of CLDND1 in any of the cell subsets (Figure 55), 
when comparing all the arthritides, suggesting that CLDND1 levels were not 
related to systemic inflammation. Analysis of each of the different disease 
subgroups showed that in non-inflammatory arthritides, the amount of CLDND1 
cell surface expression did correlate with CRP in the CD4+ and CD8+ T-cell 
subsets, but no correlation was found with ESR or in any of the inflammatory 
arthritides (Table 15). These results raised the possibility of a link between 
CLDND1 cell surface expression and the inflammatory environment but further 
investigation is required to test this potential association further. Disease activity 
was measured using the DAS28 score, which is calculated from severity of joint 
swelling and tenderness, a global assessment of disease activity and ESR 
levels. DAS28 score is only validated in RA disease and correlation of the RA 
subgroup with DAS28 score resulted in a low correlation value and a non-
significant P value (r2=0.02897, p=0.4731), indicating CLDND1 does not 
correlate with DAS28 score (Data not shown). 
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Figure 54. EA samples: correlation between CLDND1 expression and inflammation: % CLDND1 positive cells 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 
staining. Cell surface CLDND1 protein expression was measured by. percentage of CLDND1 positive cells, using FMO analysis (A) 
Correlation between ESR and all EA samples (B) Correlation between CRP score and all EA samples.
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Figure 55. EA samples: correlation between CLDND1 expression and inflammation: CLDND1 GMFI 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 
staining. Cell surface CLDND1 protein expression was measured by CLDND1 GMFI. (A) Correlation between ESR and all EA samples 
(B) Correlation between CRP score and all EA samples. 
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ESR N-IA OA I-NRA RA 
CD4 GMFI 
r2 0.0318 0.1472 0.0161 0.0000 
p value 0.5416 0.1955 0.4542 0.9966 
CD8 GMFI 
r2 0.0798 0.1998 0.0124 0.1116 
p value 0.3496 0.1257 0.5112 0.1900 
CD14 GMFI 
r2 0.0553 0.1815 0.0046 0.0028 
p value 0.4185 0.1673 0.7070 0.8287 
CD19 GMFI 
r2 0.0137 0.1952 0.0304 0.0099 
p value 0.6907 0.1505 0.3322 0.6947 
CD4 cells 
r2 0.0961 0.1865 0.0279 0.0203 
p value 0.2808 0.1406 0.3228 0.5377 
CD8 cells 
r2 0.2166 0.2302 0.0282 0.0930 
p value 0.1090 0.0971 0.3201 0.2186 
CD14 cells 
r2 0.0272 0.2425 0.2143 0.0347 
p value 0.5900 0.1033 0.4163 0.4448 
CD19 cells 
r2 0.0061 0.2650 0.0291 0.0074 
p value 0.7916 0.0868 0.3428 0.7270 
 
CRP N-IA OA I-NRA RA 
CD4 GMFI 
r2 0.3169 0.3242 0.0006 0.0200 
p value 0.0316 0.0335 0.8896 0.5517 
CD8 GMFI 
r2 0.3288 0.4383 0.0071 0.0423 
p value 0.0405 0.0099 0.6201 0.4283 
CD14 GMFI 
r2 0.0034 0.3576 0.0005 0.0256 
p value 0.8443 0.0309 0.8982 0.5133 
CD19 GMFI 
r2 0.0170 0.3836 0.0165 0.0008 
p value 0.6574 0.0240 0.4765 0.9102 
CD4 cells 
r2 0.1915 0.2784 0.0118 0.0294 
p value 0.1176 0.0525 0.5214 0.4574 
CD8 cells 
r2 0.2380 0.3768 0.0213 0.0506 
p value 0.0908 0.0195 0.3887 0.3697 
CD14 cells 
r2 0.1362 0.1881 0.0044 0.0024 
p value 0.2147 0.1387 0.7129 0.8416 
CD19 cells 
r2 0.0534 0.3322 0.0005 0.0006 
p value 0.4269 0.0392 0.9017 0.9209 
Table 15. EA samples: correlation between CLDND1 expression and ESR and CRP 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 
staining. Cell surface CLDND1 protein expression was measured by CLDND1 GMFI and percentage of CLDND1 positive cells, using 
FMO analysis. Values were correlated to ESR and CRP values. 
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As CLDND1 levels were significantly up-regulated in RA cell subsets, CLDND1 
expression profiling in RA was examined. RA can be further sub-classified 
depending on RF and CCP status, so CLDND1 cell surface expression levels 
were compared between these subclasses (Figure 56 and Figure 57). The 
percentage of CLDND1 positive cells was similar between the two RF 
populations in all of the cell types studied (Figure 56A) but the amount of 
CLDND1 cell surface expression was higher in the RF positive (RF+ve) group in 
the T-cell population (Figure 57A). Comparison of CCP status revealed no 
difference in CLDND1 cell surface expression or percentage of CLDND1 
positive cells between the CCP subgroups (Figure 56B and Figure 57B). 
 
 
 
 
 
Katherine L. Crossland                                              Chapter 5. CLDND1 Expression Profiling 
172 
 
Figure 56. EA samples: CLDND1 expression in early RA according to RF status: % CLDND1 positive cells 
Whole blood from early RA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for 
CLDND1 staining. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive cells, using FMO analysis. 
CLDND1 cell surface expression depending on (A) RF status or, (B) CCP status. Median values are illustrated by the line. Mann Whitney 
test was performed to determine statistical significance. 
 
 
 
 
 
Katherine L. Crossland                                              Chapter 5. CLDND1 Expression Profiling 
173 
 
Figure 57. EA samples: CLDND1 expression in early RA according to RF status: CLDND1 GMFI 
Whole blood from early RA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for 
CLDND1 staining. Cell surface CLDND1 protein expression was measured by CLDND1 GMFI. CLDND1 cell surface expression 
depending on (A) RF status, or (B) CCP status. Median values are illustrated by the line. *p<0.05, Mann Whitney test. 
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5.3.7 Other factors determining CLDND1 expression 
Two independent studies focussing on the effects of smoking status by whole 
blood or lymphocyte gene microarray identified CLDND1 as one of the two most 
up-regulated genes in whole blood, and one of the 50 most up-regulated genes 
in lymphocytes, in the smoking group (Beineke et al., 2012, Charlesworth et al., 
2010). It is also worth noting that in seropositive RA, smoking is considered an 
environmental association with disease susceptibility (Pratt et al., 2009). 
CLDND1 cell surface protein expression was therefore assessed in the EA 
samples, to see whether there was also an association with CLDND1 cell 
surface protein expression and smoking status (Figure 58 and Figure 59). 
Patients were divided into three groups: never smoked (never), former smoker 
(former) or current smoker (current). CLDND1 cell surface expression levels 
were comparable between the three groups, irrespective of cell type. As 
differences in CLDND1 expression was seen between the different arthritides, 
smoking status was compared to CLDND1 cell surface levels in each group, but 
no difference in CLDND1 cell surface expression was observed (Figure 60 and 
Figure 61). 
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Figure 58. EA samples: CLDND1 cell surface expression according to 
smoking status: % CLDND1 positive cells 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and 
CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 staining. Cell 
surface CLDND1 protein expression was measured by percentage of CLDND1 
positive cells, using FMO analysis. CLDND1 GMFI was determined in all EA 
samples depending on smoking status: current smoker (current), former smoker 
(former), never smoked (never). Median values are illustrated by the line. One 
way ANOVA with Dunn’s multiple Comparison correction was performed to 
determine statistical significance. 
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Figure 59. EA samples: CLDND1 cell surface expression according to 
smoking status: CLDND1 GMFI 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and 
CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 staining. Cell 
surface CLDND1 protein expression was measured by CLDND1 GMFI in all EA 
samples depending on smoking status: current smoker (current), former smoker 
(former), never smoked (never). Median values are illustrated by the line. One 
way ANOVA with Dunn’s multiple Comparison correction was performed to 
determine statistical significance. 
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Figure 60. EA samples: CLDND1 cell surface expression according to smoking status: % CLDND1 positive cells 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 
staining. Cell surface CLDND1 protein expression was measured by percentage of CLDND1 positive cells, using FMO analysis in N-IA, 
INRA and RA subsets depending on smoking status: current smoker (C), former smoker (F), never smoked (N). Median values are 
illustrated by the line. One way ANOVA with Dunn’s multiple Comparison correction was performed to determine statistical significance.  
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Figure 61. EA samples: CLDND1 cell surface expression according to smoking status: CLDND1 GMFI 
Whole blood from EA patients was stained for CD3, CD4, CD8, CD14 and CD19 prior to cell fixation in 4 % formaldehyde for CLDND1 
staining. Cell surface CLDND1 protein expression was measured by CLDND1 GMFI in N-IA, INRA and RA subsets depending on 
smoking status: current smoker (C), former smoker (F), never smoked (N). Median values are illustrated by the line. One way ANOVA 
with Dunn’s multiple Comparison correction was performed to determine statistical significance. 
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5.4 Discussion 
This chapter has identified CLDND1 cell surface expression on a variety of 
different immune cells. Upon T-cell activation, CLDND1 cell surface levels were 
shown to be labile, peaking around 48 hours, while the total amount of CLDND1 
cell surface expression was dependent on the type of stimulus given. The in 
vitro studies identified a major limitation with CLDND1 expression profiling, as 
CLDND1 cell surface expression was lost during cell isolation and culture. Cell 
surface CLDND1 expression profiles were also determined in selected EA 
patient cell subsets and were shown to be elevated in RA over N-IA, which was 
independent of RA inflammation status. CLDND1 cell surface levels varied 
according to RF status in T-cells, but not with CCP status. Overall these 
experiments have provided insight into CLDND1 expression profiles and 
potentially suggest a function for CLDND1 within the immune response. 
5.4.1 CLDND1 in T-cell activation 
CLDND1 cell surface levels increased during both CD4+ and CD8+ T-cell 
activation. The increase in CLDND1 cell surface expression does not 
necessarily represent a pro-inflammatory role for CLDND1 as both activatory 
and regulatory proteins have been shown to be up-regulated at similar time-
points, e.g. CD25 and CTLA-4 (Xia et al., 1999), and so these kinetics do not 
imply a specific role for CLDND1 in T-cells.  
CLDND1 protein expression during T-cell activation was transient in nature 
consistent with a functional process, where protein levels are more likely to 
fluctuate, as opposed to a more static marker for a specific T-cell subset. 
CLDND1 cell surface expression was detected on a subpopulation of cells, as 
determined by the percentage of CLDND1 positive cells seen. The CLDND1 
positive cells may express an undiscovered receptor or ligand, which during T-
cell activation triggers up-regulation of CLDND1 expression. To date, however, 
no ligand or receptor for CLDND1 has been identified. 
During full TCR triggering, the transcription factors AP-1, NFAT and NFκB 
complement the transcription of pro-inflammatory mediators that allow for cell 
cycle progression and the elicitation of an immune response. During a clonal 
anergy response, a unique set of NFAT-dependent anergy genes are 
expressed (Paolino and Penninger, 2009). Because CLDND1 is up-regulated 
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during full TCR activation, this is inconsistent with a role solely in maintenance 
of the anergic state. 
The change in CLDND1 cell surface expression observed during T-cell 
activation was more pronounced when observing changes in CLDND1 GMFI 
rather than the percentage of CLDND1 positive cells, possibly suggesting that 
the amount of CLDND1 displayed on a cell is a more critical factor in CLDND1-
mediated T-cell function than the total number of cells expressing CLDND1.  
Although CLDND1 cell surface levels were shown to increase during T-cell 
activation, the relative changes in CLDND1 seen varied depending on whether 
RNA or protein was measured. Comparison between changes in CLDND1 
transcript levels and the changes in CLDND1 cell surface protein showed that 
during activation, the CLDND1 transcript levels did not increase above 1.9 ± 0.3 
SEM fold, whereas the change in CLDND1 protein intensity was 6.0 ± 1.33 
SEM fold above resting values. The smaller fold changes in RNA values may 
indicate post-transcriptional regulation mechanisms for CLDND1. Even though 
protein and RNA are measured using different techniques and there will be 
potential noise associated with either technique, a study performed in circulating 
monocytes identified differences at the cellular level between RNA and protein 
levels of proteins classified as regulators of cellular function (Guo et al., 2008). 
A specific example of this is TGF-β, a well-known regulator of T-cell function. 
The levels of TGF-β protein do not correlate with the amount of RNA due to 
post-translational regulation of the TGF-β transcript (Kim et al., 1992). My 
findings indicate that CLDND1 may also be regulated post-translationally. 
The strength of the stimulus used for T-cell activation resulted in differences in 
CLDND1 cell surface and total CLDND1 levels. Higher CLDND1 cell surface 
expression was seen in CD4+ T-cells activated with a stronger stimulus (α-
CD3/CD28 expander bead), than with weaker stimuli (mat- or tolDC) but total 
CLDND1 protein levels varied less with the strength of stimulus. These data 
suggest that stimulation strength is an important factor determining the amount 
of CLDND1 at the cell surface but that this is less dependent on the total 
amount of protein. In turn these data suggest that CLDND1 function may be 
regulated through trafficking between distinct cellular locations. Additionally, 
there could be additional factors present on DC which modulate CLDND1 
expression, independently of activation strength. 
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CLDND1 activation kinetics in CD4+ T-cells share similarities to some of the 
claudins. Claudin-1 is up-regulated during T-cell activation with a hypothesised 
tight-junction function due to co-localisation with the integral TJ protein ZO-1 
(Mandel et al., 2012). Previous studies with the mouse homologue of CLDND1 
showed co-localisation of mouse CLDND1 with ZO-1 in epithelial cells (Mineta 
et al., 2011) and so co-staining CLDND1 and ZO-1 on human CD4+ T-cells may 
reveal a TJ-like role of CLDND1. Claudin-1 staining on T-cells showed limited 
expression on a subpopulation of these cells (Mandel et al., 2012), which was 
also identified with CLDND1 staining. It was suggested that claudin-1 may be 
present on a defined T-cell subset, but this was not investigated further. 
Given the reduction in CLDND1 expression during cell isolation and culture, in 
vitro cultures may not be the best environment to look at CLDND1 expression. 
The time-points identified for CLDND1 up-regulation may not reflect similar 
kinetics in vivo. CLDND1 expression profiling between whole blood and PBMC 
highlighted potential differences between in vivo and in vitro studies and 
identifies some limitations with in vitro studies, if molecules are artificially down-
regulated as part of the cell isolation and culture process. 
5.4.2 CLDND1 in EA 
Comparisons of EA based on disease classification identified increased 
CLDND1 cell surface expression on T-cells in RA compared to N-IA, suggesting 
CLDND1 may be associated with early RA. No correlation between CRP levels 
and CLDND1 cell surface expression were detected in EA when analysed as a 
whole, suggesting that CLDND1 was not associated with increased 
inflammation.  
In RA, the disease can be classified further depending on autoantibody status; 
the two main ones being RF and CCP. No relationship was identified between 
CLDND1 cell surface levels and CCP status. In the RF positive RA subgroup, 
CLDND1 cell surface expression was increased on T-cells. Interestingly, the 
amount of CLDND1 detected on the surface of the cells correlated with RF 
status, but the percentage of CLDND1 positive cells did not. This observation 
may suggest that the amount of CLDND1 expressed on a cell may be more 
important for function than the total number of cells expressing CLDND1. It is 
known that RF status can fluctuate in early disease (Barra et al., 2013), and so 
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to accurately determine whether CLDND1 levels correlated with RF titres, 
additional studies would be required. 
RF can be present in several different antibody isoforms; IgM, IgA and IgG, but 
clinically, levels of IgM RF are measured. The roles of RF in RA disease are not 
fully understood. Studies have shown that immune complexes are widely found 
in RA patient joints (Okroj et al., 2007) and polyclonal IgM RF can fix and 
activate complement (Tanimoto et al., 1975). Along with its well understood role 
in innate immunity, complement can also activate adaptive immune responses 
through binding to complement receptors on CD4+ T-cells and DC (Heeger and 
Kemper, 2012). Fragments of the complement cascade C3a and C5a can bind 
to these receptors on CD4+ T-cells and DC (C3aR and C5aR, respectively) and 
induce heightened T-cell activation. The possibility of RF to activate 
complement and signal through complement receptors to increase T-cell 
activation may be an explanation for elevated CLDND1 levels in T-cells of RF 
positive RA patients. As a role for complement in CLDND1 expression was not 
explored during this thesis, additional studies would need to be performed to 
ascribe a role for complement in the function of CLDND1.
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Chapter 6.  Determining a Function for CLDND1 in CD4+ T-cells 
6.1 Aims 
This chapter documents experiments performed to elucidate a function for 
CLDND1 in primary human CD4+ T-cells. The main aim was to determine 
whether CLDND1 plays a role CD4+T-cell activation, by transfecting CLDND1-
expressing vectors into these cells. Firstly, optimisations were performed to 
select for a vector enabling CLDND1 cell surface expression, then these cells 
were activated with a variety of different stimuli to determine whether CLDND1 
played a role in T-cell viability, proliferation, cytokine production and co-
stimulation and activation marker expression. Re-stimulation assays were 
performed with the CLDND1 over-expressed T-cells, as a surrogate model for 
anergy. Finally, as a result of generating a truncated version of CLDND1 to 
generate more in-house antibodies, the effect of this mutation on CLDND1 
function was assessed. 
6.2 Introduction 
6.2.1 Proposed CLDND1 function 
The CLDND1 gene is differentially expressed during T-cell activation and 
anergy in the CD4+ T-cell clone, HA1.7, with CLDND1 transcript levels stable in 
the anergic cells and lower in activated cells, 2 hours into anergy induction 
(Figure 6) (Ali, M. and Isaacs, J. D., unpublished data). From these data, a role 
for CLDND1 in T-cell anergy was proposed and a pilot experiment was 
performed to validate this hypothesis. Silencing and over-expressing the 
CLDND1 transcript in primary human CD4+ T-cells obtained from one donor 
identified a potential role for CLDND1 in the regulation of T-cell proliferation 
(Dixon, C., unpublished data). CLDND1 gene silencing induced more T-cell 
proliferation in response to stimulation whereas CLDND1 transcript over-
expression induced reduced T-cell proliferation (Section 1.11.10, Figure 9). In 
the absence of an α-CLDND1 antibody at the time of this work, an internal 
ribosome entry site (IRES) biscistronic system, in which H2Kk is expressed in 
parallel with CLDND1 (Tahvanainen et al., 2006), was used to estimate 
CLDND1 expression. 
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6.2.2 TCR signalling during activation 
Two signals are required for full T-cell activation, complemented by the cytokine 
milieu, which tailors the immune response. TCR ligation constitutes the first 
signal and is triggered through MHC molecule interaction expressed on APC or 
direct binding by an α-CD3 antibody. TCR triggering initiates a phosphorylation 
cascade and subsequent activation of down-stream calcium and ras signalling 
pathways. Co-stimulatory molecule receptor signalling, for example CD28 
interaction with CD80 or CD86 on APC, provides the second signal. The co-
operation of these signalling pathways results in the transcription of IL-2, an 
important cytokine for T-cell proliferation, along with a wide range of other 
genes involved in pro-inflammatory responses (Figure 1)(Morice et al., 1993, 
Nourse et al., 1994). 
6.2.3 TCR signalling during anergy 
Anergy is classified as a hypo-responsive state of a viable T-cell, where T-cell 
proliferation and IL-2 production is lost. Several models of anergy have been 
documented, most of which involve TCR triggering in the absence of co-
stimulation (Schwartz, 2003) (Figure 3). 
6.3 Results 
6.3.1 Phylogenetic analysis of the PMP-22/EMP/MP20/claudin superfamily  
During the original identification of CLDND1, the predicted protein sequence 
was assessed for sequence similarities to other proteins. Conserved motifs 
were shared with PMP-22/EMP/MP20/claudin superfamily members (Fayein et 
al., 2002) and so CLDND1 has been classified as one if its member. This 
superfamily contains several proteins with diverse functions.  
To gain insight into potential functions for CLDND1, the CLDND1 protein 
sequence was compared with proteins within the human genome to identify the 
closest homologies. BLAST analysis of the CLDND1 protein sequence 
(NP_001035289.1) identified a list of proteins with homology to CLDND1 (Table 
16). The majority of the proteins identified were members of the PMP-
22/EMP/MP20/claudin superfamily, with the highest homology to the family 
member, transmembrane protein (TMEM)114. 
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Description Accession 
Max 
score 
Query 
coverage 
E-
value 
CLDND1 isoform b NP_001035272.1 497 100 0.0 
CLDND1 isoform a NP_063948.1 496 100 0.0 
TMEM114 NP_001139808.1 43.5 86 1e-7 
CACNG5 NP_665810.1 38.1 69 8e-6 
PMP-22 NP_000295.1 34.7 24 5e-5 
TMEM178b NP_001182207.1 32.3 28 5e-4 
EMP-2 NP_001415.1 31.6 24 7e-4 
EMP CAA64393.1 31.6 24 7e-4 
TMEM235 isoform 1 NP_001191139.1 31.2 33 0.001 
TMEM235 isoform 2 NP_001191140.1 30.8 33 0.001 
Olfactory receptor 11H6 NP_001004480.1 30.4 24 0.001 
Claudin-19 isoform b NP_001116867.1 29.6 32 0.004 
Claudin-19 isoform a NP_683763.2 29.3 32 0.004 
CACNG8 EAW72168.1 29.6 39 0.005 
 
Table 16. CLDND1 bioinformatics 
BLAST query of CLDND1 protein sequence (NP_001035289.1) identified 
sequences with greatest similarity. The search parameters were ranked 
according to max score, query coverage and E-value. Max score relates to 
sequence alignment with higher scores corresponding to a better alignment. 
The query coverage identifies the length of the aligned sequence matching the 
hit within the database. The E-value describes the number of hits expected to 
be seen by chance when searching the database of a particular size. The lower 
the E-value, the more significant the alignment. 
 
 
The TMEM114 transcript is expressed in the developing human eye and central 
nervous system (Maher et al., 2011) and is linked with normal ocular function 
(Jamieson et al., 2007). Maher et al., (2011) constructed a phylogenetic tree to 
determine the evolutionary lineage of TMEM114. The alignment included all 
members of the PMP-22/EMP/MP20/claudin superfamily, along with the more 
distantly related CACNG. TMEM114 grouped within the CACNG family and not 
with the claudins, as was previously suggested (Maher et al., 2011).  
Based on these findings, CLDND1 phylogenetic analysis was performed, 
according to Maher et al., (2011) (Figure 62). A similar phylogenetic profile was 
achieved, with TMEM114 branching within the CACNG family. CLDND1 also 
branched within this family, suggesting CLDND1 shared more sequence 
homology with the CACNG than with the claudins.  
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Figure 62. CLDND1 bioinformatics: phylogenetic analysis 
Sequences were aligned using clustalW2 before neighbour joining phylogenetic 
analysis was performed, according to Maher et al., (2011). CLDND1 is indicated 
by the arrow. 
 
 
No reference to the CACNG function in immune cell subsets is available, and so 
no inferences could be made to CLDND1 function from these proteins. To 
determine a function for CLDND1 in primary human CD4+ T-cells, CLDND1 
transfection into primary human CD4+ T-cells was performed, using 
nucleofection. 
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6.3.2 Validation of the CLDND1 over-expression pilot study 
In the pilot study to determine a function for CLDND1 (Dixon, C., unpublished 
data), CLDND1 over-expression was performed using the pIRES2-H-2Kk 
expression system (Tahvanainen et al., 2006). This expression system utilises a 
biscistronic vector where both CLDND1 and H2Kk are expressed from the same 
transcript, and translation creates two individual proteins through the use of an 
IRES. Expression of H2Kk allows for the indirect identification of CLDND1 
expressing cells, as during the pilot experiments and the experiments 
performed in this section, the α-CLDND1 antibody was not yet available. 
Another advantage of using the CLDND1-H2K vector in the preliminary studies 
was the ability to separate the transfected population from untransfected cells. 
The resulting homogenous transfected cell population could then be used to 
determine the effects of CLDND1 on CD4+ T-cell function. As part of this 
selection method dead cell removal was required prior to transfected cell 
isolation due to the possibility of dead cells binding the H2Kk selection beads. 
The combination of the dead cell removal step and the resulting isolation of 
H2Kk transfected cells, resulted in a loss of 20 % of H2Kk positive cells from the 
transfected population (Figure 63A, dead fraction), but did increase H2Kk 
positivity (40.7 % in alive fraction to 60.3 % in post-isolation fraction) (Figure 
63A and B). Two antibodies were used to detect the purity of the selected cells, 
as during the selection process, the α-H2Kk antibody binding site can be 
masked by the H2Kk positive selection beads. The MACSelect control antibody 
binds to the H2Kk positive selection beads and will identify the positively 
selected cells with masked α-H2Kk antibody epitopes. Transfection of the 
pIRES2-H-2Kk vector omitting a target gene resulted in high expression of 
H2Kk, showing that H2Kk can be expressed in the absence of a target protein 
(Figure 63C, courtesy of Amy Anderson). Therefore, using H2Kk as a marker for 
CLDND1 protein expression may not have been a reliable read-out. In addition, 
the presence of the xenogeneic MHC molecule on the T-cell surface, albeit a 
truncated version, could stimulate T-cell proliferation in its own right, 
irrespective of a CLDND1-mediated functional phenotype. 
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Figure 63. Validation of the CLDND1-H2K vector 
CD4+ T-cells were transfected with CLDND1-H2K or pIRES-H2Kk vector. 18 hours after transfection, dead cells were removed from the 
sample with a dead cell removal kit (Miltenyi) and selection of H2Kk transfected cells was performed. (A) Flow cytometry analysis of 
CD4+ transfected cells post dead cell removal and before H2Kk positive selection. (B) Flow cytometry analysis of CD4+ transfected cells 
post H2Kk selection. Transfected cells were stained with either α-H2Kk antibody, or MACSelect control antibody, due to potential H2Kk 
antibody epitope masking during the positive selection. (C) Transfection of pIRES-H2Kk vector alone. Viable cells were selected based 
on Via-Probe™ staining (data courtesy of Amy Anderson). Data represent at least two experiments. 
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6.3.3 Assessing CLDND1 protein over-expression 
In light of the concern of the presence of the xenogeneic MHC molecule on the 
T-cell surface, four different vectors, containing only the CLDND1 (UCB) protein 
sequence, were generated (see Section 2.2): CLDND1-HCMV, CLDND1-Elf, 
CLDND1-FerL and CLDND1-PIMMS. These vectors each contain different 
promoters (Table 7) and so different levels of CLDND1 gene expression could 
potentially be achieved. CD4+ T-cells were transfected with each of these four 
vectors or mock transfected and transfection efficiencies were determined 
(Figure 64). 
CLDND1 RNA expression profiling was performed on both endogenous 
CLDND1 (Figure 64A) and against the transfected CLDND1 sequence 
(CLDND1(V)) (Figure 64B). The two sequences could be distinguished by 
different qRT-PCR primer pairs and probes as CLDND1(V) is a codon optimised 
sequence, so the transcript bases were different. A 81.5 ± 7.0 SEM fold 
increase in CLDND1(V) mRNA expression was seen with the CLDND1-PIMMS 
vector, compared to the mock transfected control, while only a minimal fold 
change in CLDND1(V) mRNA expression was observed with CLDND1-HCMV, 
CLDND1-Elf or CLDND1-FerL (3.6 ± 0.2 SEM, 5.7 ± 0.8 SEM or 9.8 ± 0.8 SEM, 
respectively) (Figure 64B). The transfection of DNA into CD4+ T-cells reduced 
endogenous CLDND1 transcript levels, as vector-transfected samples had 
lower CLDND1 expression levels than the mock and untransfected control 
samples (0.3 ± 0.04 SEM, 0.3 ± 0.01 SEM, 0.4 ± 0.02 SEM, 0.1 ± 0.01 SEM, 
respectively) (Figure 64A). 
To determine whether the increase in CLDND1(V) transcript resulted in human 
CLDND1 (UCB) protein over-expression, CLDND1 protein levels were 
assessed (Figure 64C). For CLDND1-PIMMS transfections, three bands were 
detected within the predicted molecular weight range for CLDND1, which 
corresponded to different CLDND1 glycosylation states (Section 3.3.6, Figure 
26). A faint band was also seen for CLDND1-HCMV, CLDND1-Elf and 
CLDND1-FerL transfections, however this was likely to be endogenous 
CLDND1 protein, as this band was also present in the mock and untransfected 
samples. CLDND1-PIMMS was therefore used for all subsequent transfection 
experiments. 
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Figure 64. Validation of CLDND1 (UCB)-containing vectors 
CD4+ T-cells were transfected with CLDND1-HCMV (HCMV), CLDND1-Elf (Elf), CLDND1-FerL (FerL) or CLDND1-PIMMS (PIMMS), 
mock transfected or left untransfected. 18 hours after transfection, CLDND1 RNA and protein levels were assessed. RNA was extracted 
from cell lysates and CLDND1 qRT-PCR values were normalised to pol2a. (A) Endogenous CLDND1 transcript expression. (B) 
CLDND1(V) transcript expression. (C) Transfected cell lysates were prepared and Western blot analysis was performed with α-CLDND1 
antibody. Mean values + SEM are plotted. Data illustrate a single experiment.  
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6.3.4 CLDND1 transfection into primary human CD4+ T-cells 
In the analysis of the above experiments, CLDND1 expression levels were 
compared to untransfected and mock transfected controls. I found that DNA 
transfection resulted in a decrease in the endogenous CLDND1 RNA 
expression (Figure 64A) and so additional controls were required to account for 
this presence of DNA. Two PIMMS control vectors were therefore generated; 
one containing a non-coding stuffer fragment (PIMMS-non-coding) and the 
other containing the coding sequence for the human κ antibody light chain 
(PIMMS-coding). During data analysis, two methods were adopted to compare 
CLDND1-PIMMS read-out values to control cells: the two control values were 
averaged to give one control value, or samples were assessed individually.  
6.3.5 CLDND1 transfection efficiency and cell viability 
CLDND1-PIMMS, PIMMS-non-coding and PIMMS-coding vectors were 
transfected into CD4+ T-cells and after 18 hours, CLDND1 cell surface 
expression and total CLDND1 expression was determined (Figure 65). A 
significant increase in the amount of both CLDND1 cell surface (Figure 65A) 
and total protein (Figure 65B) was detected in the CLDND1-PIMMS transfected 
cells, compared to the PIMMS-non-coding, PIMMS-coding or the averaged 
control values. The transfection efficiencies in the CLDND1-PIMMS samples 
averaged 27 ± 3 % SEM for cell surface CLDND1 expression and 44 ± 3 % 
SEM for total CLDND1 expression and were determined by the percentage of 
CLDND1 fluorescence greater than mock-transfected control CLDND1 
fluorescence. Figure 65C represents the increase in CLDND1 fluorescence 
identified in the CLDND1-PIMMS transfected samples. The CLDND1 GMFI 
values were calculated from the whole population. 
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Figure 65. CLDND1 expression during primary human CD4+ T-cell transfection 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection, CLDND1 protein levels were assessed. An average was taken of the control vectors (control, upper panels) or values were 
plotted independently (lower panels). CLDND1 (A) cell surface expression, or (B) total expression. (C) Representative histogram plot 
depicting CLDND1 cell surface and total CLDND1 protein levels determined by flow cytometry. Data illustrate four independent 
experiments. Mean values ± SEM were plotted. Paired Student’s t-test analysis was performed *p<0.05, **p<0.01.
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A large amount of cell death was discovered in all the PIMMS-transfected 
samples (Figure 66 “pre values”). Incorporation of a dead cell removal step 
helped to increase the proportion of viable cells for the resulting functional 
assays (Figure 66 “post values”). The amount of dead cells present in each 
sample post dead cell removal reduced on average by 56 %. Only viable cells 
were counted when determining cell population concentrations for subsequent 
experiments, so the same number of viable cells was present for each assay. 
 
 
Figure 66. Viability during primary human CD4+ T-cell transfection 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
control vectors or with the CLDND1-PIMMS (CLD) vector. 18 hours after 
transfection, CLDND1 protein levels were assessed. An average was taken of 
the control vectors (control) or values were plotted independently. Annexin V 
and Via-Probe™ staining were used to determine cell viability 18 hours post 
transfection or after the dead cell removal step was performed. Data illustrate 
four independent experiments. Mean values + SEM were plotted. paired 
Student’s t-test analysis was performed *p<0.05, **p<0.01.   
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The experimental protocol for all the functional assays performed in this chapter 
is depicted in Figure 67. 
 
 
Figure 67. Experimental protocol for CLDND1-transfected T-cell assays 
CD4+ T-cells were transfected and cultured for 18 hours. T-cell tranfection 
efficiency, phenotyping and dead cell removal was performed before T-cell 
proliferation was assessed by culturing with α-CD3/CD28 expander beads for 3 
days, or mat- or tolDC for 3 or 6 days. After 24 hours of co-culture IL-2 
production was assessed. After co-culture, T-cell proliferation, cytokine 
production, cell viability and phenotype were assessed. MatDC stimulated cells 
were also re-stimulated immediately for 3 days. 24 hours after re-stimulation IL-
2 production was assessed. After 3 days of re-stimulation, T-cell proliferation, 
cytokine production, cell viability and phenotype were assessed. 
 
6.3.6 CLDND1-transfected T-cell proliferation in response to α-CD3/CD28 
expander bead stimulation 
The transfected CD4+ T-cells were incubated with 10:1 (10 T-cells: 1 bead) 
ratio of α-CD3/CD28 expander beads for 3 days and T-cell proliferation was 
measured (Figure 68A). CLDND1 over-expression resulted in a decrease in 
CD4+ T-cell proliferation in some donors, in keeping with the preliminary 
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findings (Section 1.11.10, Figure 9), however this was not consistent in all 
samples. Differences in T-cell proliferation were also observed between the 
PIMMS-control samples (Figure 68A). The PIMMS-non-coding transfected cells 
responded less than the PIMMS-coding transfected cells, albeit still with a 
higher proliferative capacity than the CLDND1-PIMMS transfected cells.  
 
 
Figure 68. CLDND1-transfected T-cell proliferation in response to α-
CD3/CD28 expander bead stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD). 18 hours post transfection cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
α-CD3/CD28 expander beads for 3 days. An average was taken of the control 
vectors (control) or values were plotted independently. (A) Proliferation was 
measured by 3HTdR incorporation. (B) Annexin V and Via-Probe™ staining was 
performed to assess cell viability post proliferation. Data illustrate at least four 
independent experiments. Mean values (+ SEM) were plotted. Paired Student’s 
t-test analysis was performed *p<0.05, **p<0.01.  
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To determine whether the differences in proliferation were a result of cell death, 
cell viability was assessed post-proliferation (Figure 68B). A significant 
reduction in cell viability was seen in the CLDND1-PIMMS transfected samples 
compared to the averaged PIMMS-control value, suggesting CLDND1 may be 
involved in cell death pathways. In addition, cell viability was mirrored by the 
amount of proliferation in each sample and as such, suggested the differences 
seen in T-cell proliferation between the cell populations may have reflected the 
viability of those cells. Regression analysis of a limited number of data values 
identified a significant correlation between CLDND1-transfected T-cell viability 
and T-cell proliferation (Figure 69). 
 
 
 
 
Figure 69. Regression analysis of T-cell proliferation and viability 
CD4+ T-cells were transfected with CLDND1-PIMMS. 18 hours post 
transfection cells were harvested and dead cells were removed. Cells were 
incubated with 10:1 ratio of α-CD3/CD28 expander beads for 3 days. 
Proliferation was measured by 3HTdR incorporation and cell viability was 
determined by Annexin V and Via-Probe™ staining. Data illustrate four 
independent experiments.  
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To assess proliferation in the viable T-cells, CFSE staining was performed 
(Figure 70). No differences were seen between the CFSE dilutions of the 
PIMMS-transfected T-cells, and proliferation itself was very low. These data 
may suggest that the introduction of DNA into T-cells by nucleofection affects T-
cell proliferation. In addition to T-cell proliferation, cytokine production was also 
investigated. Over-expressed CLDND1 does not seem to play an important role 
in the skewing of T-cell responses, as no differences in IFN-y, IL-10, TNF-α, IL-
5 or IL-17 production were seen (Figure 71). 
 
 
Figure 70. CLDND1-transfected T-cell CFSE staining in response to α-
CD3/CD28 expander bead stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS or light-PIMMS controls or 
with CLDND1-PIMMS. 18 hours post transfection cells were harvested and 
dead cells were removed. Cells were stained with CFSE then incubated with 
10:1 ratio of α-CD3/CD28 expander beads for 3 days.  CFSE staining was 
measured by flow cytometry and histograms of CFSE staining are shown. Data 
represent two independent experiments.
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Figure 71. CLDND1-transfected T-cell cytokine production in response to α-CD3/CD28 expander bead stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with the CLDND1-PIMMS (CLD). 18 hours post 
transfection, cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of α-CD3/CD28 expander beads for 
3 days. An average was taken of the control vectors (control) or values were plotted independently. Cytokines from supernatants taken at 
the end of the proliferation were measured by ELISA. Data illustrate four (or two for IL-5) independent experiments. Mean values (+ 
SEM) were plotted. Paired Student’s t-test analysis was performed.  
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6.3.7 Effect of CLDND1 over-expression on T-cell activation by DC 
Previous experiments (Section 5.3.5, Figure 51) have shown that differential 
CLDND1 expression during T-cell activation was dependent on the type and 
strength of stimulus, with the highest CLDND1 expression seen during 
activation with α-CD3/CD28 expander beads, followed by intermediate levels of 
CLDND1 expression with matDC, and the lowest level of expression with tolDC. 
As the type and strength of stimulus may be an important factor for CLDND1 
function in CD4+ T-cells, the CLDND1-transfected cells were also stimulated 
with mat- or tolDC. After 3 days or 6 days of co-culture, T-cell proliferation and 
cytokine production were assessed.  
CLDND1-PIMMS transfected cells proliferated significantly less than control 
cells after 3 day stimulation with either mat- or tolDC (Figure 72). There was 
also a trend for less IFN-γ production in the matDC stimulated CLDND1-PIMMS 
cells in three of the four donors (Figure 73). The levels of TNF-α and IL-10 
detected at day 3 were low in all samples, close to the limit of detection. 
 
 
Figure 72. CLDND1-transfected T-cell proliferation in response to 3 day 
DC stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (Ncd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD). 18 hours post transfection, cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
mat- or tolDC for 3 days. An average was taken of the control vectors (control) 
or values were plotted independently. Proliferation was measured by 3HTdR 
incorporation. Data illustrate four or three independent experiments for matDC 
or tolDC, respectively. Mean values (+ SEM) were plotted. Paired Student’s t-
test analysis was performed *p<0.05, **p<0.01. 
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Figure 73. CLDND1-transfected T-cell cytokine production in response to 3 day DC stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection, cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of mat- or tolDC for 3 days. An 
average was taken of the control vectors (control) or values were plotted independently. Cytokines from supernatants taken at the end of 
the proliferation were measured by ELISA. Data illustrate four or three independent experiments for the mat- and tolDC, respectively. 
Mean values (+ SEM) were plotted. Paired Student’s t-test analysis was performed *p<0.05, **p<0.01.
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After 6 days of stimulation with either mat- or tolDC, CLDND1-PIMMS 
transfected T-cell proliferation was also significantly lower (Figure 74), and the 
difference in proliferation between CLDND1-PIMMS and control transfected T-
cells varied between donors. Transfection efficiency correlations to CLDND1 
cell surface expression indicated a strong significant correlation between the 
two values, with more CLDND1 on the cell surface in samples with higher 
transfection efficiencies (Figure 75A). Comparison of the transfection efficiency 
against CLDND1-PIMMS transfected T-cell proliferation identified a weak 
inverse correlation between transfection efficiencies and proliferation in 
response to matDC stimulus (Figure 75B), although this correlation was not 
significant. 
 
 
Figure 74. CLDND1-transfected T-cell proliferation in response to 6 day 
DC stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD). 18 hours after transfection cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
mat- or tolDC for 6 days. An average was taken of the control vectors (control) 
or values were plotted independently. Proliferation was measured by 3HTdR 
incorporation. Mean values (+ SEM) were plotted. Data illustrate nine or five 
independent experiments, for mat- or tolDC, respectively. Paired Student’s t-test 
analysis was performed p<0.05, **p<0.01.  
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Figure 75. CLDND1-transfected T-cell correlations between transfection 
efficiency, CLDND1 cell surface GMFI and proliferation 
CD4+ T-cells were transfected with CLDND1-PIMMS vector. 18 hours after 
transfection cells were harvested and dead cells were removed. (A) 
Transfection efficiency was determined and values were correlated to CLDND1 
cell surface GMFI (B) Cells were incubated with 10:1 ratio of matDC for 6 days 
and proliferation was measured by 3HTdR incorporation and correlated to 
transfection efficiency. Data illustrate eight independent experiments. 
 
 
Transfected T-cell viability was also assessed; as differences in this parameter 
were seen between α-CD3/CD28 expander bead stimulated cells. No significant 
difference was seen in T-cell viability in the mat- or tolDC stimulated cultures 
after 6 days of co-culture (Figure 76). Analysis of each donor did show a trend 
for CLDND1-overexpression to reduce cell viability, albeit not significant, 
suggesting CLDND1 may still play a role in cell death. A significant difference in 
proliferation (Figure 74) but no significant difference in cell viability (Figure 76) 
was identified, suggesting that the differences seen in proliferation were due to 
additional CLDND1 specific effects rather than solely due to different amounts 
of live cells within the cultures.  
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Figure 76. CLDND1-transfected T-cell viability in response to 6 day DC 
stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD). 18 hours post transfection, cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
mat- or tolDC for 6 days. An average was taken of the control vectors (control) 
or values were plotted independently. Cell viability was determined at the end of 
the experiment by Annexin V and Via-Probe™ staining by flow cytometry. Mean 
values (+ SEM) were plotted. Data illustrate six or two independent 
experiments, for mat- or tolDC, respectively. Paired Student’s t-test analysis 
was performed.  
 
 
One of the main indicators of an anergic phenotype is the reduction in IL-2 
production (Schwartz, 2003) and so IL-2 levels were measured from the 
supernatants of the transfected co-cultures 24 hours after the initiation of the 
co-culture (Figure 77). A significant reduction in IL-2 production was observed in 
the CLDND1-PIMMS transfected samples co-cultured with matDC. This pattern 
was also mirrored with the IFN-γ levels detected after 6 days of co-culture in the 
majority of donors, but did not reach significance with all controls (Figure 78). 
IL-10, TNF-α and IL-5 levels were comparable between PIMMS-controls and 
CLDND1-PIMMS transfected cells.
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Figure 77. CLDND1-transfected T-cell IL-2 production in response to 6 day DC stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of mat- or tolDC for 6 days. An 
average was taken of the control vectors (control) or values were plotted independently. IL-2 levels were determined from the 
supernatants 24 hours after the start of co-culture, by ELISA. Mean values (+ SEM) were plotted. Data illustrate four or two independent 
experiments for mat- or tolDC, respectively. Paired Student’s t-test analysis was performed p<0.05.  
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Figure 78. CLDND1-transfected T-cell cytokine production in response to 6 day DC stimulation 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection, cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of mat- or tolDC for 6 days. An 
average was taken of the control vectors (control) or values were plotted independently. Cytokines from supernatants taken at the end of 
the proliferation were measured by ELISA (for IFN-y, IL-10 and TNF-α matDC n=9, tolDC n=4; for IL-5 matDC n=6, tolDC n=2). Mean 
values (+ SEM) were plotted. Paired Student’s t-test analysis was performed *p<0.05.
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6.3.8 Accessory molecule expression during CLDND1-transfected T-cell 
activation  
To determine whether DC stimulation of CLDND1-PIMMS transfected cells 
resulted in changes in co-stimulatory or accessory molecule expression which 
in turn was causing the reduction in proliferation, CLDND1, CD4 and CD28 
expression on PIMMS-transfected T-cells was assessed. CD25 expression was 
also assessed. CD25 is the alpha chain of the IL-2 receptor, which forms part of 
the heterotrimeric receptor structure. Binding of IL-2 to the IL-2 receptor 
propagates IL-2 signalling and so a reduction in CD25 expression would 
suggest reduced activation. 18 hours post transfection, but before co-culture, 
(Figure 79) a significant increase in CLDND1 cell surface and total protein  was 
seen in the CLDND1-PIMMS transfected cells, as expected (Figure 79A). There 
was a trend in three of the four donors studied for an increase in CD4 
expression and a decrease in CD28 expression (Figure 79B). In all four donors 
studied, there was a subtle increase in CD25 expression on CLDND1-PIMMS 
transfected T-cells than on control-PIMMS cells (Figure 79B).  
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Figure 79. CLDND1-transfected T-cell surface marker expression 
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection cells were harvested and dead cells were removed. An average was taken of the control vectors (control) or values were 
plotted independently. (A) CLDND1 protein expression (n=9) (B) cell surface marker expression (For CD4 and CD28 n=4, for CD25 n=3). 
Mean values (+ SEM) were plotted. Paired Student’s t-test analysis was performed *p<0.05, **p<0.01.
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By day 6 of co-culture (Figure 80), CLDND1 cell surface protein levels were 
lower than seen post transfection but were still significantly higher compared to 
the averaged control values. This significance was lost on comparison to each 
control individually (Figure 80A). CD25 expression had flipped, with the 
CLDND1-PIMMS transfected cells having a significantly lower cell surface 
expression of CD25 than the PIMMS-control cells (Figure 80B), which is 
consistent with the down-regulation in proliferation. The increased CD4 
expression in the CLDND1-transfected cells seen at the start of the co-culture 
was comparable to the control cells by the end of culture and the levels of CD28 
varied depending on the donor.
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Figure 80. CLDND1-transfected T-cell surface marker expression in response to 6 day DC stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of matDC for 6 days. An average 
was taken of the control vectors (control) or values were plotted independently. (A) CLDND1 protein expression (n=6). (B) Cell surface 
marker expression (n=6). Mean values (+ SEM) were plotted. Paired Student’s t-test analysis was performed *p<0.05.
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6.3.9 CLDND1-transfected T- cell re-stimulation: proliferation and cytokine 
production 
Re-stimulation assays were performed to recapitulate an anergy model. As 
peptide specific responses could not be used, I utilised the recall response to a 
specific MHC class II mismatch in a MLR. Transfected T-cells were stimulated 
for 6 days with matDC and then immediately re-stimulated for 3 days in the 
presence of DC obtained from the same donor as the first round of stimulation 
(same DC) or with an independent DC donor (diff DC). If CLDND1 is important 
in the induction or maintenance of anergy, re-stimulation of CLDND1-
transfected cells with the same DC donor should result in less T-cell 
proliferation and IL-2 production, than when stimulated with a MHC mismatched 
DC donor. It is important to note, that at the stage of re-stimulation, CLDND1 
levels were still significantly elevated in the CLDND1-PIMMS transfected cells 
(Figure 80A). 
In two of the three donors studied, CLDND1-PIMMS T-cell proliferation was 
reduced in response to same DC re-stimulations (Figure 81A), however, this 
response was mirrored in the diff DC re-stimulations, suggesting a non-specific 
effect rather than donor-specific anergy induction. Cell viability was also 
assessed in the re-stimulation cultures and no difference was observed overall 
in the percentage of viable cells stimulated with either same or diff DC (Figure 
81B), but with two experiments, it is difficult to draw robust conclusions from 
these data.  
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Figure 81. CLDND1-transfected T-cell proliferation and viability in 
response to DC re-stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD). 18 hours post transfection cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
matDC for 6 days. Cells were then re-stimulated with same DC or with diff DC 
for 3 days. An average was taken of the control vectors (control) or values were 
plotted independently. (A) Proliferation was measured by 3HTdR incorporation 
(n=3). (B) Viability of the cells was determined by Annexin V and Via-Probe™ 
staining by flow cytometry (n=2). Mean values (+ SEM) were plotted. Paired 
Student’s t-test analysis was performed. 
 
 
Cytokine secretion was also examined (Figure 82). IL-2 was assessed 24 hours 
after re-stimulation but was below the threshold for detection (data not shown). 
In two of the three CLDND1-PIMMS transfected donors, IFN-γ and IL-10 levels 
were decreased and IL-5 production levels were increased, but this was not 
DC-donor specific. Interestingly, TNF-α production increased in the same DC 
re-stimulated CLDND1-PIMMS cultures from all three donors, in contrast to a 
consistent reduction when diff DCs were used for restimulation.  
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Figure 82. CLDND1-transfected T-cell cytokine production in response to DC re-stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD). 18 hours post 
transfection cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of matDC for 6 days. Cells were 
then re-stimulated with same DC or diff DC for 3 days. An average was taken of the control vectors (control) or values were plotted 
independently. Cytokines from supernatants taken at the end of the proliferation were measured by ELISA (n=3). Mean values (+ SEM) 
were plotted. Paired Student’s t-test analysis was performed *p<0.05.
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6.3.10 CLDND1-transfected T- cell re-stimulations: accessory molecules 
As with previous experiments, the levels of cell surface and total CLDND1 were 
measured (Figure 83) along with CD4, CD25 and CD28 (Figure 84). The levels 
of cell surface CLDND1 fell dramatically in re-stimulated CLDND1-PIMMS cells, 
regardless of the re-stimulation signal, while total levels remained similar 
(Figure 83). CD4, CD25 and CD28 expression was also reduced in CLDND1-
PIMMS re-stimulated cells, regardless of the type of restimulation DC (Figure 
84). From one or two experimental replicates it is difficult to draw firm 
conclusions, however.  
 
 
 
Figure 83. CLDND1-transfected T-cell CLDND1 expression in response to 
DC re-stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
control or with CLDND1-PIMMS (CLD). 18 hours post transfection cells were 
harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
matDC for 6 days. Cells were re-stimulated with same DC or diff DC for 3 days 
then CLDND1 expression was assessed. An average was taken of the control 
vectors (control) or values were plotted independently. Mean values were 
plotted. Data illustrate a single experiment.
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Figure 84. CLDND1-transfected T-cell surface marker expression in response to DC re-stimulation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) control or with CLDND1-PIMMS (CLD). 18 hours post 
transfection cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of matDC for 6 days. Cells were 
then re-stimulated with same DC or with diff DC for 3 days. An average was taken of the control vectors (control) or values were plotted 
independently. Mean values (+ SEM) were plotted. Data illustrate two independent experiments. 
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6.3.11 Functional domains of CLDND1 
As part of the protocol for generating antibodies against full length CLDND1, 
vectors expressing truncated versions of CLDND1 were produced (Section 
3.3.7, Figure 28). The CLDND1-trunc protein had part of its C-terminal domain 
removed containing the clathrin endocytosis signal along with two potential 
tyrosine phosphorylation sites. CLDND1-trunc over-expression into T-cells 
could either have one of two effects: i) the lack of the clathrin mediated 
endocytosis signal could potentially increase the effects of CLDND1 seen from 
the over-expression due to increased cell surface location, as this protein 
cannot be internalised by clathrin-coated pits; or ii) the lack of phosphorylation 
sites could prevent the functional effects seen with full length CLDND1. Both 
CLDND1-PIMMS and CLDND1-trunc-PIMMS were transfected into primary 
human CD4+ T-cells and 18 hours after transfection, CLDND1 cell surface and 
total CLDND1 levels were measured (Figure 85). A significant increase in 
CLDND1 cell surface protein was identified in the CLDND1-trunc-PIMMS 
transfected cells compared to control cells, yet there was not a trend for 
increased CLDND1 cell surface location in the CLDND1-trunc-PIMMS 
transfected samples compared to the full length CLDND1-PIMMS, suggesting 
that, in this system, clathrin mediated endocytosis may not be important in 
maintaining cell surface expression. Total levels of CLDND1 were comparable 
between the CLDND1-PIMMS and CLDND1-trunc-PIMMS transfected samples. 
Comparison of transfection efficiencies identified that 43.5 ± 3.1 % SEM cells 
were transfected with CLDND1-PIMMS while only 25.4 ± 3.7 % SEM cells were 
transfected with CLDND1-trunc-PIMMS.
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Figure 85. Truncated CLDND1-transfected T-cell CLDND1 expression  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD) or CLDND1-trunc-PIMMS (C-trun). 18 
hours post transfection, cells were harvested and dead cells were removed. 
Cells were incubated with 10:1 ratio of matDC for 6 days. An average was taken 
of the control vectors (control) or values were plotted independently. CLDND1 
protein expression 18 hours post transfection. Mean values (+ SEM) were 
plotted. Data illustrate at least three independent experiments. Red and blue 
coloured points represent donors where restoration of T-cell proliferation was 
seen (Figure 86). Paired Student’s t-test was performed, *p<0.05, **p<0.01.  
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The effect of CLDND1 truncation on T-cell proliferation was assessed (Figure 
86). A significant reduction in proliferation was seen in the CLDND1-PIMMS 
transfected cells compared to the PIMMS-non-coding control, as seen 
previously. In only two of the four donors, (Figure 86, blue and red data points) 
a difference in proliferation was seen between truncated and full length 
CLDND1, and proliferation was elevated compared to CLDND1-PIMMS cells. 
Analysing more individuals may confirm a functional role for CLDND1 C-
terminal domain in CLDND1’s regulation of T-cell proliferation, however this 
may also reduce the significance of this observation. Analysis of cytokine 
secretion in the transfected samples mirrored the proliferation data (Figure 87), 
with the exception of IL-10 which did not differ greatly in any of the transfected 
samples.  
 
 
Figure 86. Truncated CLDND1-transfected T-cell proliferation  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) 
controls or with CLDND1-PIMMS (CLD) or CLDND1-trunc-PIMMS (C-trun). 18 
hours post transfection, cells were harvested and dead cells were removed. 
Cells were incubated with 10:1 ratio of matDC for 6 days. An average was taken 
of the control vectors (control) or values were plotted independently. 
Proliferation was measured by 3HTdR incorporation. Mean values (+ SEM) were 
plotted. Data illustrate four independent experiments. Red and blue coloured 
points represent donors where restoration of T-cell proliferation was seen. 
Paired Student’s t-test was performed, *p<0.05.  
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Figure 87. Truncated CLDND1-transfected T-cell cytokine production  
CD4+ T-cells were transfected with stuffer-PIMMS (NCd) or light-PIMMS (Cd) controls or with CLDND1-PIMMS (CLD) or CLDND1-trunc-
PIMMS (C-trun). 18 hours post transfection cells were harvested and dead cells were removed. Cells were incubated with 10:1 ratio of 
matDC for 6 days. An average was taken of the control vectors (control) or values were plotted independently. Cytokines from 
supernatants taken at the end of the proliferation were measured by ELISA. Mean values (+ SEM) were plotted. Data illustrate at least 
two independent experiments. Red and blue coloured points represent donors where restoration of T-cell proliferation was seen. Paired 
Student’s t-test analysis was performed*p<0.05, **p<0.01.
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6.4 Discussion 
Throughout this chapter, a function for CLDND1 in the regulation of CD4+ T-cell 
proliferation was sought. Based on conserved motifs identified during the 
discovery of the protein, CLDND1 was categorised as a member of the PMP-
22/EMP/MP20/claudin superfamily. Further phylogenetic analysis revealed 
CLDND1 shared more homology to the more distantly related proteins 
TMEM114 and CACNG. Over-expression of CLDND1 resulted in significant 
increases in both cell surface and total CLDND1, which depending on the type 
of activation stimulus resulted in an increase in cell death, or a reduction in 
proliferation and pro-inflammatory cytokine production. In order to determine the 
specific effects of CLDND1 in T-cell recall responses, re-stimulations assays 
were performed. Minimal differences were observed between different 
allogeneic stimuli used in the re-stimulation assay, suggesting that CLDND1 
may not influence antigen-specific T-cell recall responses. However as MLR 
provide a particularly strong and heterogeneous immune stimulus, similar 
studies need to be executed with more subtle T-cell stimuli to define a potential 
role for CLDND1 in anergy. A reduction in CLDND1-transfected T-cell 
proliferation during first round stimulations is consistent with the hypothesised 
role for CLDND1 in the regulation of T-cell responses. 
6.4.1 Phylogenetic findings and the implications on CLDND1 function 
Sequence analysis of CLDND1 revealed it shares more homology to TMEM114 
and the CACNG than to the claudins. Although the former proteins have no 
identified function in immune cells, differences in protein post-translational 
modifications and their function in other cells may provide clues to CLDND1 
function. 
CLDND1 contains N-glycosylation sites (Section 3.3.6, Figure 26), and 
equivalent sites are important in the plasma-membrane localisation of 
TMEM114 (Maher et al., 2011). The CACNG family members are also heavily 
glycosylated (Section 1.11.5, Figure 8), but whether this is important for plasma-
membrane localisation or function remains to be determined. Claudins do not 
have glycosylation sites in their extracellular loops (Koval, 2006). It is worth 
noting that in primary human CD4+ T-cells, differential glycosylation states were 
not observed for endogenous CLDND1 by western blot analysis (Section 5.3.2, 
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Figure 39A). Caution should therefore be applied when linking glycosylation to 
CLDND1 function in primary human CD4+ T-cells. With claudin-14, 
palmitoylation plays a similar role to TMEM114 glycosylation as this post 
translation modification is required for efficient localisation at tight junctions, but 
is not essential for protein stability or the formation of tight junction strands (Van 
Itallie et al., 2005). However, no palmitoylation sites have been documented for 
CLDND1. Similar roles for palmitoylation and glycosylation in the cellular 
localisation of PMP-22/EMP/MP20/claudin superfamily members may suggest 
that the location of TMEM114 was dependent on glycosylation and not due to 
the role glycosylation plays in protein stability, as previously suggested (Section 
3.4.2). 
Limited studies with truncated CLDND1 suggested a possible functional role for 
the cytoplasmic C-terminal domain of CLDND1. However, the differences were 
subtle in a limited number of experiments. Nonetheless, many PMP-
22/EMP/MP20/claudin superfamily members are phosphorylated and the 
phosphorylation is implicated in localisation or function. Phosphorylation of 
serine or threonine residues within claudins -3, -4, -5 and -16 regulate their 
localisation as well as the barrier properties of tight junctions (D'Souza et al., 
2005, Aono and Hirai, 2008, Ishizaki et al., 2003, Ikari et al., 2006). Additionally, 
phosphorylation of the C-terminal tail of CACNG2 has been shown to impair 
interactions with PDZ binding proteins and AMPA receptor synaptic trafficking 
(Choi et al., 2002). Further experiments are required to confirm or refute a role 
for the potential phosphorylation sites within the C-terminus sequence of 
CLDND1. 
Some PMP-22/EMP/MP20/claudin superfamily members contain other 
important motifs within their C-terminal domain. The γ-2, -3, -4 and -8 subunit 
cluster of the CACNG family are TARP, regulators of AMPA receptor signalling, 
and possess a PDZ domain, which is the binding domain required for this 
regulatory function (Tomita et al., 2003). As CLDND1 does not contain this 
motif, functional characteristics of CLDND1 may be more similar to the non-PDZ 
possessing family members: TMEM114, γ-1, -5, -6 or -7. Although TMEM114 
plays an important role in ocular development in vertebrates, its exact function 
remains uncertain (Maher et al., 2011) and no inferences to CLDND1 function 
can be made from this protein. The γ-1 subunit was the first CACNG to be 
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described and it decreases expression and activity of the pore forming α subunit 
(Cav1.1) of calcium channels (Sandoval et al., 2007). The γ-6 subunit interacts 
with and negatively regulates Cav3.1 through a conserved GxxxG motif in the 
first transmembrane domain of the protein (Hansen et al., 2004, Lin et al., 
2008). Although not identical, CLDND1 contains an AxxxA motif, in the first 
transmembrane region, which has the same proposed functions as the motif in 
the γ-6 subunit. The γ-5 and -7 subunits have also been classified as a distinct 
subset of TARP which can positively modulate glutamate-evoked currents via 
AMPA receptors (Kato et al., 2008, Kato et al., 2007), without altering receptor 
trafficking, like conventional TARP (Tomita et al., 2003, Kato et al., 2008). As 
well as their well-known location in neuronal cells, AMPA receptors are also 
present on human lymphocytes, and can modulate T-cell function through 
altering calcium flux (Lombardi et al., 2001). 
Linking the phylogenetic studies, the role of CACNG in modulating calcium flux 
in lymphocytes, and the CLDND1 proliferation studies may suggest a role for 
CLDND1 as a regulator of calcium channels. Calcium signalling is of pivotal 
importance for both positive and negative regulation of T-cell function 
(Beyersdorf et al., 2009, Oh-hora and Rao, 2008, Gwack et al., 2008). A 
proposed model for signalling through store operated calcium channels has 
been suggested by Qu et al. (2011), where proliferation, apoptosis or tolerance 
can occur depending on the strength and duration of calcium signalling (Figure 
88). 
A role for CLDND1 in the regulation of calcium ion channels is also consistent 
with its expression in glial cells. Oligodendrocytes were originally described as 
myelin producing cells, important for the modelling of the axons of the nervous 
system. More recently, a lot of interest has been generated in the function of 
these cells due to their pivotal role in multiple sclerosis (Prineas and Parratt, 
2012). One aspect has focussed on the role of calcium signalling within these 
cells. Several experiments indicate that cells of oligodendroglial lineage exhibit 
remarkable plasticity with regard to the expression of ion channels and 
receptors linked to calcium signalling and that perturbation of calcium 
homeostasis contributes to the pathogenesis of demyelinating diseases, 
primarily though the induction of apoptosis in these cells (Alberdi et al., 2005). 
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Figure 88. [Ca]i signalling and T-cell proliferation, apoptosis and tolerance  
The strength of [Ca]i signalling within a T-cell dictates its response. High [Ca]i signalling can induce T-cell apoptosis, moderate strength 
signalling can induce T-cell proliferation and low signal strength can induce T-cell tolerance. Adapted from Qu et al. (2011).
Katherine L. Crossland               Chapter 6. Determining a Function for CLDND1 in CD4+ T-cells 
223 
6.4.2 CLDND1 function during primary T-cell responses 
The effect of CLDND1 transfection on CD4+ T-cell proliferation was dependent 
on the type of stimulus. Activation of CLDND1-transfected T-cells with α-
CD3/CD28 expander beads resulted in a decrease in cell viability and no 
consistent effect on proliferation, whereas stimulation with either mat- or tolDC 
resulted in a reduction in proliferation, CD25 expression and IL-2 and IFN-γ 
production, which was independent of cell death. One hypothesis for the 
differences observed between the two stimuli relates to the differences in 
strength of activating signal, as illustrated by the proliferation and IFN-γ 
production of non-transfected cells (Section 5.3.5, Figure 50), and a selection of 
examples have been chosen to represent this hypothesis. 
Firstly, I have already shown that higher cell surface expression of endogenous 
CLDND1 was observed in samples stimulated with α-CD3/CD28 expander 
beads compared to DC (Figure 51). Therefore a certain threshold of CLDND1 
cell surface expression, reached during stimulation with α-CD3/CD28 expander 
beads but not with DC, may have promoted the initiation of cell death pathways. 
In contrast, regulatory pathways could be induced in DC stimulated cells. 
Although proposed CLDND1 function is distinct from Foxp3, it serves as an 
example of altered T-cell phenotypes as a result of different expression patterns 
of this gene. In scurfy mice, which lack CD4+CD25+ Treg due to absent Foxp3 
expression, CD4+ T-cells are hyper-responsive to TCR stimulation (Brunkow et 
al., 2001) and induction of Foxp3 expression in CD4+CD25- T-cells results in 
the acquisition of a Treg-like phenotype (Hori et al., 2003, Fontenot et al., 
2003). On the other hand, elevating Foxp3 beyond a certain threshold leads to 
increased susceptibility to apoptosis following T-cell activation, through 
activation induced cell death (AICD) (Kasprowicz et al., 2005).  
Another example in which protein function is modulated by the amount of 
protein expressed is mTOR. In this case higher levels of mTOR are associated 
with T-cell activation and not cell death, like Foxp3, and inhibition results in 
anergy. The function of mTOR is also dependent on the cell type in which it is 
expressed. In CD4+ CD25+ Treg, mTOR signalling can induce AICD under 
stimulatory conditions whereas the same activation through mTOR in 
CD4+CD25- T-cells promotes cell survival (Strauss et al., 2009). In addition, 
inhibition of mTOR signalling in whole CD4+ T-cell populations induces anergy 
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under stimulatory conditions (Zheng et al., 2007). Determining the effects of 
CLDND1 in specific cell subsets may depict specific effects for CLDND1 in 
these subsets, which may not be evident in whole CD4+ T-cell populations. 
If the strength of stimulus influenced a threshold level of cell surface CLDND1 
and subsequent T-cell function, then functional differences might also have 
been observed between the mat- and tolDC stimulated CLDND1-transfected 
cells, because mat- and tolDC promote different strengths of T-cell responses 
(Section 5.3.5, Figure 50). However, similar effects were identified between the 
mat- and tolDC stimulated CLDND1-transfected cells. By definition mat- and 
tolDC impart major differences on T-cells which could have over-ridden any 
influences of CLDND1 per se. Furthermore, any quantitative relationship 
between CLDND1 expression and function has not been defined by my work; 
this would require titrations of both α-CD3/CD28 expander bead and DC 
stimulus to determine whether CLDND1 function is regulated in a dose 
dependent manner.  
The fact that DC themselves express CLDND1 (Section 5.3.5, Figure 49) is 
another key difference between experiments studying bead or DC stimulation. It 
is well accepted that claudin family members mediate homotypic interactions 
(Findley and Koval, 2009), which could have a profound influence on 
interactions between DC and CLDND1-transfected T-cells if CLDND1 behaved 
similarly.  
Other regulatory interactions between DC and T-cells include CD40/CD154 and 
1-IBB/4-IBBL receptor interactions. Through the use of CD154-knock-out mice, 
an interaction between CD40 and CD154 has proved important in the efficient 
priming of T-cell responses in vivo (Grewal et al., 1995). Similarly, interactions 
between 4-IBB/4-IBBL are important in the priming of some T-cell responses in 
the absence of CD28 (DeBenedette et al., 1997). Although these receptors aid 
the priming of T-cell responses, they serve as an example of the complex 
signalling pathways between T-cell and DC, not present with α-CD3/CD28 
expander beads, which CLDND1 could directly or indirectly influence. 
Post CLDND1 transfection, T-cells had increased CD4 and CD25 and reduced 
CD28 expression. Independently, CD4high and CD25high T-cells have been linked 
to an enhanced susceptibility to activation in a number of diseases (Li et al., 
2007, Stanzani et al., 2004). In contrast, it is well established that Treg cells 
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also have high CD25 expression, and are characteristically anergic, which is 
consistent with the subsequent fall in CD25 expression in the CLDND1-
transfected cells and a reduced level of activation. Based on contradictory 
examples, the relevance of CLDND1 induced changes in CD4 and CD25 
expression remains uncertain. 
6.4.3 CLDND1 function during secondary immune responses 
I also attempted to examine the role of CLDND1 in the regulation of T-cell 
anergy. Owing to the lack of a peptide-reactive T-cell clone, a surrogate system 
was adopted, where CLDND1-transfectants were re-stimulated with the same 
allogeneic DC, or with third party DC. No apparent differences were observed 
between the two different models suggesting CLDND1 may not influence recall 
responses. Nonetheless, MLR provide a particularly strong and heterogeneous 
immune stimulus and similar studies need to be executed with alternative 
modes of T-cell activation. Although no difference in proliferation was observed 
between the stimulated CLDND1-transfected cell populations, there was an 
increase in TNF-α production in the recall CLDND1-transfected cultures in 
contrast to a fall in third party DC-stimulated cultures. The source of TNF-α in 
these cultures is uncertain as both T-cells and DC can express this cytokine. 
TNF-α is linked to the induction of apoptosis (Chu, 2013), the attenuation of 
TCR signalling, T-cell proliferation and cytokine production (Cope et al., 1997) 
and the effective priming and maturation of DC in response to infection (Trevejo 
et al., 2001), and so the role of TNF- α in this system remains to be determined. 
Future work could also focus on the DC populations within these cultures, to 
determine whether the effects of CLDND1-overexpression were affecting DC 
phenotype.  
6.4.4 Mechanisms of CLDND1 function 
The limited CLDND1 truncation studies raised the possibility that part of the C-
terminal domain of CLDND1 may be important for transduction of intracellular 
signals, through its clathrin mediated endocytosis motif and phosphorylation 
sites. CTLA-4, a negative regulator of T-cell proliferation, has a clathrin 
mediated endocytosis motif in its C-terminal tail that provides an interaction 
point for the src family tyrosine kinases, fyn, lyn and lck and acts as a site for 
phosphorylation for CTLA-4 function (Miyatake et al., 1998). Claudin-4 also 
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associates with lck in human CD4+ T-cells (Kawai et al., 2011) and so the 
CLDND1 clathrin mediated endocytosis motif may indicate a potential signalling 
function. 
In summary, studies to determine a function for CLDND1 in primary human 
CD4+ T-cell have pointed towards an inhibitory role for CLDND1 in the 
induction of T-cell pro-inflammatory responses, although different effects were 
observed depending on the type of stimulus. This finding is common within the 
T-cell biology field, where several proteins have different functions depending 
on the context of the experiment; the findings also fit with current knowledge of 
other PMP-22/EMP/MP20/claudin superfamily members’ roles in different cell 
systems. These studies have not provided evidence to suggest that CLDND1 
plays a role in anergy induction, although different models need to be studied. 
The function of CLDND1 may be modulated through C-terminal sequence 
motifs, which also fits with other PMP-22/EMP/MP20/claudin superfamily 
members and other proteins involved in the regulation of T-cell responses. In 
all, my experiments have suggested many further avenues for research on 
CLDND1 in order to determine its role in T-cell proliferation or homeostasis.
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Chapter 7. General Discussion 
Preliminary work had suggested a potential role for CLDND1 in the regulation of 
T-cell proliferation and the aims of this project were to recapitulate these 
findings and provide further evidence of a role for CLDND1 in the regulation of 
T-cell responses. Using a number of approaches I have added to these original 
findings. I have investigated how CLDND1 may modulate T-cell function, how 
the protein itself is organised within cellular membranes, the way in which the 
protein is expressed, which proteins or signalling systems may modulate 
CLDND1 function and postulated a potential role for CLDND1 in autoimmune 
disease. Some findings identify similarities between CLDND1 and other 
members of the PMP-22/EMP/MP20/claudin superfamily, providing potential 
links for functional pathways. 
7.1 CLDND1 RNA and Protein Levels 
Based on differences identified between CLDND1 RNA and protein levels, a 
hypothesis was generated whereby CLDND1 may be regulated through post-
translational mechanisms rather than at the level of gene transcription. The idea 
builds further with the concept that CLDND1 function is also regulated through 
its cellular location, the amount of protein available and associations with other 
proteins. 
7.1.1 CLDND1 RNA versus protein levels 
The CLDND1 gene could be effectively silenced at the transcript level; however 
no reduction in cell surface or total CLDND1 protein was seen. The siRNA 
method used has since been successfully used to silence the tyrosine kinase 
Jak3, at both the mRNA and protein level in primary human T-cells (Gomez-
Valades et al., 2012), suggesting a CLDND1 specific observation. It was 
established that the techniques used to detect CLDND1 RNA or protein during 
the silencing experiments were effective, which therefore suggested CLDND1 
RNA and protein were independently regulated. 
The tracking of CLDND1 RNA and protein expression levels during T-cell 
activation further supported a disconnect between CLDND1 RNA and protein 
levels. In either CD4+ or CD8+ T-cells, the increase in CLDND1 RNA levels 
seen during T-cell activation was consistently smaller than the increase in 
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CLDND1 protein levels, with CLDND1 transcript levels showing 1.9 ± 0.3 SEM 
fold change and CLDND1 cell surface protein levels 6.0 ± 1.33 SEM fold 
change above the resting values. Additionally, during CLDND1 over-expression 
experiments, a large fold change in CLDND1 RNA was identified (81.5 ± 7 
SEM) in the CLDND1-transfected samples, yet the fold change in CLDND1 
protein levels was much lower (3.9 ± 0.6 SEM or 3.3 ± 0.4 SEM, depending on 
cell surface or total CLDND1 protein expression, respectively). Although in this 
instance, the changes in CLDND1 RNA levels were greater than the protein 
levels, a discrepancy between the RNA and protein levels was still observed. As 
the Central Dogma of molecular biology states that “DNA makes RNA makes 
protein” this would suggest a linear relationship between these entities. This 
linear relationship underpins the basis for a number of transcript-profiling 
experiments to identify genes that are up- and down-regulated under normal or 
disease conditions, with the underlying assumption that differences in mRNA 
levels in different phenotypes will result in differences of protein levels. As such, 
the correlations between differential expression of mRNA and proteins have 
been the centre of a number of studies. A comprehensive study correlating 
yeast mRNA and proteins identified greater than 70 % of proteins levels were 
regulated by the abundance of their mRNA (Lu et al., 2007). Similarly, in 
circulating monocytes, Guo et al., (2008) identified at a cellular level, the 
amount of total protein detected was reflected by the amount of that transcript, 
again supporting the Central Dogma. There are at least four reasons for poor 
correlations between transcript and protein levels: firstly, many post-
transcriptional mechanisms exist which are involved in turning mRNA into 
protein which may prevent the direct computation of protein expression from 
mRNA; secondly, protein half-lives are likely to differ substantially and so skew 
a linear relationship between mRNA and protein; thirdly, there will be a 
significant amount of error and noise in both protein and mRNA experiments 
(Greenbaum et al., 2003); and fourthly, post-translational modifications may 
account for the regulation of protein function and therefore mRNA abundance 
does not relate to the total amount of protein and its function. In some 
instances, discrepancies in certain mRNA and protein levels have been 
described, which occur as a result of post-translational mechanisms. The 
protein BiP, involved in the sensing of ER stress, has been shown to have 
independently regulated protein and RNA levels, as an artificial increase in 
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cellular BiP mRNA did not result in an increase in BiP synthesis. However, 
under ER stress, the translational efficiency of BiP was enhanced and cellular 
protein levels increased, independently of the abundance of transcript. These 
events were independent of the 5’ and 3’ UTR of the transcript, which instead 
suggested translational control mechanisms (Gulow et al., 2002). Additionally, 
TGF-β mRNA and protein levels are also not correlated, as a result of many 
regulatory post-translational mechanisms that influence the protein (Kim et al., 
1992). These examples demonstrate non-proportionate quantitative changes in 
mRNA and protein, and my data suggest the same may be true for CLDND1. 
7.1.2 CLDND1 protein localisation 
In conjunction with the concept that CLDND1 protein is regulated independently 
of RNA levels, the location of CLDND1 within the cell may also act as a 
regulating mechanism. During DC-mediated CD4+ T-cell activation, a significant 
increase in cell surface CLDND1 was detected whereas no significant change in 
total CLDND1 protein was seen. This finding suggests CLDND1 traffics to the 
cell surface upon activation. An example of where cell surface location is 
imperative for protein function is CTLA-4. CTLA-4 is a potent negative regulator 
of CD4+ T-cell proliferation and functions at the cell surface where it binds and 
prevents interactions between the co-stimulatory molecule CD28 and the B7 
molecules, CD80 and CD86, on DC. The cell surface location of CTLA-4 is 
tightly regulated where CLTA-4 is located in cytoplasmic vesicles in resting T-
cells and these traffic to the cell surface during T-cell activation (McCoy and Le 
Gros, 1999). 
7.1.3 CLDND1 protein quantity 
The quantity of T-cell surface CLDND1 may be an important factor in CLDND1-
mediated regulation of T-cell proliferation. Transfected CLDND1 cell surface 
expression levels weakly correlated with a reduction in T-cell proliferation, 
suggesting higher levels of CLDND1 at the cell surface result in lower T-cell 
activation. Significant changes in the quantity of cell surface CLDND1 were 
seen during T-cell activation but not for the total number of CLDND1-expressing 
cells. Similarly, in the EA patient study, the quantity of cell surface CLDND1 
correlated with RA RF status but not the total number of CLDND1-expressing 
cells. In conjunction with the observation that CLDND1 cell surface expression 
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is identified on a proportion of T-cells, these findings are consistent with the 
hypothesis that the quantity of CLDND1 expressed relates to the functional role 
of CLDND1. 
7.1.4 Potential CLDND1-protein interactions 
CLDND1 function may be governed through interactions with other proteins. 
The presence of CLDND1 on a subpopulation of cells may indicate a possible 
protein interaction with a yet to be identified receptor or ligand expressed on 
these cells. In addition, it is well accepted that claudin family members can 
mediate homotypic interactions (Findley and Koval, 2009) and as CLDND1 is 
expressed on T-cells as well as DC, CLDND1 homotypic interactions may 
provide a generic mechanism of action for CLDND1. Western blot analysis on 
CD4+ T-cell CLDND1-transfected cell lysates revealed a band with a molecular 
weight approximately double the size of CLDND1, which according to 
independent studies on two other PMP-22/EMP/MP20/claudin superfamily 
members (Suzuki et al., 2013, Mobley et al., 2007), could indicate the presence 
of a CLDND1 homodimer. 
Interactions between CLDND1 and other proteins may also be mediated from 
the intracellular portion of the protein. Limited studies to determine a function for 
the C-terminal tail of CLDND1 suggested CLDND1 regulatory function could be 
mediated through this region. Similar motifs identified in the C-terminal tail of 
CTLA-4 have been shown to provide an interaction point for the src family 
tyrosine kinases, fyn, lyn and lck and act as a site for phosphorylation (Miyatake 
et al., 1998). Claudin-4 can also associate with lck in human CD4+ T-cells 
(Kawai et al., 2011) and so this motif in the C-terminal tail of CLDND1 may 
indicate potential signalling functions for CLDND1 via lck. 
Studies using the highly homologous mouse CLDND1 protein, claudin-25, 
showed this protein interacted with the integral tight junction protein ZO-1 in 
epithelial cells (Mineta et al., 2011). In addition, staining of claudin-1 on human 
CD4+ T-cells identified co-localisation of this protein with ZO-1 and so it was 
suggested that in lymphocytes, claudins can form TJ complexes with similar 
structure or composition as reported in endothelial or epithelial TJ complexes 
(Mandel et al., 2012). Co-staining of ZO-1 with CLDND1 on CD4+ T-cells may 
indicate a role for CLDND1 in cell-cell interactions through TJ- like structures. A 
role for claudin-1 in T-cell motility was also postulated in that study, based on 
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similar claudin-1 kinetics in melanoma cells (Mandel et al., 2012). CLDND1 may 
therefore also play a role in T-cell motility or similar mechanisms such as T-cell 
diapedesis. 
The presence of TGF-β may in part be responsible for modulating CLDND1 cell 
surface expression, yet as the results obtained from these experiments were 
variable and not consistently reproducible, a role for TGF-β in the modulation of 
CLDND1 cell surface expression cannot currently be defined. One notion to 
explain the effects of TGF-β-mediated modulation of CLDND1 expression was 
through down-regulating T-cell activation (Delisle et al., 2013) and so lowering 
CLDND1 cell surface levels indirectly. Given the variability and inconsistency of 
my data, any role for TGF-β in modulating CLDND1 expression in CD4+ T-cells 
may be minor. 
7.2 CLDND1 during T-cell Activation 
CLDND1 cell surface protein levels were transiently increased during T-cell 
activation and so initial thoughts reflected on an inflammatory role for CLDND1 
during the T-cell response. However, both positive and negative regulators of T-
cell activation are also up-regulated at similar time-points, such as CD25 and 
CTLA-4 (Xia et al., 1999). CLDND1 cell surface levels were transiently 
increased in both CD4+ and CD8+ T-cells, suggesting CLDND1 function during 
T-cell activation is not restricted to the CD4+ T-cell subset.  
7.3 CLDND1 during Anergy 
A role for CLDND1 in the induction and maintenance of anergy was sought as 
part of this project, yet the lack of a sufficiently sensitive anergy model has 
limited the ability to collect this information. Based on the lack of a peptide 
specific model, a surrogate system was adopted to determine a role for 
CLDND1 in anergy induction. CLDND1-transfected cells were re-stimulated with 
the same allogeneic stimulus or with an alternative allogeneic stimulus, to 
determine any effect CLDND1 may impart on T-cell recall responses. Based on 
the data collected, there were no obvious differences identified between the 
differentially stimulated CLDND1-transfected populations, suggesting that 
CLDND1 may not be a major factor in recall responses in this model. Until a 
more sensitive model is used to prove or disprove this suggestion, a potential 
role for CLDND1 in anergy remains to be determined. 
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7.4 CLDND1 structure 
A confounding and limiting finding during this thesis was the inability of the α-
CLDND1 antibody to recognise CLDND1 in its native conformation. This 
resulted in a non-functional antibody that could only recognise fixed CLDND1, 
nonetheless it was still a useful tool for investigating CLDND1. The antibody 
binding characteristics also provided insight into the structure of the CLDND1 
molecule. 
The antibody was raised against a linear epitope and so the lack of antibody 
binding could suggest this epitope is hidden within folds of the extracellular loop 
under native conditions, but can be accessed after formaldehyde treatment. The 
role of formaldehyde cross-linking with primary amines and thiol groups to open 
up the CLDND1 structure (Metz et al., 2004, Fowler et al., 2011) was 
suggested, yet this phenomenon usually results in epitope masking (Fritschy, 
2008). An additional theory where formaldehyde fixation unmasked the epitope 
was through disrupting the binding of an interacting partner. Although there is 
little evidence of unmasking epitopes via formaldehyde fixation in the literature, 
the potential for CLDND1 to interact with binding partners, such as homotypic 
interactions between CLDND1 molecules, have been suggested and this 
interaction may explain a lack of antibody binding to CLDND1 in its native 
conformation. 
CLDND1 exists in different glycosylation states, potentially on residues in the 
first extracellular loop. Based on homology to the superfamily member 
TMEM114, in which glycosylation was required for the cell surface location of 
the protein (Maher et al., 2011), it may be that glycosylation plays a role in 
regulating cell surface expression of CLDND1. It is worth noting that in primary 
human CD4+ T-cells differential glycosylation states were not observed for 
endogenous CLDND1 and therefore caution should be applied in relating the 
importance of glycosylation to CLDND1 function in these cells. 
Other post-translational modifications may also play a role in CLDND1 cell 
signalling. The cytoplasmic C-terminal domain of CLDND1 has been implicated 
in mediating interactions, possibly with lck, as similar interactions are found on 
other PMP-22/EMP/MP20/claudin superfamily members (Kawai et al., 2011). 
Many of the PMP-22/EMP/MP20/claudin superfamily members are 
phosphorylated and these phosphorylation motifs are implicated in cell location 
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or functional attributes of the proteins (D'Souza et al., 2005, Aono and Hirai, 
2008, Ishizaki et al., 2003, Ikari et al., 2006, Choi et al., 2002). Therefore, 
potential phosphorylation sites within the CLDND1 C-terminal sequence may be 
important for its function. 
7.5 Proposed Functional Model for CLDND1 
Combining all the data for CLDND1, a model for the role for CLDND1 in CD4+ 
T-cells can start to be developed. The effect of CLDND1 on T-cell proliferation 
was dependent on the type of stimulus given to the cells, where a strong 
stimulus (α-CD3/CD28 expander beads) induced cell death and a weaker 
stimulus (mat- or tolDC) resulted in the reduction in T-cell proliferation. As the 
types of stimuli were different, two hypotheses were developed to explain the 
functions observed: firstly, that the strength of stimulation governs CLDND1 
responses; and secondly, that unique factors present on the DC mediate unique 
signalling interactions.  
The first hypothesis was generated from combining CLDND1 expression 
profiles with differences in CLDND1 function. T-cell stimulation with α-
CD3/CD28 expander beads increased cell surface CLDND1 over mat- or tolDC 
stimulated cells. CLDND1-transfected α-CD3/CD28 expander bead stimulated 
T-cell viability was low, whereas CLDND1-transfected mat- or tolDC stimulated 
T-cells had a less activated phenotype and sustained viability. Therefore, during 
CLDND1-transfected T-cell stimulation, α-CD3/CD28 expander bead stimulus 
may have elevated CLDND1 cell surface levels beyond those in the DC 
stimulated cells which surmounted cellular mechanisms to regulate cell death 
and so cell death pathways were initiated. Failure to initiate cell death pathways 
due to a weaker stimulus (mat- or tolDC) instead led to a hypo-responsive 
phenotype. Similar protein expression kinetics and functions are seen with the 
Foxp3 protein, where high Foxp3 levels induce cell death, induced expression 
of Foxp3 induces a regulatory T-cell phenotype, in particular Treg, and loss of 
Foxp3 expression results in a hyperproliferative phenotype (Brunkow et al., 
2001, Hori et al., 2003, Fontenot et al., 2003, Kasprowicz et al., 2005). 
The second hypothesis promotes DC-specific interactions with CLDND1 to 
support the differences in CLDND1 function with the two types of stimuli. 
Potential CLDND1-interacting partners on the DC which are not present with the 
α-CD3/CD28 expander bead stimulus may include homotypic interactions 
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between CLDND1 molecules on T-cells and DC; interactions between CLDND1 
and a yet to be identified ligand; or CLDND1 may be modulated indirectly as a 
consequence of other activatory or inhibitory binding partners present on DC 
and T-cells. Examples of this include: OX40 on T-cells interacting with OX40L 
on DC which enhances T-cell proliferation and activation through NFAT 
transcription factor activation (Yan et al., 2013); or PD-1 expression on T-cells 
interacting with PD-L1 molecule expression on DC which results in the inhibition 
of T-cell receptor-mediated lymphocyte proliferation through inhibition of TCR 
proximal phosphorylation events (Gianchecchi et al., 2013). 
Some members of the PMP-22/EMP/MP20/claudin superfamily have been 
shown to regulate the activity of calcium channels through interactions with the 
channel subunit responsible for calcium permeability (Sandoval et al., 2007, 
Hansen et al., 2004, Lin et al., 2008). CLDND1, therefore, may have a role as a 
regulator of calcium channels. Calcium signalling in T-cells is of pivotal 
importance for T-cell physiology, as determined by a number of knock-out mice 
studies (Beyersdorf et al., 2009, Oh-hora and Rao, 2008, Gwack et al., 2008). A 
model for signalling through store operated calcium channels has been 
proposed by Qu et al., (2011), where tolerance, proliferation or apoptosis can 
occur with increasing strength and duration of calcium signalling. Additionally, 
the correlation of genes from RA patients and the anergic T-cell clone HA1.7, 
from which this work stemmed, also identified genes involved in calcium 
signalling, such as calmodulin, which was downregulated in both sets of 
samples (Ali et al., 2001). From the results generated in my thesis, it may be 
postulated that the calcium load induced by the weaker DC stimulus may be 
counteracted by CLDND1 regulating calcium signalling, resulting in a 
suppressed phenotype, whereas a higher calcium load through a stronger α-
CD3/CD28 expander bead stimulus may surpass the regulatory effect of 
CLDND1 and result in cell death. 
A potential role for CLDND1 in the regulation of calcium ion channels could 
provide a link to its expression and original identification in glial cells (Fayein et 
al., 2002). Oligodendrocytes were originally described as myelin producing cells 
and so were important cells in the modelling of the axons of the nervous 
system. One aspect of oligodendrocyte function has focussed on the role of 
calcium signalling within these cells. Several pieces of experimental evidence 
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indicate that cells of oligodendroglial lineage exhibit remarkable plasticity with 
regard to the expression of ion channels and receptors linked to calcium 
signalling and that perturbation of calcium homeostasis contributes to the 
pathogenesis of demyelinating diseases, primarily though the induction of 
apoptosis in these cells (Alberdi et al., 2005, Orrenius et al., 2003, Stirling and 
Stys, 2010, Paez et al., 2009). 
In summary, a functional model for CLDND1 in CD4+ T-cell activation is 
proposed (Figure 89), where the functional outcomes vary depending on the 
system used, but indicate a suppressive role for CLDND1 in the regulation of T-
cell proliferation. Suggested internal pathways and interactions are also 
highlighted, yet further experimentation would be required to reinforce these 
claims. 
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Figure 89. Proposed functional model for CLDND1 in primary human CD4+ T-cells 
Depending on the type of stimulation events that occur, CLDND1 induces CD4+ T-cell death or imparts a regulatory function on the T-
cell. Pathways that have been established during this thesis (shown in black) or documented in the literature (shown in brown) are 
indicated by solid lines. Hypothesised functions and interactions are indicated by dashed lines. Arrows of differing thicknesses identify 
strength of signal, with thicker bands representing a stronger signal. 
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Chapter 8. Future Work 
8.1 Similarities to PMP-22/EMP/MP20/Claudin Superfamily Members 
The homology of CLDND1 to the PMP-22/EMP/MP20/claudin superfamily has 
linked some potentially important findings for CLDND1 to similar findings in this 
group of proteins. The observation that over-expressed CLDND1 was 
differentially glycosylated identified similarities to TMEM114 (Maher et al., 
2011), where glycosylation was important for cellular location, and to the 
CACNG family. Mutational analysis of the glycosylation sites in the extracellular 
loops of CLDND1 could be performed in conjunction with immunofluorescence 
microscopy, to determine whether glycosylation is also required for CLDND1 
cellular localisation. 
Similar cell surface expression kinetics were seen in my work with CLDND1 and 
with claudin-1 (Mandel et al., 2012), during T-cell activation. Although it has 
been suggested that CLDND1 may share more functional characteristics to the 
CACNG rather than the claudins, the following experiments are still worth 
pursuing to either strengthen this statement or to give more insight into how 
CLDND1 may function during T-cell signalling. Claudin-1 co-localised with the 
integral TJ protein ZO-1 (Mandel et al., 2012). Similarly, the mouse homologue 
of CLDND1 was also shown to co-localise with ZO-1 in epithelial cells (Mineta 
et al., 2011) so confocal microscopy of ZO-1 and CLDND1 could also indicate a 
TJ- like role for CLDND1 in T-cells, which may be important in cell-cell contacts, 
at the IS or during cell migration. 
CLDND1 truncation studies suggest that the cytoplasmic C-terminal domain of 
CLDND1 may be important for CLDND1 function, yet these studies were limited 
and require further clarification. Two potential phosphorylation sites lie within 
this region and may be important for function, based on other PMP-
22/EMP/MP20/claudin superfamily members (D'Souza et al., 2005, Aono and 
Hirai, 2008, Ishizaki et al., 2003, Ikari et al., 2006, Choi et al., 2002). Therefore 
mutational analysis of the potential phosphorylation sites could be performed to 
clarify whether CLDND1’s function in T-cell proliferation is affected and whether 
CLDND1 can signal or be modulated through these potential phosphorylation 
sites. 
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Part of the C-terminal sequence of CTLA-4 provides an interaction point for the 
src family tyrosine kinases fyn, lyn and lck, and act as a site for phosphorylation 
(Miyatake et al., 1998). In addition, claudin-4 can associate with lck in human 
CD4+ T-cells (Kawai et al 2011) and so the potential for CLDND1 to interact 
with these T-cell signalling molecules could be explored. Potential interactions 
could be determined by co-localisation studies using confocal 
immunofluorescence microscopy, or through IP studies. 
CLDND1 functional characteristics may be similar to the non-PDZ possessing 
CACNG family members, where functions range from regulating the activity of 
calcium channels (Sandoval et al., 2007, Hansen et al., 2004, Lin et al., 2008) 
to modulating AMPA receptors (Kato et al., 2008, Kato et al., 2007, Tomita et 
al., 2003). As AMPA receptors and calcium channels are present in human 
lymphocytes and can modulate T-cell function (Lombardi et al., 2001, 
Beyersdorf et al., 2009, Oh-hora and Rao, 2008, Gwack et al., 2008), 
determining whether CLDND1 also co-localises with these or similar proteins, 
through confocal immunofluorescence microscopy or IP studies, will help 
determine whether CLDND1 may play a role in calcium signalling. As a similar 
functional profile to CLDND1 has been seen with differential signalling through 
store-operated calcium channels (Qu et al., 2011), studies determining the 
effect of calcium signalling on CLDND1 expression and vice versa could be 
performed. These studies could include experiments working with calcium 
signalling agonists (e.g. ionomycin) or inhibitors (e.g. the non-selective Ca2+ 
channel inhibitor bepridil hydrochloride) to determine whether CLDND1 
expression level changes. CLDND1-transfected cells could also be stained with 
Fura-2, which stains [Ca]i (Grynkiewicz et al., 1985), to determine whether 
calcium signalling is altered during T-cell activation. 
8.2 Determining the Relationship between mRNA and Protein 
An outstanding question throughout this thesis lies in whether CLDND1 RNA is 
a good predictor of protein expression. Replication of an ingenious experiment 
performed by Gulow et al., (2002) may indicate whether CLDND1 RNA and 
protein levels are distinct. Transfecting heterologous CLDND1 RNA into a cell 
line of a different species and monitoring CLDND1 RNA and protein from the 
host and recipient species can determine CLDND1 RNA and protein kinetics, 
provided each species contained unique regions in which to target for protein or 
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RNA analysis. There are distinct regions within the human and mouse CLDND1 
transcript variant 1 sequence to allow for different probe and primer pairs to be 
designed, and while the mouse and human homologues of CLDND1 share 92 
% sequence identity, there is a unique region in the first extracellular loop, 
providing a species-specific epitope. 
8.3 Kinetics and Dynamics of CLDND1 Protein Expression  
The potency of CLDND1 in reducing T-cell proliferation varied between 
experiments. This finding may indicate the importance of sorting the transfected 
cells into pure populations, for example using a system such as the IRES-H2Kk 
dual expression system (Tahvanainen et al., 2006). The percentage of 
CLDND1-transfected cells could also be increased by performing antibiotic 
resistance selection of stable transfectants or generation of CLDND1-
transfected T-cell clones through viral transfection (Stevenson et al., 1986, 
Dardalhon et al., 2001). Generating stable transfectants by incorporating this 
gene into the T-cell genome followed by appropriate selection would ensure 
CLDND1 expression in all cells. Additionally, stable transfectants could be 
made using vectors expressing CLDND1 siRNA sequences to see whether 
CLDND1 protein could be silenced by sustained siRNA expression, in contrast 
to transient siRNA transfection. 
8.4 Depicting Protein-Protein Interactions 
In light of the differences in CLDND1 function on T-cell proliferation in response 
to α-CD3/CD28 expander beads or DC stimulation, DC-T-cell protein 
interactions could be explored. Two protein-protein interaction techniques have 
already been discussed (see Section 4.4.2): yeast-two hybrid screening and co-
IP. Given that attempts to perform co-IP were unsuccessful with the α-CLDND1 
antibody, additional native α-CLDND1-binding antibodies would need to be 
generated to use this technique. The yeast-two hybrid screening could still be 
attempted using a genomic expression system or limiting expression to potential 
interacting partners on the DC. Another method reliant on robust functional 
antibodies is antibody blocking experiments to disrupt potential interaction sites 
on CLDND1 acting in an agonistic or antagonistic fashion. This also requires the 
generation of more antibodies (see Section below). Alternatively, if interaction 
sites on CLDND1 were identified, blocking peptides could also be used. 
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8.5 Future Immunisations 
I originally intended to utilise antibodies to manipulate the function of CLDND1. 
A function for CLDND1 in the modulation of T-cell proliferation has been 
suggested and so further immunisation using full length protein (see Section 
3.3.7) may create an array of antibodies, which impart agonistic, neutral or 
antagonist effects on CLDND1 function. Subsequently, an antibody that 
recognises native CLDND1 can be used for live cell imaging to determine 
trafficking patterns and CLDND1 interactions. Additionally, this antibody could 
be utilised for co-IP experiments (see Section 8.4) to find potential binding 
partners for CLDND1. 
8.6 Stimulation Strength and CLDND1 Expression 
I have postulated that CLDND1 may dictate T-cell responses during activation 
in relation to the strength of the stimulus, in comparison to similar effects seen 
with Foxp3 (Brunkow et al., 2001, Hori et al., 2003, Fontenot et al., 2003, 
Kasprowicz et al., 2005). In order to determine whether the protein expression 
patterns for CLDND1 are similar to Foxp3, CLDND1-knockout mice studies 
could be developed, imitating the Foxp3 experiments. A CLDND1 null mouse, 
or if this proved embryonic lethal, a conditional knockout could be generated. 
Similarly, in order to depict the role of stimulation strength further, titrations of 
both the quantities of α-CD3/CD28 expander bead and DC stimulus would 
determine whether CLDND1 function is regulated in a dose dependent manner. 
The execution of these experiments with the potential effects from calcium 
signalling pathways in mind may link stimulation strength and calcium signalling 
to similarities to PMP-22/EMP/MP20/claudin superfamily members.  
8.7 Further Work from EA Patient Samples 
CLDND1 expression was shown to associate with RF status in early RA 
patients; however RF titres could not be correlated with CLDND1 levels. 
Performing in vitro experiments titrating RF in PBMC cultures and then 
assessing changes in CLDND1 protein expression would indicate a direct 
connection between RF and CLDND1. Developing from this hypothesised link 
between RF and CLDND1 cell surface expression, it was further hypothesised 
that complement may form the basis of this connection. Immune complexes are 
widely found in RA patient joints (Okroj et al., 2007) and polyclonal IgM RF can 
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fix and activate complement (Tanimoto et al., 1975). Complement also binds to 
receptors on CD4+ T-cells and DC and heightens T-cell activation (Heeger and 
Kemper, 2012). I have shown that CLDND1 cell surface expression is up-
regulated during T-cell activation (Section 5.3.2, Figure 38), therefore elevated 
CLDND1 cell surface levels in RF positive early RA patients may be linked 
through complement, although in reality this link is likely to be more complex 
due to the heterogenous attributes of RF positive and negative RA disease. In 
order to generate a basic link between CLDND1 expression levels and 
complement activation, co-staining of CLDND1 and complement receptors by 
flow cytometry could be performed, followed by complement receptor activation 
studies, using complement receptor agonists (Asgari et al., 2013), to assess 
changes in CLDND1 expression levels.  
8.8 Further Functional Studies 
Ultimately, in order to study a physiological function for CLDND1 in vivo, an 
appropriate mouse model would need to be generated. The translation of 
CLDND1 function in a mouse model to a human system however, is dependent 
on a number of factors. Firstly, low mouse and human CLDND1 homology may 
indicate species-unique function, but the human and mouse CLDND1 proteins 
share high (92 %) homology (Figure 90). The sequence variations do however 
occur within the two extracellular loop regions, which may indicate differences in 
protein interactions or alternatively, may be a consequence of complementary 
modifications in the same potential mouse interacting partners. 
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H 1  MDNRFATAFVIACVLSLISTIYMAASIGTDFWYEYRSPVQENSSDLNKSIWDEFISDEAD 60 
Hom. MDNRFATAFVIACVLSLISTIYMAASIGTDFWYEYRSP-QENSSD-NK--W--F--DEAD 
M 1  MDNRFATAFVIACVLSLISTIYMAASIGTDFWYEYRSPIQENSSDSNKIAWEDFLGDEAD 60 
 
H 61  EKTYNDALFRYNGTVGLWRRCITIPKNMHWYSPPERTESFDVVTKCVSFTLTEQFMEKFV 120 
Hom.  EKTYND-LFRYNG--GLWRRCITIPKN-HWY-PPERTESFDVVTKC-SFTL-EQFMEK-V 
M 61  EKTYNDVLFRYNGSLGLWRRCITIPKNTHWYAPPERTESFDVVTKCMSFTLNEQFMEKYV 120 
 
H 121 DPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALIGLCACICRSLYPTIATGILHLLA 180 
Hom.  DPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALIGLCACICRSLYPT+ATGILHLLA 
M 121 DPGNHNSGIDLLRTYLWRCQFLLPFVSLGLMCFGALIGLCACICRSLYPTLATGILHLLA 180 
 
H 181 GLCTLGSVSCYVAGIELLHQKLELPDNVSGEFGWSFCLACVSAPLQFMASALFIWAAHTN 240 
Hom.  GLCTLGSVSCYVAGIELLHQK-ELP--VSGEFGWSFCLACVSAPLQFMA-ALFIWAAHTN 
M 181 GLCTLGSVSCYVAGIELLHQKVELPKDVSGEFGWSFCLACVSAPLQFMAAALFIWAAHTN 240 
 
H 241 RKEYTLMKAYRVA 253 
Hom.  RKEYTLMKAYRVA 
M 241 RKEYTLMKAYRVA 253 
 
Figure 90. Human and mouse homology of the CLDND1 protein 
Human (H) and mouse (M) CLDND1 isoform A were aligned using the basic 
local alignment tool, with the blasp alogarithm. Underlined regions indicate 
transmembrane regions. The “hom.” sequence identifies identical amino acids. 
Mismatches are indicated by “-”. 
 
 
Additionally, the type of mouse model generated must reflect the predicted 
consequences of CLDND1 function. If a CLDND1 null mouse proved 
embryonically lethal, this would suggest CLDND1 expression was essential in 
foetal development. A conditional or selective knockout may therefore be more 
suitable. There are numerous possible approaches and one example is the 
cre/loxP recombinase system to excise the CLDND1 gene. Two mice stains are 
utilised: one expresses an inducible cre recombinase and the other expresses 
the transgene of interest (in this case CLDND1) flanked by loxP sequences. 
Mating the two strains of mice allows for selective control of CLDND1 
expression by inducing cre recombinase expression (Jaisser, 2000). Depending 
on the type of cre recombinase induction, this technique can ablate all 
CLDND1, or alternatively can selectively inhibit CLDND1 expression in a 
lymphocyte-specific manner, using a T-cell specific inducible promoter (Zhang 
et al., 2005) and would provide a model for determining a physiological role for 
CLDND1 in the immune system.
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Appendix 
Protein NCBI Label 
TMEM114 NP_001139808.1 
TMEM235 NP_001191139.1 
CLARIN-1 NP_777367.1 
Claudin-1 NP_066924.1 
Claudin-2 NP_065117.1 
Claudin-3 NP_001297.1 
Claudin-4 NP_001296.1 
Claudin-5 NP_001124333.1 
Claudin-6 NP_067018.2 
Claudin-7 NP_001298.3 
Claudin-8 NP_955360.1 
Claudin-9 NP_066192.1 
Claudin-10 NP_878268.1 
Claudin-11 NP_005593.2 
Claudin-12 NP_001172001.1 
Claudin-14 NP_652763.1 
Claudin-15 NP_001172009.1 
Claudin-16 NP_006571.1 
Claudin-17 NP_036263.1 
Claudin-18 NP_057453.1 
Claudin-19 NP_683763.2 
Claudin-20 NP_001001346.1 
Claudin-21 NP_001094859 
Claudin-22 NP_001104789.1 
Claudin-23 NP_919260.2 
Claudin-24 NP_001172078.1 
EMP-1 NP_001414.1 
EMP-2 NP_001415.1 
EMP-3 NP_001416.1 
PMP-22 NP_000295.1 
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Protein NCBI Label 
MP20 NP_001155220.1 
CLP24 NP_078876.2 
CACNG1 NP_000718.1 
CACNG2 NP_006069.1 
CACNG3 NP_006530.1 
CACNG4 NP_055220.1 
CACNG5a NP_665810.1 
CACNG6 NP_665813.1 
CACNG7 NP_114102.2 
CACNG8 NP_114101.4 
CLDND1 isoform A NP_001035289.1 
CLDND1 isoform B NP_001035272 
CLDND1 isoform D NP_001035290.1 
Mouse CLDND1 isoform A NP_741968.1 
 
Appendix Table 1. Accession numbers for all the protein sequences used 
through the thesis  
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v6 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
v7 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
v3 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
v1 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
v2 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
v4 TATCGCCGCCTCAGACAGCTTTCAGTCTGTCCCTCCTACAACTCCCACAAGGCCCCTCGG 60 
   ************************************************************ 
v6 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
v7 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
v3 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
v1 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
v2 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
v4 CCCCGGGCCGCGGCCCGGCCCGGAGTGGGGGCGGGCGGAGGCGCGGGAGTTATGGAGGGG 120 
   ************************************************************ 
v6 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
v7 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
v3 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
v1 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
v2 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
v4 GCGGGCTCTGCAGGGAAGTGCGTCAGAGGAGGCGCGGGGAGAGTAGGGTGCTGTGGTCTG 180 
   ************************************************************ 
v6 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCGGTGAGTGAGCGGGACCTGCGTC 240 
v7 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCG---------------------- 218 
v3 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCG---------------------- 218 
v1 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCG---------------------- 218 
v2 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCGTATGCAGGTGATAGACTAGAGA 240 
v4 AGCTAGAGGGTGAAGCTGGCGGAGCAGGAGGATGGGCG-------GTGATAGACTAGAGA 233 
   **************************************                       
v6 GCCGGGCAGGGGTCGCGTCGCGGTTCCATGTTCCCGGCGGTTTGAAGAGGGGCCCCCTTC 300 
v7 ------------------------------------------------------------ 
v3 ------------------------------------------------------------ 
v1 ------------------------------------------------------------ 
v2 ACAAG------------------------------------------------------- 245 
v4 ACAAG------------------------------------------------------- 238 
                                                                            
v6 CCGGGCGTGGTCGGGCTGGGCGGGTTCCGAGCGGCGGATTTGTCCCAGGGCCGAGCCCTC 360 
v7 ------------------------------------------------------------ 
v3 ------------------------------------------------------------ 
v1 ------------------------------------------------------------ 
v2 ------------------------------------------------------------ 
v4 ------------------------------------------------------------ 
                                                                                   
v6 TAGGGCGGGGCCTGGTCGGGTACCGGGGGACCCTGGCCCGGGGCCGAGCACGGCTGCCCC 420 
v7 ------------------------------------------------------------ 
v3 ------------------------------------------------------------ 
v1 ------------------------------------------------------------ 
v2 ------------------------------------------------------------ 
v4 ------------------------------------------------------------ 
                                                                                   
v6 GCCCCAGCCCTGGCCTTCTCCGGCCCCGCCGTGAGGCCCAGGAGGTGGCTGCTGCAGGCG 480 
v7 ------------------------------------------------------------ 
v3 ------------------------------------------------------------ 
v1 ------------------------------------------------------------ 
v2 ------------------------------------------------------------ 
v4 ------------------------------------------------------------ 
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v6 TCCGGCTTGGACGAACCGCCGTTCCCAGTGCTGGGACCCTTTAAGAGCAGTCTGAATGCC 540 
v7 ------------------------------------------------------------ 
v3 --------------------------------------------------TCTGAATGCC 228 
v1 ---------------------------------------------AGCAGTCTGAATGCC 233 
v2 ---------------------ACCTCTGTCTCCGTAGCATCCTGGAGCAGTCTGAATGCC 284 
v4 ---------------------ACCTCTGTCTCCGTAGCATCCTGGAGCAGTCTGAATGCC 277 
                                                                                   
v6 AGAATGGATAACCGTTTTGCTACAGCATTTGTAATTGCTTGTGTGCTTAGCCTCATTTCC 600 
v7 ------------------------------------------------------------ 
v3 AGAATGGATAACCGTTTTGCTACAGCATTTGTAATTGCTTGTGTGCTTAGCCTCATTTCC 288 
v1 AGAATGGATAACCGTTTTGCTACAGCATTTGTAATTGCTTGTGTGCTTAGCCTCATTTCC 293 
v2 AGAATGGATAACCGTTTTGCTACAGCATTTGTAATTGCTTGTGTGCTTAGCCTCATTTCC 344 
v4 AGAATGGATAACCGTTTTGCTACAGCATTTGTAATTGCTTGTGTGCTTAGCCTCATTTCC 337 
                    
v6 ACCATCTACATGGCAGCCTCCATTGGCACAGACTTCTGGTATGAATATCGAAGTCCAGTT 660 
v7 ------------------------------------------------------------ 
v3 ACCATCTACATGGCAGCCTCCATTGGCACAGACTTCTGGTATGAATATCGAAGTCCAGTT 348 
v1 ACCATCTACATGGCAGCCTCCATTGGCACAGACTTCTGGTATGAATATCGAAGTCCAGTT 353 
v2 ACCATCTACATGGCAGCCTCCATTGGCACAGACTTCTGGTATGAATATCGAAGTCCAGTT 404 
v4 ACCATCTACATGGCAGCCTCCATTGGCACAGACTTCTGGTATGAATATCGAAGTCCAGTT 397 
                                                                                   
v6 CAAGAAAATTCCAGTGATTTGAATAAAAGCATCTGGGATGAATTCATTAGTGATGAGGCA 720 
v7 ------------------------------------------------------------ 
v3 CAAGAAAATTCCAGTGATTTGAATAAAAGCATCTGGGATGAATTCATTAGTGATGAGGCA 408 
v1 CAAGAAAATTCCAGTGATTTGAATAAAAGCATCTGGGATGAATTCATTAGTGATGAGGCA 413 
v2 CAAGAAAATTCCAGTGATTTGAATAAAAGCATCTGGGATGAATTCATTAGTGATGAGGCA 464 
v4 CAAGAAAATTCCAGTGATTTGAATAAAAGCATCTGGGATGAATTCATTAGTGATGAGGCA 457 
                                                                                   
v6 GATGAAAAGACTTATAATGATGCACTTTTTCGATACAATGGCACAGTGGGATTGTGGAGA 780 
v7 ------------------------------------------------------------ 
v3 GATGAAAAGACTTATAATGATGCACTTTTTCGATACAATGGCACAGTGGGATTGTGGAGA 468 
v1 GATGAAAAGACTTATAATGATGCACTTTTTCGATACAATGGCACAGTGGGATTGTGGAGA 473 
v2 GATGAAAAGACTTATAATGATGCACTTTTTCGATACAATGGCACAGTGGGATTGTGGAGA 524 
v4 GATGAAAAGACTTATAATGATGCACTTTTTCGATACAATGGCACAGTGGGATTGTGGAGA 517 
                                                                                   
v6 CGGTGTATCACCATACCCAAAAACATGCATTGGTATAGCCCACCAGAAAGGACAGAGTCA   840 
v7 -------------------------------------------------------AGTCA   223 
v3 CGGTGTATCACCATACCCAAAAACATGCATTGGTATAGCCCACCAGAAAGgacagagtca 528 
v1 CGGTGTATCACCATACCCAAAAACATGCATTGGTATAGCCCACCAGAAAggacagagtca 533 
v2 CGGTGTATCACCATACCCAAAAACATGCATTGGTATAGCCCACCAGAAAGGACAGAGTCA   584 
v4 CGGTGTATCACCATACCCAAAAACATGCATTGGTATAGCCCACCAGAAAGGACAGAGTCA   577 
                                                          ***** 
v6 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 900 
v7 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 283 
v3 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 588 
v1 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 593 
v2 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 644 
v4 TTTGATGTGGTCACAAAATGTGTGAGTTTCACACTAACTGAGCAGTTCATGGAGAAATTT 637 
   ************************************************************ 
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v6 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGgacctatctttGGCGTTGC 960 
v7 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGGacctatctttgGCGTTGC 343 
v3 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGGACCTATCTTTGGCGTTGC   648 
v1 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGGACCTATCTTTGGCGTTGC   653 
v2 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGGacctatctttGGCGTTGC 704 
v4 GTTGATCCCGGAAACCACAATAGCGGGATTGATCTCCTTAGGacctatctttGGCGTTGC 697 
   ************************************************************ 
v6 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 1020 
v7 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 403 
v3 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 708 
v1 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 713 
v2 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 764 
v4 CAGTTCCTTTTACCTTTTGTGAGTTTAGGTTTGATGTGCTTTGGGGCTTTGATCGGACTT 757 
   ************************************************************ 
v6 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 1080 
v7 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 463 
v3 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 768 
v1 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 773 
v2 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 824 
v4 TGTGCTTGCATTTGCCGAAGCTTATATCCCACCATTGCCACGGGCATTCTCCATCTCCTT 817 
   ************************************************************ 
v6 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 1140 
v7 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 523 
v3 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 828 
v1 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 833 
v2 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 884 
v4 GCAGGTCTGTGTACACTGGGCTCAGTAAGTTGTTATGTTGCTGGAATTGAACTACTCCAC 877 
   ************************************************************ 
        CLDND1 siRNA 1 
v6 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 1200 
v7 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 583 
v3 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 888 
v1 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 893 
v2 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 944 
v4 CAGAAACTAGAGCTCCCTGACAATGTATCCGGTGAATTTGGATGGTCCTTCTGCCTGGCT 937 
   ************************************************************ 
       CLDND1 siRNA 2 
v6 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 1260 
v7 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 643 
v3 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 948 
v1 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 953 
v2 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 1004 
v4 TGTGTCTCTGCTCCCTTACAGTTCATGGCTTCTGCTCTCTTCATCTGGGCTGCTCACACC 997 
   ************************************************************ 
v6 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 1320 
v7 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 703 
v3 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 1008 
v1 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 1013 
v2 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 1064 
v4 AACCGGAAAGAGTACACCTTAATGAAGGCATATCGTGTGGCATGAGCAAGAAACTGCCTG 1057 
   ************************************************************ 
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v6 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 1380 
v7 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 763 
v3 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 1068 
v1 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 1073 
v2 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 1124 
v4 CTTTACAATTGCCATTTTTATTTTTTTAAAATAATACTGATATTTTCCCCACCTCTCAAT 1117 
   ************************************************************ 
v6 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 1440 
v7 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 823 
v3 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 1128 
v1 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 1133 
v2 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 1184 
v4 TGTTTTTAATTTTTATTTGTGGATATACCATTTTATTATGAAAATCTATTTTATTTATAC 1177 
   ************************************************************ 
v6 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 1500 
v7 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 883 
v3 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 1188 
v1 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 1193 
v2 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 1244 
v4 ACATTCACCACTAAATACACACTTAATACCACTAAAATTTATGTGGTTTACTTTAAGCGA 1237 
   ************************************************************ 
v6 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 1560 
v7 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 943 
v3 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 1248 
v1 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 1253 
v2 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 1304 
v4 TGCCATCTTTCAAATAAACTAATCTAGGTCTAGACAGAAAGAAATGGATAGAGACTTGAC 1297 
   ************************************************************ 
v6 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1620 
v7 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1003 
v3 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1308 
v1 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1313 
v2 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1364 
v4 ACAAATTTATGAAAGAAAATTGGGAGTAGGAATGTGACCGAAAACAAGTTGTGCTAATGT 1357 
   ************************************************************ 
v6 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1680 
v7 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1063 
v3 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1368 
v1 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1373 
v2 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1424 
v4 CTGTTAGACTTTTCAGTAAAACTAAAGTAACTGTATCTGTTCAACTAAAAACTCTATATT 1417 
   ************************************************************ 
v6 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1740 
v7 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1123 
v3 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1428 
v1 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1433 
v2 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1484 
v4 AGTTTCTTTGGGAAACCTCTCATCGTCAAAACTTTATGTTCACTTTGCTGTTGTAGATAG 1477 
   ************************************************************ 
v6 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1800 
v7 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1183 
v3 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1488 
v1 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1493 
v2 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1544 
v4 CCAGTCAACCAGCAGTATTAGTGCTGTTTTCAAAGATTTAAGCTCTATAAAATTGGGAAA 1537 
   ************************************************************ 
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v6 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1860 
v7 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1243 
v3 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1548 
v1 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1553 
v2 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1604 
v4 TTATCTAAGATCATTTTCCCTAAGCATTGACACATAGCTTCATCTGAGGTGAGATATGGC 1597 
   ************************************************************ 
v6 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1920 
v7 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1303 
v3 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1608 
v1 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1613 
v2 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1664 
v4 AGCTGTTTGTATCTGCACTGTGTCTGTCTACAAAAAGTGAAAAATACAGTGTTTACTTGA 1657 
   ************************************************************ 
v6 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1980 
v7 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1363 
v3 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1668 
v1 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1673 
v2 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1724 
v4 AATTTTAACTTTGTAACTGCAAGAATTCCAGTTCAGCCGGGCGAGGATTAGTATTATTTT 1717 
   ************************************************************ 
v6 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 2040 
v7 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 1423 
v3 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 1728 
v1 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 1733 
v2 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 1784 
v4 TAACTCTCCGTAAGATTTTCAGTACCACCAAATTGTTTTGGATTTTTTTTCTTTCCTCTT 1777 
   ************************************************************ 
v6 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 2100 
v7 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 1483 
v3 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 1788 
v1 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 1793 
v2 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 1844 
v4 CACATACCAGGGTTATTAAAAGTGTGCTTTCTTTTTACATTATATTACAGTTACAAGGTA 1837 
   ************************************************************ 
     CLDND1 siRNA 3 
v6 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 2160 
v7 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 1543 
v3 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 1848 
v1 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 1853 
v2 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 1904 
v4 AAATTCCTCAACTGCTATTTATTTATTCCAGCCCAGTACTATAAAGAACGTTTCACCATA 1897 
   ************************************************************ 
v6 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 2220 
v7 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 1603 
v3 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 1908 
v1 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 1913 
v2 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 1964 
v4 ATGACCCTCCAGAGCTGGGAAACCTACCACAAGATCTAAAGTTCTGGCTGTCCATTAACC 1957 
   ************************************************************ 
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v6 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 2280 
v7 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 1663 
v3 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 1968 
v1 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 1973 
v2 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 2024 
v4 TCCAACTATGGTCTTTATTTCTTGTGGTAATATGATGTGCCTTTCCTTGCCTAAATCCCT 2017 
   ************************************************************ 
v6 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 2340 
v7 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 1723 
v3 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 2028 
v1 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 2033 
v2 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 2084 
v4 TCCTGGTGTGTATCAACATTATTTAATGTCTTCTAATTCAGTCATTTTTTTATAAGTATG 2077 
   ************************************************************ 
        CLDND1 siRNA 4 
v6 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 2400 
v7 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 1783 
v3 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 2088 
v1 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 2093 
v2 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 2144 
v4 TCTATAAACATTGAACTTTAAAAAACTTATTTATTTATTCCACTACTGTAGCAATTGACA 2137 
   ************************************************************ 
v6 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 2460 
v7 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 1843 
v3 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 2148 
v1 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 2153 
v2 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 2204 
v4 GATTAAAAAAATGTAACTTCATAATTTCTTACCATAACCTCAATGTCTTTTTTAAAAAAT 2197 
          ************************************************************ 
v6 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 2500 
v7 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 1883 
v3 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 2188 
v1 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 2193 
v2 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 2244 
v4 AAAATTAAAAATGAAAAGAGACTCAATTGTAAAAAAAAAA 2237 
 
Appendix Figure 1. Accell CLDND1 siRNA and CLDND1 Taqman assay 
binding 
The 6 CLDND1 transcripts were aligned using clustalW2 (EBI). CLDND1 ORF 
are highlighted with the boxed regions. Underlined regions represent where 
each CLDND1 siRNA binds. Lower-case bold letters indicate the exon junction 
where the CLDND1 taqman assay for qRT-PCR binds. 
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